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The PI3K/AKT pathway is one of the most frequently dysregulated pathways in 
human cancer. The serine/threonine protein kinase AKT, a central node in the 
pathway, regulates various cellular processes, several of which are involved in 
cancer hallmarks. This, together with the observation that AKT is often 
hyperactivated in cancer, makes the kinase a promising and attractive therapeutic 
target. However, clinical trials using small molecule-inhibitors to interfere with AKT 
have not yielded the expected results. The occurrence of dose-limiting adverse 
effects curtails the efficacy of these inhibitors. The disappointing results from 
clinical trials can be explained by the existence of three closely-related AKT 
isoforms (AKT1, AKT2 and AKT3) that share a high degree of sequence identity, 
but are non-redundant and can even have opposing functions. Despite the efforts 
made by both pharmaceutical companies and academic researchers, there are 
currently no inhibitors that allow the selective inhibition of a single AKT isoform. 
There is a need for innovative and AKT isoform-selective tools to tackle this 
problem. By generating nanobodies for the AKT isoforms we use a fundamentally 
different approach in order to obtain AKT isoform-specific modulators. Nanobodies, 
discovered by the Hamers-Casterman group in 1993, are derived from the antigen-
binding domain of camelid heavy chain only antibodies. They are the smallest 
naturally occurring antigen-binding fragment and possess several characteristics 
that make them superior to conventional antibodies or the antibody fragments 
derived thereof.  
 
In an initial study, we generated and characterized nanobodies for the AKT1- 
and AKT3-PH domains, and for full-length, active AKT2. Throughout this study, the 
key criterion for retaining nanobodies was their specificity for a single AKT isoform. 
Eventually, our approach was only successful for AKT1 and AKT2. We obtained a 
single AKT1 Nb that bound to both the wild-type AKT1 PH domain and an 
oncogenic mutant, and three AKT2-specific nanobodies that interacted with distinct 
epitopes and domains. The nanobodies that recognised the PH domain interfered 
 
xviii 
with the binding of those domains to PIP3. For the AKT1 Nb this included the 
oncogenic PH domain mutant which has an increased affinity for this 
phosphoinositide. The nanobodies that were characterized in this study can be 
used to target AKT1 or AKT2 in cells, and serve as complementary tools to gene 
knockdown techniques to study the function of these isoforms. 
 
The AKT2-specific nanobodies and their effects on AKT2 signalling in breast 
cancer cells were characterized in more detail. Two nanobodies modulated AKT2 
signalling and reduced the viability or proliferation of MDA-MB-231 cells. An AKT2 
nanobody, which interacted with the regulatory domain and reduced 
phosphorylation of the hydrophobic motif induced a cell cycle arrest, autophagy, 
and downregulated focal adhesions and stress fibers in this breast cancer cell line. 
By using this Nb as a research tool we were able to map a part of AKT2’s signalling 
cascade, further strengthened AKT2 as a bona fide target for cancer therapy and 
established the importance of the hydrophobic motif for AKT2 signal transduction. 
This hydrophobic motif represents a potential new allosteric regulation site that can 
be used to modulate the AKT2 isoform. This functional AKT2 nanobody shows 
great promise as a research tool for untangling the isoform-specific and context-
dependent functions of AKT2. This nanobody, or its epitope, can be used in the 
rational design of an isoform-specific AKT2 inhibitor. 
 
This thesis provides new tools that can be used to study AKT isoforms in cells, 
advocates the use of complementary techniques to study protein function and 





De PI3K/AKT pathway is een van de meest frequent ontregelde pathways in 
humane kankers. Het serine/threonine eiwit kinase AKT, een centraal knooppunt 
in deze pathway, reguleert verschillende cellulaire processen. Hiervan zijn 
meerdere betrokken bij typische kenmerken van tumoren. Dit, samen met de 
observatie dat AKT dikwijls hyperactief is in tumoren, maakt het kinase een 
veelbelovend en prominent therapeutisch doelwit voor kankertherapie. Klinische 
proeven waar men small-molecules gebruikt om te interfereren met AKT hebben 
echter niet de verwachte resultaten opgeleverd. Het frequent voorkomen van 
bijwerkingen beperkt de dosis van deze inhibitoren die men kan toedienen, wat op 
zijn beurt de werkzaamheid limiteert. Een verklaring voor het falen van deze 
inhibitoren is dat er drie AKT isovormen (AKT1, AKT2 en AKT3) bestaan die qua 
aminozuursequentie zeer sterk op elkaar lijken, maar toch een verschillende en 
soms tegengestelde functie hebben. Ondanks de pogingen van zowel 
farmaceutische bedrijven als academici, bestaat er geen inhibitor die toelaat om 
selectief één enkele AKT isovorm te inhiberen. 
Er is dus nood aan innoverende, AKT isovorm-selectieve tools. Door nanobodies 
te produceren voor de AKT isovormen gebruiken wij een totaal verschillende 
strategie om de functie van specifieke AKT isovormen te kunnen beïnvloeden. 
Nanobodies werden in 1993 ontdekt door de Hamers-Casterman groep en zijn 
afgeleid van het antigen-bindend domein van zware keten antilichamen die 
voorkomen in het serum van kameelachtigen. Dit zijn de kleinste natuurlijk 
voorkomende antigen-bindende fragmenten en deze zijn op vele vlakken superieur 
aan conventionele antilichamen of derivaten daarvan. 
 
In een eerste studie werden nanobodies opgewekt en gekarakteriseerd voor het 
AKT1- en AKT3-PH domein, en full-length actief AKT2. Gedurende deze studie 
was de specificiteit voor één enkele AKT isovorm het belangrijkste selectiecriterium 
om een nanobody te behouden voor verdere experimenten. Uiteindelijk is dit enkel 
voor AKT1 en AKT2 gelukt. We verkregen een nanobody dat bindt met zowel wild-
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type AKT1 PH domein als met de oncogene mutant en drie nanobodies die 
specifiek zijn voor AKT2. Elk van de AKT2 nanobodies bindt met een ander epitoop 
en domein. De nanobodies die met de PH domeinen binden, verstoren de interactie 
van dat domein met PIP3. Voor het AKT1 nanobody geldt dit eveneens voor de 
oncogene mutant die een hogere affiniteit heeft voor dit fosfoinositide. De 
nanobodies die gekarakteriseerd werden in deze studie kunnen gebruikt worden 
als hulpmiddel om de rol van deze AKT isovormen in levende cellen te 
onderzoeken. 
 
De AKT2 nanobodies en hun effect op AKT2 signaaltransductie in 
borstkankercellen werden meer in detail onderzocht. Twee nanobodies 
beïnvloeden de werking van AKT2 en verminderen celproliferatie of celviabiliteit 
van de MDA-MB-231 cellijn. Voor een nanobody dat bindt op het regulatorisch 
domein en de fosforylatie van het hydrofobe motief vermindert, tonen we aan dat 
het de celcyclus stillegt, autofagie induceert en de aanwezigheid van focal 
adhesions en stress fibers in deze cellijn sterk vermindert. Dankzij dit nanobody 
was het mogelijk om een deel van het AKT2 signaaltransductienetwerk in kaart te 
brengen. We konden bevestigen dat AKT2 een bonafide doelwit is voor 
kankertherapie en toonden het belang aan van het hydrofobe motief voor de 
werking van AKT2. Dit hydrofobe motief vertegenwoordigt mogelijks een nieuwe 
allosterische regulatieplaats waarmee men de functie van dit kinase kan 
beïnvloeden. Dit functionele nanobody is veelbelovend als middel voor 
fundamenteel onderzoek naar de isovorm-specifieke en context-afhankelijke 
functies van AKT2. Het nanobody zelf, of zijn epitoop, kan ook gebruikt worden 
voor het ontwerpen van een isovorm-specifieke AKT2 inhibitor. 
 
Deze thesis biedt nieuwe tools aan die gebruikt kunnen worden in onderzoek 
naar de AKT isovormen, promoot het gebruik van complementaire technieken om 
de functie van eiwitten te bestuderen en toont aan dat nanobodies daarbij een 
waardevolle bijdrage kunnen leveren. 
 





Chapter 1  
AKT: a critical signalling node 
“DON’T PANIC” 
-The Hitchhiker’s Guide to the Galaxy 
 Background Information 
In 1987 Stephen Staal discovered v-Akt, a nonviral, oncogenic sequence in the 
AKT8 transforming retrovirus[1]. A few years later, three distinct research groups 
identified the cellular homolog of this oncogene as a 57 kDa serine and threonine 
protein kinase, which is related to Protein Kinase A (PKA) and Protein Kinase C 
(PKC). As all creative protein names were apparently already taken, this novel 
kinase was named ‘Related to A- and C-Protein Kinase’ (RAC-PK), ‘Protein Kinase 
B’ (PKB) or ‘Protein Kinase AKT’[2–4]. Mammalian genomes code for three AKT/PKB 
isoforms: AKT1/PKBα, AKT2/PKBβ and AKT3/PKBγ[1,5]. These isoforms are 
encoded by separate genes located on different chromosomes and the human AKT 
isoforms share 77-83% sequence identity in pairwise alignments. At least one 
isoform is expressed in each tissue[4]. Overall, AKT1 is the most predominantly 
expressed isoform, AKT2 is most abundant in tissues affected by insulin, while 
AKT3 is mainly expressed in the brain[6]. As a protein kinase, AKT regulates the 
function of a wide array of proteins by phosphorylation of Serine (Ser) or Threonine 
(Thr) amino acids. 
 
The discovery that AKT is activated downstream of growth factor receptors and 
promotes cell survival has made it a prime target for cancer therapy[7]. Indeed, AKT 
is one of the most frequently hyperactivated kinases in cancer cells[8,9]. Over the 
past three decades, a staggering amount of research has been performed to 
elucidate the role of this kinase family and it is still a hot topic. A search in Web of 
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Science for articles that contain ‘AKT’ or ‘Protein Kinase B’ in their title yields 2,266 
research articles published in 2020 alone[10]. So, we already know quite a bit about 
the AKT kinases but, as is often the case, many answers raise new questions. The 
AKT pathway has proven to be a complex and convoluted signalling cascade. 
 Structure of the AKT kinase family 
In biochemistry, structure determines function. The three-dimensional structure of 
a protein is determined by which fold is adopted by the amino acid sequence or 
primary structure. If the structure of a protein has been resolved (through X-ray 
Crystallography, Cryo-EM or NMR) or one knows which protein domains are 
included in a protein, some extrapolations on protein function can be made[11,12]. 
But often the sum is greater than its parts. There are several AKT1 and AKT2 3-D 
structures available in the Protein Data Bank, and the information they provide goes 
a long way towards understanding how AKT works and what it can do. 
 
The AKT isoforms range in length from 479 to 481 amino acids and share the 
same basic blueprint: each isoform has an N-terminal Pleckstrin Homology (PH) 
domain which is connected to the protein kinase domain by a linker region and, 
finally, a C-terminal regulatory domain (Figure 1)[6]. Overall, the isoforms have up 
to 83% amino acid sequence identity, but this differs greatly between domains. The 
protein kinase-, PH- and regulatory-domains have the highest sequence identity, 
while the sequence of the linker regions diverges much more. Each protein domain 




Figure 1 The AKT kinase family. A: Schematic representation of AKT. All AKT 
isoforms are constructed from the same modules: an N-terminal PH domain 
followed by a linker (L), a central protein kinase domain and a C-terminal 
regulatory domain (REG). The numbers below the domains indicate the 
amino acid residues that form the boundaries of a domain for a specific AKT 
isoform. The amino acid residues indicated in bold red are critical post-
translational modification sites involved in the activation of the kinase. B: 
Sequence identity. The amino acid sequence of each AKT isoform was 
obtained from UniProtKB (accession numbers P31749, P31751 and 
Q9Y243 for AKT1, AKT2 and AKT3, respectively), aligned using NCBI 
BLAST and visualized using NCBI MSA. Amino acid matches are shown in 
grey, mismatches in red. The sequence identity from pairwise alignments is 
shown for the whole proteins and for each domain separately. The protein 
kinase domain has the highest amount of matches, closely followed by the 
PH and regulatory domains, but the sequence of the linker region diverges 
quite a lot. 
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1.2.1 The AKT Pleckstrin Homology domain 
A PH domain is a protein fold of approximately 120 amino acids and can be found 
in a wide range of human proteins1 involved in cell signalling or that are part of the 
cytoskeleton. This protein domain serves as a scaffold for protein-lipid and protein-
protein interactions[13–15]. 
 
In general, the PH domains from unrelated proteins have low sequence identity, 
yet their three-dimensional structure is highly conserved[16]. The standard PH 
domain fold consists of seven β-strands forming two perpendicular anti-parallel β-
sheets, capped at one end with a C-terminal α-helix (Figure 2). The loops which 
connect individual β-strands on the opposite side from the α-helix are highly 
variable in sequence and length[17,18]. These variable loops form a positively 
charged surface that constitutes the binding site for negatively charged 
phosphatidylinositol (PI) lipids. Not all PH domains can bind PIs and some only do 
so with low affinity and little specificity[19]. Although the protein- and lipid-interaction 
sites are distinct, it is not clear whether PH domains contain a single dedicated 
protein interaction site[20,21]. The AKT PH domains belong to a subgroup that binds 
phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) and phosphatidylinositol 
(3,4,5)-trisphosphate (PI(3,4,5)P3 or PIP3) with high affinity and specificity[19]. 
 
Figure 2 (Caption opposite). 
  
 
                                           
1 At least 288 human proteins contain a Pleckstrin Homology domain[516]. 
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Figure 2 (Opposite). Ribbon diagram of the AKT1 PH domain structure in 
complex with Ins(1,3,4,5)P4. A: β-strands are shown in orange, the C-
terminal α-helix in green and the flexible loops (L1, L2 and L3) which are 
involved in lipid binding are colored blue and numbered according to the 
sequence in which they occur from N- to C-terminus. Ins(1,3,4,5)P4 is bound 
to the flexible loops. B: 90° counter clockwise rotation of A. Hydrogen bond 
interactions between the AKT1 PH domain and Ins(1,3,4,5)P4 are shown as 
dashed lines, the side-chains of amino acids that participate in the reaction 
are shown and colored magenta. Image of PDB 1H10 created in PyMOL[22]. 
The PH domain plays an important role in the regulation of AKT activity. In fact, 
it inhibits AKT catalytic activity. The interaction of the AKT PH domain with the 
kinase domain locks AKT in an inactive conformation as shown by both molecular 
modelling and X-ray crystallography[23–25]. The binding of the AKT PH domain to 
PI(3,4)P2 or PI(3,4,5)P3 induces a conformational change in AKT: a shift from “PH-
in” to “PH-out” where the PH domain disengages from the protein kinase domain. 
This alleviates the auto-inhibitory effect of the PH domain interaction and recruits 
AKT to the membrane for activation[23,24]. 
 
When expressed as an isolated domain, the AKT2 PH domain interacts with the 
second messengers2 PI(3,4)P2 and PI(3,4,5)P3 embedded in lipid vesicles with a 
KD3 of 220 ± 30 nM and 440 ± 50 nM, respectively[26–28]. The PH domains of AKT1 
and AKT3 have slightly lower affinity for those PIs and all isolated PH domains have 
an approximately twofold higher affinity for PI(3,4)P2 over PI(3,4,5)P3[29,30]. The 
importance of the 3’-phosphate group for interaction with AKT PH domains is 
explained by the crystal structure of the AKT1 PH domain bound to Inositol 
(1,3,4,5)-tetrakisphosphate (Ins(1,3,4,5)P4) which revealed that the variable loops 
of the AKT1 PH domain form most interactions with the 3’- and 4’-phosphate 
groups, few interactions with the 1’- and none with 5’-phosphate groups (Figure 2B 
and Figure 5)[22]. But this does not explain why the isolated PH domains 
preferentially interact with PI(3,4)P2. 
A mutation which is frequently observed in cancer, Glutamic acid (Glu) 17 to 
Lysine (Lys) of the AKT1 PH domain increases its affinity for phosphatidylinositol 
 
                                           
2 Second messengers are intracellular signaling molecules generated in response to exposure to 
extracellular signaling molecules (the first messengers). In the PI3K/AKT pathway the second 
messengers are lipids confined to membranes, but second messengers are very diverse. Nucleotides, 
gasses (nitric oxide, carbon monoxide) and inorganic ions (Ca2+) are other examples of second 
messengers. 
 
3 The KD or dissociation constant is the ratio of an interaction off-rate and on-rate (koff/kon). This unit is 
used to describe the affinity of a non-convalent interaction between a protein and ligand (lipid, 
nucleotide, small-molecule, protein, …). Lower values indicate higher affinity. 
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(4,5)-bisphosphate (PI(4,5)P2). This mutation induces a structural shift that favours 
the PH-out conformation, constitutive membrane localization and an uncontrolled 
increase in AKT1 activity[25,31]. 
In addition to its role in AKT activation, the PH-domain also contains sites for 
interaction with proteins, such as GRB10 and RASAL1, that regulate AKT 
activity[21]. 
1.2.2 Unstructured linker 
The linker region, which connects the PH domain to the catalytic domain, is poorly 
conserved between AKT isoforms (Figure 1). With a length of only 42, 44 and 41 
amino acids for AKT1, AKT2 and AKT3, it is also the smallest of the building blocks 
that constitute an AKT isoform. As its name implies, the exact three-dimensional 
structure of this domain is unknown. Due to its flexibility, the linker region is either 
not or, at best, partly modelled in AKT crystal structures[25,32,33]. 
 
Because of the low sequence identity, the influence of the linker region differs 
somewhat between isoforms. For example, it determines which PIs are 
preferentially bound by an AKT isoform. Although all isolated AKT PH domains 
have a clear selectivity for PI(3,4)P2 over PI(3,4,5)P3, the opposite is true for full-
length AKT1 and AKT3. It was found that, replacing the linker region of AKT1 or 
AKT3 with that from AKT2, reverses this. As some PIs are enriched on specific 
cellular membranes this has implications for the subcellular localization of the AKT 
isoforms[30,34]. 
This small peptide also plays a role in protein-protein interactions. The Actin 
bundling protein PALLADIN only interacts with AKT1, but a chimeric4 AKT2, where 
the linker region has been swapped with that from AKT1, can bind and also 
phosphorylate PALLADIN[35]. As such, the linker region plays an important part in 
the selective localization of the AKT isoforms to specific membranes and the 
phosphorylation of specific substrates[30,36]. This domain also contains several post-
translational modification (PTM) sites, not all of which are conserved in each 
isoform. The AKT2 linker region contains a Cysteine (Cys) residue, that if oxidised 
by reactive oxygen species (ROS) reduces AKT2 activity[37]. 
 
                                           
4 A chimeric protein is an artificially designed fusion protein that contains domains from seperate 
proteins or is a combination of whole proteins. This nomenclature originates in Greek mythology where 




1.2.3 The protein kinase domain 
The AKT family belongs to the AGC kinase group, which contains around 60 
members of the human kinome[38]. This grouping is based purely on the sequence 
similarity of their catalytic domains, so not only do the catalytic domains of the AKT 
family share up to 91% sequence identity, they are also closely related to those 
from other members of the AGC kinase group such as PKA (43%), PKC (49%), 
RSK (46%) and SGK (54%)[38–40]. A sequence identity of around 50% might seem 
low, but proteins with a sequence identity above 35-40% are highly likely to have 
similar three-dimensional structures[41]. 
 
The AKT catalytic domain has a typical bilobal structure with a small amino-
terminal lobe (N-lobe) that consists of a five-stranded antiparallel β-sheet and a 
larger carboxy-terminal lobe (C-lobe) which mostly consists of α-helices 
(Figure 3)[39,40]. The ATP-binding pocket is located in a cleft between lobes. 
Many AGC kinases, including the AKT family, require phosphorylation of two 
amino acid residues in order to become active. One such site is located in the 
activation loop of the catalytic domain (Thr308, Thr309 and Thr305 for AKT1, AKT2 
and AKT3, respectively), the second site is found in the hydrophobic motif of the 
regulatory domain. The AKT activation loop is located in the C-lobe, next to the 
ATP-binding pocket. In un-phosphorylated AKT, the αC-helix, which connects the 
N-lobe and the C-lobe, is disordered, the ATP-binding pocket is inaccessible and 
the substrate binding site is blocked. This is AKT in a catalytically inactive state. 
Phosphorylation of the activation loop induces a disorder-to-order shift in the 
catalytic domain resulting in the correct alignment of the residues involved in 





Figure 3 Structure of activated AKT2. Amino acid residues 146-481 of AKT2 with a 
S474→D substitution to mimic S474 phosphorylation. The protein is in a 
complex with a peptide derived from an AKT substrate (GSK3β, 
GRPRTTSFAE, green) and AMP-PNP (a non-hydrolysable ATP analogue, 
cyan). Critical modification sites for kinase activation (Thr309 and Asp474) 
are shown in red, the αC-Helix in dark green and the (partial) C-terminal 
regulatory domain in blue. Structure from PDB 1O6K[39] modified in 
PyMOL. 
1.2.4 The C-terminal regulatory domain 
The regulatory domain can either inhibit or stimulate AKT activity depending on the 
conformation of the protein as a whole. In the PH-in conformation it folds back onto 
the kinase domain and interacts with the PH domain, further stabilizing this inactive 
conformation[43–45]. This interaction is disrupted when the PH domain binds PIs or 
the hydrophobic motif (HM) is phosphorylated. 
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This motif (F-P-Q-F-S-Y), which is found in the C-terminal regulatory domain of 
all AKT isoforms, holds the second phosphorylation site (Ser473, Ser474 and 
Ser472 for AKT1, AKT2 and AKT3, respectively) required for full AKT activation 
(Figure 3). The negative charge introduced by phosphorylation increases 
association of the HM with a hydrophobic groove within the AKT N-lobe near the 
αC-helix. This allosteric activation site only exists when the activation loop is 
phosphorylated, and binding of the HM to this site re-aligns catalytic residues by 
stabilizing the ordered αC-helix in the active conformation[39,40,43]. 
 The canonical AKT signalling cascade 
Through transmembrane receptors, cells can sense changes in their environment 
and initiate a cascade of chemical reactions that enables them to respond to those 
changes or communicate with one another. For multicellular organisms, the 
coordination of cellular activities is essential and lies at the base of development, 
homeostasis, immunity or even the coordinated muscle movement that moves your 
eyes across this page. The dysregulation of signalling pathways can have major 
consequences for the well-being of an organism. 
 
AKT is a central node in the PI3K/AKT/mTOR pathway, a pathway that integrates 
many extracellular signals and regulates several cellular processes including, but 
not limited to, metabolism, cell proliferation, cell survival, protein synthesis, cell 
growth and cell migration[6,46]. As a master kinase in this pathway AKT controls the 
function of a diverse assortment of proteins through phosphorylation (Figure 4). 
Phosphorylation is one of the most frequently occurring PTMs and consists of 
the covalent addition of a phosphate group, from a donor such as ATP, to Ser, Thr, 
Tyr, His, Arg, Lys, Asp, Glu or Cys. Hydroxyl-group containing amino acids (Ser, 
Thr, Tyr) have long been considered the main form of phosphorylation signalling in 
humans, but a growing body of evidence suggest other ‘non canonical’ 
phosphorylations also occur, albeit at a lower frequency[47]. 
It has been shown that over two-thirds of all human proteins can be 
phosphorylated, but computational predictions suggest this type of PTM is much 
more prevalent. Since proteins can, and often do, contain multiple phosphorylation 
sites, 293,934 phosphorylation sites have been identified in the human proteome 
and another 672,883 putative sites are predicted by models. These data only 
include Ser, Thr and Tyr phosphorylation[48,49]. The addition of a phosphoryl group 
to an amino acid can activate, inactivate or otherwise modify the function, stability 
 
12 





Figure 4 The AKT pathway at a glance. The AKT signalling cascade starts with the 
activation of transmembrane receptors such as RTKs, GPCRs, and Integrin 
or cytokine receptors. The mechanisms differ, but this invariably results in 
activation of PI3K, which catalyzes the phosphorylation of the 3’ hydroxyl 
group of PI4,5P2, creating PIP3. The presence of PIP3 at the membrane 
attracts proteins containing a specific subtype of PH domain, such as AKT. 
At the membrane AKT is phosphorylated by PDK1, another membrane-
tethered kinase, on Thr309 (T309). This modification partially activates AKT 
and reduces its membrane localization. AKT is phosphorylated on a second 
site, Ser474 (S474) located in the hydrophobic motif by mTORC2. Doubly-
phosphorylated AKT is fully active and changes the activity, localisation, 
stability, … of a vast array of proteins through phosphorylation of serine or 
threonine amino acid residues. Through these substrates AKT controls 
multiple cellular processes including, but not limited to, metabolism, 
survival, growth, proliferation and protein synthesis. Signalling is 
terminated at several levels. PTEN antagonizes PI3K by catalyzing the 
dephosphorylation of PIP3 to form PI4,5P2, ending AKT recruitment to the 
plasma membrane. AKT itself is dephosphorylated and inactivated by PP2A 
and PHLPP1/2 on Thr309 and Ser474, respectively. Red arrows indicate an 
activating phosphorylation and red t-bars indicate an inhibiting 
phosphorylation. Based on the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) PI3K-AKT signalling pathway, created in BioRender.com[52]. 
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1.3.1 Upstream regulation of AKT: Phosphoinositide 3-kinase 
There are multiple signalling paths that converge on Phosphoinositide 3-Kinase 
(PI3K), resulting in the downstream activation of AKT (Figure 4). 
The binding of Growth Factor (GF) ligands to Receptor Tyrosine Kinases (RTKs) 
such as the epidermal growth factor receptor (EGFR), receptor tyrosine-protein 
kinase erbB-2 (HER2), receptor tyrosine-protein kinase erbB3 (HER3), insulin 
receptor (INSR) and insulin-like growth factor receptor (IGF-1R) leads to 
multimerization and autophosphorylation of the intracellular segment of the 
receptor and/or phosphorylation of adapter proteins such as the insulin receptor 
substrate 1/2 (IRS-1/2) and GRB2-associated-binding protein 1/2 (GAB1/2)[53]. The 
generated phosphotyrosine residues are docking sites for proteins containing SH25 
domains[54,55]. A similar event occurs downstream of cytokine receptor activation[56]. 
Alternatively, a ligand such as lysophosphatidic acid, binding to the extracellular 
part of a G-Protein Coupled Receptor (GPCR) activates its Guanine Nucleotide 
Exchange Factor domain[57,58]. This exchanges the Guanosine Diphosphate in the 
α-subunit of the heterotrimeric G-protein for Guanosine Triphosphate. Then, the α-
subunit dissociates from the βγ-complex enabling both to propagate downstream 
signalling by (in)activating proteins, including PI3K[59–61]. In addition to growth 
factors and cytokines, cell-matrix- or cell-cell-adhesion can, through Integrin, recruit 
Focal Adhesion Kinase (FAK) to focal adhesions where it is activated through 
autophosphorylation[62,63]. These are some examples of events that lead to the 
activation of PI3K. 
 
PI3Ks are a family of lipid kinases that phosphorylate the 3’-OH position of the 
PI inositol head group (Figure 5). Based on their structure and substrate specificity, 
this family is subdivided into three classes: PI3K class I, II and III[55,61,64–66]. Class I 
PI3Ks, which catalyze the next step in AKT activation, is made up of classes IA and 
IB. Class IA are heterodimers consisting of a catalytic (p110α, p110β and p110δ) 
and a regulatory subunit (p85α, p85β, p55α, p55γ and p50α) that are activated 
downstream of RTKs, cytokine receptors and FAK[63]. The interaction between the 
catalytic and regulatory subunit keeps the complex in an inactive state, localized to 
the cytosol. The regulatory subunits contain an SH2 domain that can interact with 
phosphorylated Tyr motifs generated by, for example, RTKs. This recruits Class IA 
PI3Ks to the membrane, in proximity of their substrate and allows catalytic activity. 
Class IB is activated by the G βγ-complex downstream of GPCRs and consists of a 
 
                                           
5 SH2 or SRC Homology 2 domains are structurally conserved protein domains that can dock to 
phosphorylated tyrosine residues. This type of domain is frequently found in adapter proteins that play 
a part in RTK signalling[517]. 
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p110γ catalytic subunit that forms a heterodimer with either a p84 or a p101 
regulatory subunit. Both class IA and IB catalytic subunits can also be activated by 
membrane-bound small GTPases such as RAS, RAC1 and CDC42. 
Class I PI3Ks phosphorylate PI(4,5)P2 to produce PI(3,4,5)P3, which can be 
metabolized to PI(3,4)P2 by the 5’ lipid phosphatase SHIP1/2[55,66] (Figure 5). Under 
basal conditions, PI(3,4)P2 and PI(3,4,5)P3 represent <0.1% and <0.05% of the 
total PIs in human cells, respectively. Within the first seconds to minutes after a cell 
is stimulated by GFs, PI3K activity can be detected as an increase in PI(3,4)P2 and 
PI(3,4,5)P3 levels that peaks within the hour at a 100-fold increase compared to 
basal conditions. PI(3,4,5)P3 is mainly located in the Plasma Membrane (PM) while 
PI(3,4)P2 can also be found in endosomal membranes[67]. These second 
messengers, produced by PI3K, create docking sites at membranes for proteins 
containing a specific subtype of PH domain (cfr. 1.2.1). 
 
Cell signalling has to be kept in check to maintain homeostasis. Therefore, all 
signalling pathways contain built-in mechanisms responsible for shutting down the 
signalling cascade. Transmembrane receptors are uncoupled from the pathway by 
internalization or dephosphorylation; the lipid phosphatases Phosphatase and 
Tensin Homologue (PTEN) or TPTE2 antagonize PI3K by dephosphorylating the 
3’ group of PI(3,4,5)P3 or PI(3,4)P2 to regenerate PI(4,5)P2 or Phosphatidylinositol 
4-phosphate (PI(4)P) and inositol polyphosphate-4-phosphatase type II (INPP4B) 
converts PI(3,4)P2 to Phosphatidylinositol 3-phosphate (PI(3)P)[55,68] (Figure 5). 
This terminates the membrane recruitment and activation of AKT. The timeframe 
for PI(3,4,5)P3 downregulation is highly dependent on the cell type[67,69,70]. 
Interestingly, the PI3K regulatory subunit p85α, reportedly binds to PTEN and 





Figure 5 Phosphoinositides involved in the PI3K/AKT signalling pathway. 
Phosphatidylinositol, the precursor of all phosphoinositides is built from a 
glycerol backbone, two fatty acid chains (stearic acid and arachidonic acid) 
for insertion into membranes and a phosphate group substituted with an 
inositol[28]. PI(4,5)P2 (upper left) is the most abundant PI derivative and is 
produced by sequential phosphorylation of PI to PI(4)P and then to 
PI(4,5)P2. Activated PI3K phosphorylates the 3’ position of the inositol ring 
and creates PI(3,4,5)P3. From here on, two reactions are relevant for AKT 
signalling. PTEN dephosphorylates the 3’ group of both PI(3,4,5)P3 and 
PI(3,4)P2. As the AKT PH domain can bind both PI(3,4,5)P3 and PI(3,4)P2, 
PTEN plays a very important role in down-regulating AKT activation. 
PI(3,4)P2 is generated by SHIP1/2, mainly at endosomes and is implicated 
in the endosomal location of the AKT2 isoform. At the endosomal membrane 
INPP4B can metabolize PI(3,4)P2 to PI(3)P, ending AKT2 recruitment to that 
subcellular location. Created in Chemdraw and Biorender.com. 
1.3.2 AKT activation and inactivation (Have you tried turning it Off and On 
again?) 
AKT is subject to a tight auto-inhibition that keeps the kinase in an inactive state. 
In the inactive ‘PH-in’ conformation, the 3-phosphoinositide-dependent protein 
kinase 1 (PDK1) cannot access the activation loop (Figure 6)[23]. The interaction of 
the PH domain with the kinase domain displaces the αC-helix, L3 of the PH domain 
occupies the position of the phosphorylated activation loop and a residue from that 
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same loop, Trp80, inserts into a cleft in the kinase domain creating a cavity that 
positions residues from the HM near Trp80[23–25,40,44,45]. 
 
The translocation of AKT to membranes containing PI(3,4)P2 and PI(3,4,5)P3, 
which is the first step in AKT activation, is mediated by the PH domain (Figure 4 
and Figure 5)[72]. The accumulation of AKT at the PM is transient, peaks at around 
5 minutes after GF stimulation and lasts up to 20 minutes[73,74]. This interaction 
induces a conformational shift (PH-in to PH-out) that abolishes the inhibitory effect 
of the PH domain on the kinase domain by exposing the phosphorylation site in the 
activation loop (Thr308, Thr309 and Thr305 for AKT1, AKT2 and AKT3). This 
enables phosphorylation of this site by PDK1, another member of the AGC kinase 
group. This modification enhances AKT activity by 100-fold, which is still only a 
fraction (~10%) of its maximum catalytic potential[7,13,42,75,76]. 
 
Figure 6 AKT conformations. The PH-in or inactive conformation is shown on the 
left. Here, the activation loop is inaccessible for PDK1 and Trp80 in loop 3 
of the PH domain inserts into a cleft in the catalytic domain and blocks the 
correct orientation of the activation loop. The same residue also interacts 
with residues from the HM (green) effectively locking AKT in this inactive 
conformation. The interaction with PIP3 induces a conformational shift to the 
PH-out conformation. This exposes the activation loop for phosphorylation 
by PDK1. Active AKT, with both sites phosphorylated and the disengaged 
PH domain is shown on the right. 
Full activation of AKT requires the additional phosphorylation of a Ser residue, 
located in the HM, that acts in synergy to increase AKT catalytic activity by another 
7-10-fold[43,77]. Mechanistic Target of Rapamycin Complex 2 (mTORC2), a protein 
complex defined by mechanistic target of rapamycin (mTOR), MAPKAP1/SIN1, 
RICTOR, MLST8 and PRR5 was identified as the primary kinase complex that 
phosphorylates the AKT hydrophobic motif (Ser473, Ser474 and Ser472 for AKT1, 
AKT2 and AKT3) but it has been reported that, in response to DNA damage, AKT1 
S473 can also be phosphorylated by DNA-PK[78]. Although this modification is not 
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essential for AKT activity, it stabilizes AKT in its active conformation and increases 
the catalytic activity by up to an order of magnitude[6,77]. 
 
Thus, AKT activation involves interaction of the PH domain with membrane-
tethered PIs, a shift in conformation and subsequent phosphorylation of the 
activation loop and hydrophobic motif. The phosphorylation of the activation loop 
appears to be dominant as phosphorylation of the HM alone only results in a minor 
increase in catalytic activity which may not suffice to propagate AKT signalling in 
cells[79]. Along this line, the use of non-phosphorylatable AKT mutants has shown 
that Thr308Ala has no catalytic activity, while mutation of the HM (Ser473Ala) did 
not completely abolish catalytic activity[72,80]. 
As is the case with other kinases of the AGC kinase group, both modifications 
could be interdependent, but the reports on the order of modification are conflicting. 
Phosphorylation of the HM could disrupt its interaction with Trp80 of the PH domain, 
and would allow the PH domain to disengage from the kinase domain after binding 
PIP3. These reports indicate that HM phosphorylation stimulates the transition to 
the PH-out conformation where the activation loop is exposed[23,24,45]. This is 
supported by the observation that, in some cases, a phosphomimetic6 mutation of 
the Ser residue in the AKT HM to Aspartic acid (Asp) led to increased 
phosphorylation of the activation loop. However, this was not observed in all studies 
that make use of AKT with phosphomimetic mutations[39,40,77,81,82].  
On the other hand, the three-dimensional structures of inactive and active AKT 
show that the hydrophobic groove, where the HM interacts with the kinase domain, 
only exists in the active state when the activation loop is phosphorylated[39,83]. Thus, 
even if phosphorylation of the HM can occur before phosphorylation of the 
activation loop, there would be no groove where the HM can bind and no active 
structure to stabilize. This would argue that phosphorylation of the activation loop 
is a requirement for the HM to exert its stimulating effect on AKT catalytic activity. 
 
Phosphorylation of the activation loop, but not the HM, reduces the affinity of 
AKT for PI(3,4,5)P3-containing membranes and results in the dissociation of AKT 
from the PM. This could be due to the re-engagement of the PH domain to a site 
 
                                           
6 Phosphomimetics involves the replacement of an amino acid that can be phosphorylated by a 
naturally occurring amino acid that structurally resembles the phosphorylated original amino acid. For 
example, an aspartic acid can be used to mimic a phosphorylated serine. There is some controversy on 
the use of phosphomimetics as the carboxylate of Asp and Glu has less electronegativity, a smaller 
hydration sphere and volume compared to a phosphate. In the case of AKT the use of phosphomimetics 




on the phosphorylated AKT kinase domain that is distinct from the interaction site 
in the PH-in conformation[23,44]. Consequently, AKT has a far shorter retention time 
at the PM compared to the presence of its anchors, PI(3,4,5)P3 or PI(4,5)P2[23,84]. 
However, tracking AKT and its activity by using fluorescent reporters in cells, 
showed that AKT has a slower diffusion speed than can be expected for a protein 
of that size, indicating that a subpopulation of activated AKT transiently re-engages 
PIs on the PM or endomembranes after activation[73,85]. This binding-and-release is 
rate-limiting for AKT inactivation and explains how AKT phosphorylation is 
sustained far longer (>60 minutes) than the initial translocation to the PM, as 
engagement of the PH domain by PI(3,4,5)P3 also protects AKT from 
dephosphorylation. This closely couples AKT activity to the activity of PI3K and its 
antagonists such as PTEN[73]. 
 
Phosphorylated AKT in the cytoplasm is rather short-lived. Phosphatases such 
as protein phosphatase 2A (PP2A) and PH domain leucine-rich repeat protein 
phosphatase (PHLPP1/2) terminate AKT activity by dephosphorylation of the 
activation loop (Thr309) and HM (Ser474), respectively[74,86]. After roughly 30 
seconds, the amount of phosphorylated AKT in the cytoplasm is reduced by half[87–
89]. These phosphatases control the amplitude of AKT signalling, a depletion of 
PHLPP1/2 causes a drastic increase in both the level and duration of AKT 
phosphorylation. In Hs578Bst cells, the effect of Epidermal Growth Factor (EGF) 
stimulation in PHLPP1/2 depleted cells was increased by 30-fold and AKT 
phosphorylation was sustained for much longer (up to 24 hours instead of 1 hour). 
Although it took much longer, AKT phosphorylation did diminish to basal levels 
while AKT expression remained stable. As AKT associates with Heat-shock protein 
90 (HSP90) in the cytoplasm, and has a half-life of up to 36 hours this suggests the 
existence of additional phosphatases that control AKT activity[86,90]. 
1.3.3 Downstream of AKT (It’s all downhill from here) 
AKT phosphorylates Ser and Thr amino acid residues in substrates (proteins) that 
contain the minimal consensus motif R-X-R-X-X-S/T-B (where “X” can be any 
amino acid and “B” is a bulky, hydrophobic amino acid) (Figure 7). This consensus 
sequence is highly similar to that of PKC, but unlike PKC, AKT has a preference 
for a Thr before (-2) and residues that form tight turns in the protein backbone after 
(+2) the modification site (0)[91]. The mere presence of this sequence motif in a 
protein does not make it an AKT substrate by default. This sequence can be found 
in thousands of proteins but accessibility, interaction with AKT (directly or through 
adapters) and subcellular compartmentalisation are all factors that determine 
whether AKT can truly modify a protein[6]. PhosphoSitePlus® reports 232 AKT 
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substrates, but these are not necessarily exclusive to AKT. A site modified by AKT 
could, in other cell types or under other conditions, be phosphorylated by other 
protein kinases. 
 
There are quite a few AKT substrates and I need to stress that, the cellular 
processes, mechanisms and substrates discussed next are by no means an 
exhaustive list of AKT signalling in cells, but rather a select few that are relevant to 
the results discussed later in my thesis[6,46]. 
 
Figure 7 AKT substrate sequence logo. Amino acid frequency for known AKT1, 
AKT2 and AKT3 substrates centered on the PTM site (0). The logo indicates 
a clear preference for arginine (R) at -3 and -5, a Thr at -2 and amino acids 
that can form tight turns (Ser, Gly and Thr) at +2. Residues below the x-axis 
are under-represented at that position based on the total frequency of that 
amino acid in AKT substrate sequences. This figure was generated based 
on 372 input sequences (some proteins contain more than one AKT 
substrate site) from PhosphoSitePlus®[49]. 
 Cell survival (to be, or not to be)  
Maintaining the balance between cell death and survival is essential for multicellular 
organisms and dysregulation of these processes is associated with disease. 
Certain events, such as excessive DNA damage or GF withdrawal, can lead to the 
elimination of the compromised cell through apoptosis[92–95]. 
 
The B-cell lymphoma-2 (BCL-2) protein family, which has both pro-apoptotic 
(BAX, BAK, BIM and BAD) and anti-apoptotic (BCL-2, BCL-XL and BCL-w) 
members, plays an integral role in regulating apoptosis. The intricate equilibrium in 
relative abundance of pro- and anti-apoptotic BCL-2 proteins determines the fate 
of a cell. When that balance tilts towards pro-apoptosis, BAX and BAK will 
oligomerize and create pores in the outer membrane of the mitochondria. This 
results in the release of pro-apoptotic factors, such as Cytochrome c, into the 
cytoplasm. These bind APAF-1, thereby inducing multimerization and assembly of 
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the apoptosome, leading to caspase-9 activation (Figure 8). This starts a cascade 
of caspase activation, culminating in active executioner caspases 3 and 7, which 
commits the cell to apoptosis[93,96]. 
 
The AKT signalling pathway is well established as one of the most important 
pathways that promotes cell survival (Figure 8). The introduction of constitutively 
active AKT blocks apoptosis in cells exposed to apoptotic stimuli (GF withdrawal, 
UV irradiation, TGFβ)[97]. 
The pro-apoptotic BAD, which binds and inactivates BCL-2, BCL-XL and BCL-w, 
is a direct AKT substrate. Phosphorylation of BAD Ser99 by AKT causes BAD to 
dissociate from the anti-apoptotic BCL-2 proteins. It also creates an interaction site 
for 14-3-3 proteins7 which sequester BAD in the cytoplasm[96–99]. By displacing BAD 
from its targets at the mitochondria, AKT activity tilts the balance towards cell 
survival. However, AKT activity can still prevent apoptosis even after the release of 
Cytochrome c from the mitochondria. This is possible because AKT also affects the 
function of proteins such as Caspase-9 and p53, which function further downstream 
in the apoptosis pathway. Caspase-9, an initiator caspase, is inhibited by AKT 
through phoshorylation of Ser196[100]. p53, the guardian of the genome, regulates 
the cell’s response to stress and damage. When the damage is too great, p53 will 
act as a transcriptional activator for pro-apoptotic genes. To prevent p53 activity in 
healthy cells, Murine Double Minute 2 (MDM2) induces ubiquitination and the 
subsequent proteasomal degradation of p53. AKT interacts with MDM2 and 
phosphorylates Ser166 and Ser186, stimulating its activity[101–103]. 
 
Apart from directly influencing the activity of proteins in the apoptosis pathway, 
AKT also regulates the transcription of numerous pro- and anti-apoptotic proteins. 
In the absence of GFs and AKT activity, the Forkhead Box O (FOXO) family of 
transcription factors translocates to the nucleus. There, they induce transcription of 
the pro-apoptotic BIM, BNIP3 and PUMA, and suppress expression of the anti-
apoptotic BCL-XL through upregulation of BCL-6[104–107]. AKT phosphorylates 
FOXO1, FOXO3 and FOXO4 at three residues (Thr24, Ser256 and Ser319 for 
FOXO1). These phosphorylations occur in the nucleus and enable interaction with 
14-3-3 proteins that displaces the FOXO transcription factors from their target 
genes. This is followed by cytoplasmatic retention and proteasomal degradation of 
 
                                           
7 14-3-3 proteins are a protein family consisting of seven structurally similar isoforms expressed by 
different genes. These proteins can interact with phosphorylated serines or threonines within an R-X-X-
pS/T-X-P sequence. The interaction of a 14-3-3 protein with its target can influence protein localization, 




the FOXO transcription factors[108]. NF-κB is another transcription factor, but for 
anti-apoptotic genes such as BCL-XL. AKT stimulates NF-κB, through 
phosphorylation of IKKα Thr23, inducing degradation of the inhibitor of NF-κB, IκB. 
Additionally, IKKβ, the second part of the IKK complex, also phosphorylates and 
inactivates FOXO3[97,109]. 
AKT activity promotes cell survival through inhibition of several pro-apoptotic 





Figure 8 AKT regulation of cell survival. AKT phosphorylates and inactivates 
FOXO transcription factors, reducing the transcription of pro-apoptotic 
proteins such as BCL-6, BIM and PUMA. Phosphorylation of the pro-
apoptotic BAD by AKT leads to its cytosolic sequestration where it can no 
longer antagonize BCL-XL and BCL-2. AKT also enables activity of NF-κB, 
a transcription factor for anti-apoptotic genes. These events ensure the 
availability of BCL-XL and BCL-2 to inhibit the pro-apoptotic BAX and BAK. 
This prevents permeabilization of the mitochondrial membrane, release of 
Cytochrome C and assembly of the apoptosome. p53 is inhibited by AKT 
through phosphorylation of MDM2, and AKT directly phosphorylates and 
inhibits Caspase-9. Proteins with anti-apoptotic effects are coloured green, 
those with pro-apoptotic effects red. Transcription factors are grey and 
brown for anti- and pro-apoptotic effects of their targets, respectively. A 
mitochondrion is drawn in green. Activating and inactivating phosphorylation 
are indicated through red arrows and t-bars, respectively. Inhibitory 
interactions are shown as red lines with a dot as head and tail. Based on the 




 Cell cycle regulation (This is getting out of hand, now there are two of them!) 
The mammalian cell cycle is a tightly regulated process that entails the growth of 
the parent cell, duplication of its DNA and subsequent division into two daughter 
cells. Quiescent cells are not actively cycling but, unlike differentiated or senescent 
cells, they can still enter the cell cycle. These cells are said to be in the resting or 
Gap 0 (G0) phase. The cell cycle itself can be subdivided into four distinct phases: 
Gap 1 (G1), Synthesis (S), Gap 2 (G2) and Mitosis (M)[110,111]. The G1 phase is, in 
essence, a growth phase with two restriction points, one GF-sensing and the 
second nutrient-sensing which determine whether the cell will commit to the cell 
cycle or re-enter G0[112]. The genetic material is duplicated during the S phase, the 
G2 phase is a second growth phase that is followed by the M phase which ends 
with separation of the chromosomes into two separate nuclei and cell division[113]. 
The transition between each of these phases is promoted by specific Cyclin-
Dependent Kinases (CDKs) which are, in turn, dependent on cell cycle checkpoint 
pathways. These control mechanisms ensure that a cell is undamaged and ready 
to enter the next stage of the cell cycle[110]. 
 
AKT drives the G1- to S-phase transition and the G2- to M-phase transition, 
either by direct phosphorylation of multiple proteins related to cell cycle 
progression, or by regulating their expression levels (Figure 9)[114,115]. AKT controls 
the stability of Cyclin D1, a G1 phase cyclin, through phosphorylation of Glycogen 
Synthase Kinase 3β (GSK3β) Ser9. GSK3β is constitutively active and 
phosphorylates Cyclin D1 Thr286, resulting in its export from the nucleus and 
proteolytic degradation[114–117]. The modification of GSK3β Ser9 by AKT is 
inhibitory, thus AKT ensures the presence of Cyclin D1 in the nucleus where it 
complexes with and activates CDK4 and CDK6. These complexes phosphorylate 
Retinoblastoma-Associated Protein (RB1), alleviating RB1’s inhibitory effect on the 
transcription of multiple genes essential for the G1- to S-phase transition, DNA 
synthesis and subsequent cell cycle phases[118,119]. In addition to indirectly 
regulating Cyclin D1 stability, AKT also up-regulates the expression of Cyclin D1 
through phosphorylation of FOXO3 and FOXO4[120]. 
Two members of the CDK inhibitor family, p21Cip1/WAF1 (CDKN1A) and p27Kip1 
(CDKN1B) are directly regulated by AKT through phosphorylation. p21Cip1/WAF1, 
which inhibits the activity of both CDK2 and CDK4 is phosphorylated by AKT on 
Thr145, a site located within the Nuclear Localization Sequence (NLS). This 
decreases the affinity of p21Cip1/WAF1 for CDK2 and CDK4, and triggers cytoplasmic 
retention through interaction with 14-3-3 proteins [101,121–125]. A second site modified 
by AKT, Ser 146, increases the stability of the protein and changes the function of 
p21Cip1/WAF1 to an enhancer of Cyclin D1-CDK4/6 complex stability[121,126]. p27Kip1 
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localization is regulated in the same manner: AKT phosphorylates the p27Kip1 NLS 
at Thr157. For p27Kip1, there are two additional AKT phosphorylation sites (Ser10 
and Thr198) that result in cytoplasmic accumulation when modified[115]. As is the 
case for proteins involved in cell survival and Cyclin D1, the expression of 
p21Cip1/WAF1 and p27Kip1 is also regulated by AKT through phosphorylation of 
FOXO1/3/4 transcription factors[120]. A checkpoint at the end of the G1-phase 
ensures that the cell’s DNA is intact and ready to be duplicated, if not, p53 will put 
a stop to cell cycle progression. As mentioned in paragraph 1.3.3.1, AKT regulates 
p53 through MDM2 phosphorylation. 
The role of AKT in G1- to S-phase progression is well established, but there is 
less consensus on the role of AKT in the G2- to M-phase transition. There are 
indications that AKT can phosphorylate several proteins (CDC25B, WEE1, 
PKMYT1 and possibly also CDK2) to promote mitosis[127]. 
 
AKT activity regulates the activity, localization and expression levels of multiple 
proteins involved in the G1- to S-phase transition and possibly also the G2- to M-
phase transition. 
 
Figure 9 AKT activity promotes G1-to-S phase transition. AKT phosphorylates 
and inactivates three proteins that inhibit cell cycle progression: GSK3β, p21 
and p27. By inactivating FOXO transcription factors it also reduces the 
expression of p21 and p27 while up-regulating Cyclin D1 expression. AKT 
activation ensures Cyclin D1-CDK4/6 and CDK2 activity at the appropriate 
time in the G1 phase. This inactivates RB1 and enables the transcription of 
proteins that are essential for later cell cycle phases and allows cells to 
progress into the S phase. Proteins that promote cell cycle progression are 
colored green, inhibitors red and transcription factors brown. An inhibitory 
phosphorylation is shown as a red t-bar ending in a phosphoryl, an inhibitory 
interaction is shown as a red line beginning and ending in a dot. Effects on 
transcription are shown as dashed lines, those ending in an arrow indicate 
increased expression while t-bars indicate decreased expression 




 Metabolism, cell growth and autophagy (you are what you eat) 
AKT regulates glucose uptake in a cell-type-specific manner. In Insulin-sensitive 
cells, such as adipocytes and myocytes, PI3K/AKT activity increases glucose 
uptake by up-regulating the trafficking of vesicles containing the GLUT4 transporter 
to the cell membrane[129,130]. AKT Substrate of 160 kDa (AS160) was first identified 
as the direct AKT substrate that triggers this process, but evidence has emerged 
that indicates the presence of AS160-independent mechanisms (Figure 10)[129,131]. 
In other cell types, AKT upregulates GLUT1 expression to ensure that there is 
sufficient energy to fuel the cell growth stimulated by GFs[132,133]. The conversion of 
glucose to its active form by hexokinases is also stimulated by AKT activity[46]. 
Activated glucose (glucose-6-phosphate) can be stored as glycogen or catabolized 
to produce energy, processes which are regulated by AKT through GSK3α/β and 
the expression of glycolytic enzymes. AKT activity is thus intricately linked to energy 
storage and maintaining energy levels. 
 
AKT stimulates cell growth primarily through activation of the mechanistic target 
of rapamycin complex 1 (mTORC1). This protein complex is defined by mTOR, 
regulatory-associated protein of mTOR (RAPTOR), MLST8, and the two inhibitory 
subunits Proline-Rich AKT Substrate of 40kDa (PRAS40) and DEP domain-
containing mTOR-interacting protein (DEPTOR) (Figure 10)[134]. Two mechanisms 
have been reported through which AKT can control mTORC1 activity. The first 
involves phosphorylation of Tuberin (TSC2) S939 and T1462. This weakens its 
interaction with Hamartin (TSC1), destabilizing the TSC1/2 complex, an upstream 
inhibitor of mTORC1[135,136]. However, experiments in Drosophila have shown that 
mutating the AKT phosphorylation sites in TSC2 to alanine or a phosphomimetic 
had no drastic effect on TSC2 activity[137]. This indicates that there is no simple 
linear pathway between AKT and mTORC1. Indeed, in addition to directly inhibiting 
TSC2, AKT also reduces the AMP-activated protein kinase (AMPK)-mediated 
phosphorylation of TSC2[138,139]. Both the direct inhibition through phosphorylation 
by AKT and the removal of AMPK’s stimulating effect are required for full TSC2 
inhibition. The second mechanism by which AKT regulates mTORC1 involves 
PRAS40. PRAS40 interacts with and inhibits mTOR only in the presence of 
RAPTOR. AKT phosphorylates PRAS40 on Thr246, after which it is bound by 14-
3-3 proteins and can no longer interact with mTOR, removing PRAS40’s inhibitory 
effect on mTORC1[140]. It seems that either activity of the TSC1/2 complex or the 
presence of PRAS40 suffices to inhibit mTORC1. In cells that express a TSC2 
mutant that lacks AKT phosphorylation sites, mTORC1 remains inactive despite 
insulin stimulated AKT and PRAS40 phosphorylation, and PRAS40 overexpression 




Figure 10 Metabolism, cell growth and autophagy. Phosphorylated AKT stimulates 
GLUT4 translocation to the membrane and the cellular uptake of glucose 
through inhibition of AS160. mTORC1 activity is regulated by AKT, indirectly 
through TSC2, AMPK and RPS6KA1, and directly through PRAS40. AKT 
stimulates mTORC1 activity, which in turn increases mRNA translation, 
nucleotide- and lipid-synthesis through phosphorylation of P70S6K, 4E-BP, 
LPIN1 and ATF4. In line with its anabolic programme, mTORC1 also inhibits 
autophagy through phosphorylation and inhibition of TFEB and members of 
the ULK1 Kinase Complex. The ULK1 Kinase Complex activates a class 
III PI3K which labels parts of the endoplasmatic reticulum for recruiting 
additional ATGs. This results in the formation of an isolation membrane or 
phagophore (1) which encloses part of the cytoplasm to form an 
autophagosome (2). In the next step, a lysosome (3) fuses with the 
autophagosome (4) creating the autolysosome (5). The internal cargo is 
degraded by hydrolytic enzymes and released into the cytoplasm (6). The 
resulting increase in ‘building blocks’ in the cytoplasm serves as a negative 




In addition to the activation downstream of GFs through AKT, mTORC1 activity 
is also regulated by amino acid availability. This ensures that mTORC1 can only 
attain maximal activity in GF-stimulated cells when sufficient resources are 
available[6]. mTORC1 activity stimulates anabolic processes such as protein 
synthesis (through ribosomal protein S6 kinase beta-1 (P70S6K) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4E-BP)), lipogenesis (through 
P70S6K and phosphatidate phosphatase LPIN1 (LPIN1)) and nucleotide 
production through cyclic AMP-dependent transcription factor ATF-4 (ATF4) while 
inhibiting the catabolic autophagy and lysosomal pathways[134]. 
 
Much like how certain human tissues are renewed or remodeled by cell death or 
proliferation, intracellular components also undergo a constant cycle of degradation 
and renewal[142]. Cells possess degradation systems to recycle old or damaged 
components, such as organelles and misfolded proteins. These can also be used 
as mechanisms that allow cells to adapt to, for example, stress or starvation by 
degrading superfluous organelles and freeing up biomolecules for other 
processes[143]. Two such systems have been described: the proteasome and the 
lysosome. The proteasome selectively degrades ubiquitinated substrates, 
exclusively proteins, while the lysosome can degrade most cytosolic components, 
including entire organelles, through autophagy. There are three subtypes of 
autophagy: macroautophagy, microautophagy and chaperone-mediated 
autophagy. In microautophagy, a lysosome directly engulfs a small part of the 
cytoplasm and, in chaperone-mediated autophagy, specific proteins containing a 
KFERQ sequence motif are transported across the lysosomal membrane and 
degraded[142,144–146]. Macroautophagy, which will further be referred to as 
“autophagy”, is thought to be the most prominent subtype and will be discussed in 
more detail. Autophagy involves a chain of events that lead to the formation of a 
double-membrane vesicle that contains cytosolic cargo, called an autophagosome, 
that fuses with a lysosome to degrade its contents which are eventually released 
into the cytoplasm to be recycled[146]. 
 
Autophagy involves the hierarchical activation of a core set of Autophagy-
Related (ATG) proteins (Figure 10). The first proteins in this cascade, ULK1 and 
ATG13 are phosphorylated and inactivated by mTORC1. AKT activity stimulates 
mTORC1, and thus inhibits autophagy. ULK1 and ATG13, together with ATG101 
and RB1CC1/FIP200 constitute the ULK1 kinase complex[147,148]. Both ATG13 and 
RB1CC1/FIP200 are phosphorylated by ULK1. The active ULK1 complex 
phosphorylates and activates downstream ATG proteins, leading to the activation 
of a class III PI3K that generates PI3P on specialized membranes of the 
endoplasmatic reticulum called omegasomes. This labels a specific part of that 
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membrane to recruit other factors of the autophagic machinery and eventually gives 
rise to phagophores8 [149–151]. Another ULK1 substrate, ATG9 is thought to play a 
role in the delivery of lipid membranes to the nucleating phagophore. ATG2, also 
an ULK1 substrate, is part of the ubiquitin-like conjugation systems and interacts 
with WIPI2. The elongation of the omegasome to a phagophore is dependent on 
these ubiquitin-like conjugation systems. WIPI2 recruits the E3 ligase complex 
comprising ATG5, ATG12 and ATG16L1 to PI3P-containing membranes. This 
complex inserts ATG8 (MAP1LC3B, which will further be referred to as ‘LC3B’) into 
the phagophore membrane by conjugation to the lipid Phosphatidylethanolamine 
(PE). Prior to insertion, LC3B is cleaved by the protease ATG4 to LC3B-I which, 
after PE conjugation is called LC3B-II. In addition to the targeting of specific cargo 
to the phagophore, LC3B-II, together with elements from the actin cytoskeleton 
(actin, CapZ, ARP2/3, ...) drive expansion, maintain the curved shape and, finally, 
induce closure of the phagophore, creating a double-membrane vesicle called an 
autophagosome[150–152]. Once closed, autophagosomes are transported along 
microtubules through, for example, interaction of LC3B-II with MAP1B[153]. Near the 
nucleus, autophagosomes fuse with lysosomes, the sequestered cargo is broken 
down by hydrolases9 and released into the cytosol[149]. The resulting increase in 
energy or amino acid availability serves as a negative feedback loop by stimulating 
mTORC1 and terminating autophagy (Figure 10)[142]. 
 
During starvation the cell induces a transcriptional programme that upregulates 
expression of proteins involved in the autophagic pathway including, but not limited 
to, LC3B and ATG9, but also lysosomal proteins. This program is initiated by 
Transcription Factor EB (TFEB) and FOXO3. The activity and localization of TFEB 
is regulated by mTORC1 through phosphorylation of Ser122, Ser142 and Ser211 
and is linked to nutrient availability and AKT activity. Ser122 and Ser142 are located 
near the N-terminal Nuclear Export Sequence (NES), and when these residues are 
phosphorylated, TFEB is mainly cytosolic and inactive. The presence of mTORC1 
independent sites such as Ser134 and Ser138 indicate that there exist other 
upstream elements that also regulate TFEB localization[154–156]. 
 
                                           
8 Phagophores are cup-shaped double membrane structures that originate from the ER. These engulf 
the material that needs to be degraded and closes to form a double membrane vesicle a.k.a. the 
autophagosome. 
9 Hydrolases are a class of enzymes that break chemical bonds by using a water molecule. Lysosomes 
contain around 60 different hydrolases that have an acidic pH-optimum for activity. These include 
sulphatases, glycosidases, lipases, proteases and nucleases, allowing a lysosome to degrade a broad 
assortiment of biomolecules[519]. 
 
28 
Although generally considered to be a survival mechanism, autophagy can also 
lead to cell death. This type of cell death is separate from apoptosis, does not rely 
on the activity of caspases and can be prevented though inhibition of autophagy. 
Cells undergoing autophagic cell death have an increased number and size of 
autophagic vesicles, indicating that hyperactivation of autophagy triggers this type 
of cell death. Another proposed theory is that autophagy may degrade specific 
survival factors, with reduced cell viability as result[157–161]. 
 Migration and motility (They see me rollin’) 
The pathway by which AKT promotes cell migration and motility is less well defined. 
PI3K/AKT (but also MAPK and Rho GTPase) signalling plays a role in Epithelial-
Mesenchymal Transition (EMT), a process essential in the development of 
multicellular organisms that is hijacked by cancer cells and contributes to invasion 
and metastasis. In general terms, EMT includes decreased adhesion of the cell to 
the Extracellular matrix (ECM) and other cells, cytoskeletal reorganization, 
increased mobility and resistance to anoikis10 [162,163]. 
The expression of the cell adhesion protein E-cadherin, considered a 
characteristic marker of epithelial cells, is reportedly down-regulated by AKT 
through the DNA-interacting proteins twist-related protein (TWIST), zinc finger 
protein SNAI1 (SNAIL) and zinc finger protein SNAI2 (SLUG) (Figure 11). E-
cadherin down-regulation leads to a remodeling of cytoskeletal proteins and 
reduces cell-cell adhesion. SNAIL has also been shown to affect VIMENTIN, MMP-
2 and MMP-9 expression, other markers of EMT[162,164–166]. 
Cell adhesion to the ECM is mediated by Integrins, a protein family of membrane-
spanning receptors that form heterodimers consisting of an α- and β-subunit. 
Integrin β1 (CD29) interacts with various components of the ECM, depending on 
which α-subunit is part of the heterodimer. This protein’s expression is regulated 
by AKT. On the luminal side of the membrane, integrins recruit over 50 proteins 
among which FAK, Zyxin (ZYX), Parvin (PARVA) and Vinculin. These protein 
complexes or FA (Focal Adhesions) are typically associated with stress fibers and 
form the link between Integrin receptors and the actin cytoskeleton, but they also 
act as sites for signal transduction downstream of Integrin or for mechanical forces 
(such as pressure) exerted on a cell (Figure 11)[167,168]. There is a complex interplay 
between FAK and AKT: AKT interacts with and phosphorylates FAK Ser695 and 
 
                                           
10 Anoikis (loosely based on the ancient Greek word for ‘homeless wanderer’) is a cell death mechanism 
that occurs when adherent cells, that usually have many cell-matrix and cell-cell contacts, become 
detached. Cancer cells acquire resistance to this mechanism through changes in signalling pathways, 
including the PI3K/AKT pathway, which enables metastasis[520,521]. 
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Thr700, which facilitates FAK activation by autophosphorylation of Tyr397. AKT 
activity has been shown to increase Integrin β1 expression, and the clustering of 
integrins recruits FAK to FAs which also induces autophosphorylation[169–171]. But 
that same phosphorylation site also creates an interaction motif for the SH2 domain 
of a PI3K regulatory subunit, leading to PI3K and AKT activation[63,170,172,173]. This 
implies a rather strange cycle where AKT is both upstream and downstream of 
FAK, and vice versa. AKT is also implicated in the assembly of F-Actin filaments 
into stress fibers, by regulating expression levels and phosphorylation of 
PALLADIN[35,163,174].  
Cell motility requires a dynamic remodeling of the actin cytoskeleton, including 
FAs and stress fibers, both cellular structures regulated by AKT activity[167]. 
 
 
Figure 11 The Focal Adhesion Complex and AKT regulation of EMT. A highly 
simplified version of a Focal Adhesion Complex including proteins such as 
ZYXIN, PARVIN and VINCULIN. VINCULIN is frequently used as a marker 
to detect Focal Adhesions in light microscropy. The Integrin-ECM 
interaction stimulates autophosphorylation of FAK, leading to PI3K and AKT 
activity. AKT in turn phosphorylates FAK and increases the expression of 
Integrin β1. Focal Adhesions are linked to Actin stress fibers. AKT 
regulates both PALLADIN activity -through phosphorylation- and 
expression. This Actin-bundling protein is involved in the assembly of Actin 
fibers into bundles. Through phosphorylation of GSK3, AKT activity 
stabilizes the DNA-binding proteins TWIST, SNAIL and SLUG. TWIST 
expression is also regulated by AKT through a GSK3-independent 
mechanism. These DNA-interacting proteins inhibit the expression of E-
Cadherin while stimulating VIMENTIN, MMP-2 and MMP-9 expression. 
Stimulating and inhibitory phosphorylation are indicated by a red arrow or t-
bar, respectively. A protein-protein interaction is indicated by a line 
beginning and ending in dots, up- and down-regulatrion of expression are 
indicated by a dashed arrow or t-bar, respectively. Based on KEGG Focal 
Adhesion pathway, STRING interaction database and [63,162,165,166,170,173]. 
Created in BioRender.com. 
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1.3.4 Fine-tuning AKT activity 
AKT receives and processes input from various extracellular stimuli and, in 
response, phosphorylates targets involved in different cellular processes. It is 
improbable that the signal propagation downstream of AKT is undirected and that 
AKT phosphorylates all of its targets in every setting. Thus, to trigger a specific 
response there are mechanisms that allow AKT to phosphorylate a distinct set of 
substrates. 
Although these mechanisms are poorly understood, the level of AKT activity has 
been shown to influence which substrates can be modified[46,82,86,175]. Knockdown 
of the mTORC2 members MAPKAP1/SIN1, MLST8 or RICTOR, reduces 
phosphorylation of the AKT HM, but not of the activation loop. With only its 
activation loop phosphorylated, AKT remains active but at a much lower level. 
Surprisingly, a low amount of AKT activity suffices for saturating phosphorylation of 
GSK3α/β Ser21/9 and TSC2 Ser939 and Thr1462. In contrast, certain other 
substrate sites, such as FOXO1 Thr24 and FOXO3 Thr32 show significantly 
reduced phosphorylation when the AKT HM is not modified by mTORC2. This 
demonstrates the importance of the HM in fine-tuning AKT signaling and suggest 
that the HM phosphorylation site determines which substrates can be 
phosphorylated by AKT. Different proteins (or even different sites within a protein) 
do not require the same levels of AKT activity to reach saturation[46,82,86,175,176]. The 
intensity of AKT activity, combined with a temporal factor could enable AKT to 
regulate different processes. Mitogenic signalling requires a low level of AKT 
activity that is sustained for a long time, but insulin-stimulated glucose uptake 
requires an intense but short spike in AKT activity[89]. 
Phosphorylation of the AKT activation loop and HM sites are synonymous with 
activation and are, by far, the most studied AKT modifications, but these are not 
the only PTM sites, not by a long shot. PhoshoSitePlus® lists up to 59, 41 and 18 
PTMs for AKT1, AKT2 and AKT3. These modifications include phosphorylation, 
acetylation, oxidation, ubiquitylation, SUMOylation and glycosylation[49]. 
Phosphorylation of other Ser, Thr or Tyr residues has been shown to fine-tune AKT 
signalling by changing catalytic activity, localization, substrate specificity and 
stability (Table 1)[177]. The acetylation of two residues in the AKT PH domain (Lys14 
and Lys20) prevents interaction with PIP3 and the activation of AKT[178]. Likewise, 
non-degradative ubiquitylation (Lys63-linked) also reduces AKT activation. 
Oxidation of Cys124, which has only been described for AKT2, triggers disulfide 
bond formation that reduces the activity of this isoform[37,179]. Glycosylation, 
particularly addition of O-linked GlcNAc to Ser or Thr residues by O-GlcNAc 
transferase (OGT), can compete with phosphorylation of the same site. OGT co-
localizes with AKT at membranes that contain PIP3[180]. AKT contains several 
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glycosylation sites. Modification of Thr305 and Thr312 possibly disrupts the 
interaction with PDK1 and reduces Thr308 phosphorylation. Remarkably, for 
Thr312, glycosylation has the same effect as phosphorylation on AKT activity while 
glycosylation and phosphorylation of Ser473 have opposite effects[177,181,182]. The 
majority of AKT PTMs were discovered in high-throughput proteomics studies and 
a more in-depth investigation is needed to find out which enzymes are responsible 
for the modification and what their effect on AKT is[6,177]. 
Table 1 AKT post-translational modifications. PTMs are listed with the modified 
amino acid residue (AA) for each AKT isoform, its location, the type of 
modification, the effect it has on AKT and the enzyme, if known, that 
catalyzes the modification reaction. P and N indicate positive and negative 
effects on AKT catalytic activity, respectively. S indicates that the PTM has 
a stabilizing effect on AKT, D refers to a destabilizing effect and L indicates 
that the PTM has an effect on AKT localization. A residue in bold (Ser123) 
indicates that, while the residue is conserved in that isoform, the sequence 
motif required for phosphorylation is not. Adapted from Risso et al. and 
PhosphoSitePlus®[49,177]. 
AA AKT1/2/3 PTM TYPE EFFECT ENZYME 
Lys 8/8/8 Lys63 Ubiquitylation P, L TRAF6 
Lys 14/14/14 Lys63 Ubiquitylation P, L TRAF6 
Lys 14/14/14 Acetylation N SIRT1 
Lys 20/20/20 Acetylation N SIRT1 
Thr 92/Ser92/91 Phosphorylation S Unknown 
Ser 124/126/123 Phosphorylation P Unknown 
Cys -/124/- Oxidation N Unknown 
Ser 129/131/ - Phosphorylation P CK2 
Tyr 176/178/174 Phosphorylation P, L ACK1 
Lys 276/277/273 SUMOylation P PIAS1/SENP1 
Lys 284/285/281 Lys48 Ubiquitylation D MULAN 
Thr 305/306/302 Glycosylation N OGT 
Thr 312/313/309 Phosphorylation N GSK3α 
Thr 312/313/309 Glycosylation N OGT 
Tyr 315/316/312 Phosphorylation P Src/PTK6 
Tyr 326/327/323 Phosphorylation P Scr/PTK7 
Thr 430/431/427 Glycosylation P OGT/OGA 
Thr 450/451/447 Phosphorylation S mTORC2 
Ser 473/474/472 Glycosylation N OGT/OGA 
Tyr 474/475/473 Phosphorylation S Unknown 
Ser 477/478/476 Phosphorylation S Cdk-CyclinA 
Thr 479/-/- Phosphorylation P Cdk-CyclinA 
Thr 479/-/- Glycosylation P OGT/OGA 
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1.3.5 Feedback loops 
In addition to the phosphatases that function upstream of AKT, there are also 
downstream elements that constrain AKT signalling, and these create negative 
feedback loops whereby AKT activity is self-limiting. 
In the case of insulin/IGF signaling, mTORC1 and P70S6K both phosphorylate 
IRS-1, promoting its degradation and in doing so, uncouple insulin-sensitive RTKs 
from the pathway. P70S6K also phosphorylates and inactivates the mTORC2 
member MAPKAP1/SIN1, which affects phosphorylation of the AKT HM. Through 
phosphorylation of FOXO transcription factors AKT activity also down-regulates the 
expression of various RTKs[183–185]. 
 Three isoforms (This is where it gets complicated) 
Despite the high degree of sequence identity shared between the AKT isoforms, 
they are not fully redundant (Figure 1). Their roles partially overlap but each isoform 
also functions distinctly. In certain cases, they can even counteract one another. 
 
Studies in mice, using individual gene Knockout (KO) of the isoforms report that 
AKT1-/- mice are smaller (by 15%-20%), have both pre- and post-natal growth 
defects that persist into adulthood and are more sensitive to stress-induced 
apoptosis[186,187]. AKT2-/- mice develop a diabetes-like phenotype, have a mild 
growth deficiency and severe lipoatrophy while AKT3-/- mice have 20% decreased 
brain size[188–190]. All isoforms appear to play a role in cell growth but AKT3 only in 
neuronal cells. AKT1 also promotes cell survival while AKT2 is involved in glucose 
metabolism and the development of adipose tissue[186–192]. 
This raised the question as to how three proteins, that have such a high degree 
of sequence identity, achieve specific signalling. A detailed study of the differences 
between AKT isoforms revealed several aspects and mechanisms that could 
contribute to isoform-specific signalling. These include the differential tissue 
expression, subcellular localization, intrinsic kinetic parameters, isoform-specific 
(in)activation, PTMs and isoform-specific substrates. 
It is most likely that a combination of several of these factors and mechanisms 
leads to isoform-specific signalling, but, for clarity, they will be discussed 
separately. In truth there is likely to be significant cross-talk as, for example, the 
PTM of an AKT isoform can influence its subcellular localization and/or catalytic 
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activity. An important caveat is that the majority of the AKT isoform-specific 
mechanisms described here were discovered using animal models and/or cell 
cultures. Those mechanisms that depend on the interaction of AKT with specific 
proteins and chaperones, or the activity of other enzymes, are likely to differ 
between cell types. Thus, isoform-specific signalling is dependent on cellular 
context. Despite the rich body of literature in support of isoform-specificity, the 
distinction between AKT isoforms is not always made, which only causes more 
confusion about the exact roles of the AKT isoforms. 
1.4.1 Expression and location 
One of the first theories explored was that the difference in relative expression 
levels of an AKT isoform within a specific tissue determines the effect of a KO. In 
most tissues AKT1 is the predominant isoform but not in insulin-sensitive tissues, 
such as muscle and adipose tissue, where AKT2 is most prevalent, nor in the brain 
and testes where AKT3 expression is highest[92,131]. The diabetes-like phenotype in 
AKT2-/- mice was proposed to be the consequence of the large decrease in net AKT 
activity when the dominant isoform was down-regulated. However, overexpression 
of AKT1 in AKT2-/- adipocytes did not rescue the impaired insulin signalling, nor did 
the introduction of AKT2 in AKT1-/- mouse embryonic fibroblasts restore GF-
induced cell migration[36,193,194]. These observations argue that the expression level 
of an AKT isoform by itself is not a factor that determines isoform-specific signalling. 
 
In cells, the AKT isoforms are enriched in different subcellular compartments. In 
breast cancer cell lines, including MDA-MB-231 cells, AKT1 is present throughout 
the cytoplasm, AKT2 at the mitochondria and endosomes, and AKT3 in the 
nucleus[195]. The enrichment of AKT2 at the mitochondria is in line with the proposed 
role of this isoform in the insulin response. However, in a noncancer cell line, HEK-
239, all isoforms were present in the nucleus and AKT1 was also found in the 
cytoplasm. In HEK-239T, a cell line derived from HEK-239 that expresses a mutant 
version of the SV40 large T-antigen, AKT1 was only present in the cytoplasm. 
Consequently, the localization of an AKT isoform is unlikely to be an intrinsic factor 
but rather dependent on interaction with other proteins or PTMs. Activation of the 
pathway emphasizes these differences as AKT1, in GF-stimulated mouse 
embryonic fibroblasts, was found near membrane ruffles and, in thyroid cancer 
cells, AKT2 localized to endosomes[36,68]. 
The downregulation of a single, or several, isoforms does not alter the location 
of the remaining isoform(s), indicating that each has its own subcellular niche, 
which further supports the non-redundancy of the isoforms[34]. This 
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compartmentalization of AKT isoforms could restrict access to certain substrates or 
chaperones11, leading to isoform-specific signalling pathways. 
1.4.2 Kinetic parameters (The red ones go faster)  
Although the isoforms all share the same catalytic mechanism where ATP binds to 
the catalytic pocket prior to the protein substrate, their kinetic parameters differ 
(Table 2). AKT2 has by far the highest KM12 for ATP, whereas the KM of an 
optimized peptide substrate is similar for all three isoforms. Compared to AKT1 and 
AKT2, AKT3 has a much higher catalytic activity. These kinetic parameters were 
determined in vitro and are likely affected by protein interactions or PTMs that occur 
in cells. 
As binding of ATP to AKT is needed to initiate the reaction, the ATP 
concentration could be a rate-limiting factor. Although the average intracellular ATP 
concentration is thought to be in the millimolar range, much higher than the KM, 
there could well be local fluctuations inside cells, or AKT activity could be limited 
when ATP is depleted by, for example, hypoxia. This would affect AKT2, the isoform 
with the lowest affinity for ATP, the most[42,196]. 
 
Table 2 Kinetic constants of the AKT isoforms. Recombinantly produced, purified 
and in vitro phosphorylated AKT, together with an optimized peptide 
substrate ARKRERTYSFGHHA (residues in bold show the minimal AKT 
consensus motif) were used to determine the catalytic activity (kcat). AKT 
immunoprecipitated from Rat-1 cells was used for measuring the affinity for 
ATP (KM ATP) and for the optimized peptide (KM PEPTIDE)[42,91]. 
 kcat (MINUTE-1) KM ATP (µM) KM PEPTIDE (µM) 
AKT1 22 143.3 ± 21.9 2.9 ± 0.9 
AKT2 25 564 ± 69.1 2.3 ± 1.0 
AKT3 119 118.7 ± 46.7 2.3 ± 1.1 
 
                                           
11 Molecular chaperones are proteins that, through interaction, assist the folding of another protein or 
stabilize its functional conformation. 
12 The Michaelis constant, KM, is a measure for the affinity of a given substrate for an enzyme. Lower 
values indicate higher affinity. Numerically, the KM is equal to the substrate concentration at which the 
reaction rate is half of the theoretic maximum. 
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1.4.3 Isoform-specific activation and inactivation 
The interaction of AKT with PIs is an essential step in AKT activation[73]. Although 
all isolated AKT PH domains have higher affinity for PI(3,4)P2, full-length AKT1 and 
AKT3 preferentially interact with PI(3,4,5)P3. These two isoforms translocate to the 
PM mainly in response to the generation of PI(3,4,5)P3, while AKT2’s membrane 
recruitment is primarily driven by PI(3,4)P2. This phospholipid occurs at both the 
PM and endosomal membranes and as a result, so does AKT2. Inhibition of SHIP2, 
which generates PI(3,4)P2 from PI(3,4,5)P3, increases the recruitment of AKT1 to 
the PM while reducing AKT2 accumulation at the PM and early endosomes[30]. The 
lipid phosphatase INPP4B, which converts PI(3,4)P2 to PI(3)P, co-localizes with 
AKT2 at early endosomes and suppresses the activity of AKT2 in that cellular 
compartment. That only AKT2 is affected can be explained by the preferential 
interaction of this isoform with PI(3,4)P2. 
Although the rate of PI(3,4,5)P3 down-regulation is somewhat dependent on cell-
type, PI(3,4,5)P3 is only present at the PM for a short time (± 15 minutes) but 
PI(3,4)P2 levels are sustained for much longer (± 30 minutes). This translates to 
different time-frames for AKT isoform activation, where in a first stage both AKT1 
and AKT2 are activated at the PM, but AKT2 is still recruited to endosomal 
membranes containing PI(3,4)P2 and activated long after AKT1 activation has been 
terminated[30,67,68,197]. 
 
PHLPP, the phosphatase that controls the amplitude of AKT signalling by 
dephosphorylating the AKT HM, comes in two isoforms: PHLPP1 and PHLPP2. 
Co-immunoprecipitation showed that PHLPP1 interacts with both AKT2 and AKT3 
and PHLPP2 interacts with AKT1 and AKT3. Knockdown of either isoform 
increased the phosphorylation of the AKT3 HM to the same extent, knockdown of 
PHLPP1 led to increased AKT2 HM phosphorylation, likewise for PHLPP2 and 
AKT1. This selective dephosphorylation of specific AKT isoforms could down-
regulate isoform specific signalling pathways. The combination of isoform-specific 
inactivation with isoform-specific substrates or scaffold proteins that enable 
signalling to distinct subsets of AKT substrates could add another level of 
complexity to AKT signalling. It was found that phosphorylation of p27kip1 Thr157 by 
AKT3 is affected only by a knockdown of PHLPP2, but not PHLPP1. On the other 
hand, PHLPP1 regulates phosphorylation of MDM2 Ser166 and GSK3α Ser21 by 
AKT2. Another group of substrates such as GSK3β Ser9 and TSC2 S939 and 
Thr1462 are equally affected by knockdown of either PHLPP isoform[86,88]. 
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1.4.4 Post-Translational Modifications 
As indicated in Table 1, not all AKT PTMs are conserved between isoforms. As 
the sequence of the AKT linker regions diverges the most, it is not surprising that 
this domain contains several non-conserved PTM sites. Obviously, a PTM that only 
occurs on a specific AKT isoform can only change the characteristics of that 
particular isoform. 
A site corresponding to Ser123 in AKT3 is found in all isoforms but the 
consensus sequence required for phosphorylation is not conserved in AKT3. 
Modification of this site has been observed in a large-scale phosphoproteome 
analysis which suggest that, although this site can still be phosphorylated, it is most 
likely regulated by a different kinase than for AKT1 and AKT2, perhaps even in 
response to different stimuli[198]. For AKT1 and AKT2, phosphorylation of this site 
renders the kinase more responsive to GF stimulation[72]. 
The Ser129 phosphorylation site (Ser131 for AKT2) on the other hand is absent 
in AKT3. Modification of this site promotes the association of AKT with HSP90. It 
has been reported that this interaction reduces dephosphorylation of the AKT 
activation loop, prolonging AKT1 and AKT2 activity[199,200]. 
Cys124, which is unique to the AKT2 linker, is oxidized by ROS generated in 
response to GF or cytokine signalling. Such oxidation triggers the formation of an 
intramolecular disulfide bond with Cys297 or Cys311 in the protein kinase domain 
of AKT2 and reduces catalytic activity[37,179]. 
Finally, phosphorylation of AKT1 Thr479, a CDK2-Cyclin A substrate site that is 
only present at the extreme C-terminus of AKT1 is upregulated during the cell cycle 
and is presumed to activate AKT1 by either mimicking HM phosphorylation or by 
increasing the association of AKT1 with mTORC2[201,202]. 
1.4.5 Isoform-specific substrates 
Reducing the activity of a single AKT isoform does not affect all substrates equally 
(cf. paragraph 1.4.3). Although the vast majority of AKT substrates has not been 
evaluated for isoform-specific regulation, there is a growing set of AKT substrates 
that appear to be uniquely modified by a single AKT isoform. 
p21Cip1/WAF1, a cell cycle regulator is phosphorylated only by AKT1 but can also 
be bound by AKT2. Interestingly, this interaction competes with the phosphorylation 
by AKT1[203]. The stability of SKP2, a protein which is often over-expressed in 
tumors, and the activity of the Actin-bundling protein PALLADIN are both regulated 
through phosphorylation by AKT1[35,204]. For AKT2, several isoform-specific 
substrates have been identified. The function of MDM2 and AS160 has been 
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described earlier, MYO5A, another AKT2-specific substrate, is also involved in the 
translocation of GLUT4 vesicles and ANKRD2, mainly expressed in muscle, is 
involved in the response to oxidative stress[86,193,205,206]. The only AKT3-specific 
substrate identified so far is the transcription factor TBX3[207]. 
The search for isoform-specific targets has gained some traction with the use of 
high-throughput (phospho)proteomics screens which can simultaneously identify 
direct AKT substrates affected by the KO of a single isoform and the effects on 
proteins further downstream in the AKT pathway[208,209]. 
 AKT and cancer 
In healthy cells, the activities of the PI3K/AKT pathway are tightly controlled by 
several feedback mechanisms. When these mechanisms fail, the sustained 
signalling invariably leads to disease. Dysregulation of AKT signalling is associated 
with several diseases including autoimmune-, cardiovascular-, neurological-
disorders and cancer[6,92]. 
 
Given the central role of this kinase family in several cellular processes that are 
considered to be hallmarks of cancer (growth, survival, proliferation, migration and 
metabolism), the link between AKT dysregulation and cancer should come as no 
surprise[161]. What is remarkable is that, AKT itself, and almost all known upstream 
regulators of AKT have been observed to be mutated or amplified in various types 
of cancer[210,211]. Although there is fierce competition with the p53 and RB1 
pathways, this makes the PI3K/AKT pathway one of the most frequently activated 
pathways in human cancer[92,177,210]. Not only does AKT hyperactivity promote tumor 
development it is also an indicator of poor prognosis and related to therapy 
resistance. For these reasons, the PI3K/AKT pathway and AKT in particular has 
drawn much attention as a target for cancer therapy and considerable efforts have 
been made to develop targeted therapies for AKT[212]. 
1.5.1 Genetic aberrations in the PI3K/AKT pathway 
Several genetic anomalies, in various stages of the pathway, that result in AKT 
hyperactivity have been observed and established as causal in human cancer. 
The first step in the pathway, the activation of growth factor receptors, is also the 
earliest opportunity for derailing AKT signalling. The overexpression of wild-type 
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growth factor receptors can render a tumor cell hypersensitive to GFs. Cancer cells 
are also known to secrete higher levels of GFs resulting in autocrine or higher levels 
of paracrine GF signalling (Figure 12). Alternatively, gain-of-function (GOF) 
mutations in growth factor receptors such as the EGFR, INSR, IGF-1R, HER2 and 
PDGFR, can also lead to constitutive receptor activation and downstream 
signalling[9,161,211]. 
 
PI3K, the downstream target of these receptors, consists of a catalytic and a 
regulatory subunit. PIK3CA, the gene that codes for the catalytic subunit p110α, is 
mutated in 19.74% and up-regulated in 10.6% of breast cancer samples. PI3KCA 
mutations predominantly occur in the kinase and helical domains of the protein. 
Three hotspot GOF mutations E542K, E545K and H1047R, that account for >75% 
of all alterations, confer constitutive kinase activity and induce oncogenic 
transformation[9,211,213–215]. Mutations in other class I catalytic subunits are rare, the 
mutation of PIK3CB (p110β), and overexpression of p110γ and p110δ have been 
observed in human tumors but at a very low frequency[61,66]. The regulatory subunit, 
p85α, encoded by the PIK3R1 gene, is mutated in 2.49%; or has loss of 
heterozygosity (LOH) in 0.8% of breast cancer samples. The p85α mutations 
perturb its interaction with the catalytic PI3K subunits and PTEN, alleviating the 
inhibitory effect on the catalytic PI3K subunits and the stabilizing effect on 
PTEN[9,61,212,215]. A single oncogenic driver mutation13 in PIK3CA or PIK3R1 suffices 
for pathway activation and oncogenesis, co-occurring mutations in both genes is 
rare but could possibly provide an even greater proliferative advantage to the 
malignant cell[216–218]. 
 
In healthy cells, PI3K signalling is down-regulated by lipid phosphatases, 
particularly PTEN. Apart from the reduction in protein stability as a consequence of 
p85α mutation, PTEN activity is frequently lost, through mutation (5.37%) or loss of 
expression (4.26%) in breast cancer. PTEN mutations most frequently occur within 
the exon that codes for the dual specificity phosphatase domain[219]. PIK3CA and 
PTEN mutations can co-occur, an indication that the presence of both types of 
mutation could act in synergy to amplify AKT signalling[211]. Apart from PTEN, the 
INPP4B gene was found to be frequently deleted in breast cancer and this deletion 
correlates with lower patient survival[220]. 
 
 
                                           
13 Oncogenic driver mutations are mutations that are responsible for the initiation progression of 
cancer. This type of mutation confers a proliferative advantage to the cancer cell.  
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Increased activity of growth factor receptors, PI3K or reduced PTEN activity all 
lead to higher levels of PI(3,4,5)P3 at the membrane and increased AKT and PDK1 
recruitment. PDK1 gene amplification further enhances the uncontrolled signalling 
of upstream genetic lesions and is also associated with poor prognosis in breast 
cancer[221]. 
 
Figure 12 Schematic diagram of genetic aberration in the PI3K/AKT pathway. 
Mechanisms that lead to increased PI3K activity in cancer include 
Autocrine and Paracrine stimulation of RTKs/GPCRs, overexpression of- 
or Gain of Function (GOF) mutations in- these receptors, overexpression 
of the catalytic PI3K subunit (PI3CA) and GOF mutations that perturb the 
interaction with the regulatory subunit (PI3KR) or confer constitutive catalytic 
activity, Loss of Heterozygosity (LOH) or Loss of Function (LOF) mutations 
in the PI3KR. PTEN, the phosphatase that antogonizes PI3K is frequently 
deleted or displays LOF mutations. These events all lead to higher levels of 
PIP3 at the membrane and AKT activation. Overexpression of PDK1, the 
kinase that activates AKT, further amplifies AKT signalling. For AKT itself, 
some GOF mutations have been reported and it has also been observed to 
be overexpressed. Finally, LOH or LOF mutations in PHLPP1/2 ensure that 
the aberrant AKT signalling is sustained for much longer than is desired for 
healthy cells. Created in BioRender.com. 
 
The common denominator is that all of these changes upstream in the PI3K/AKT 
pathway result in increased AKT activity. The AKT isoforms themselves are also 
overexpressed in diverse types of cancer. For breast cancer this varies from 6.25%, 
8.61% to 7.88% for AKT1, AKT2 and AKT3, respectively[215]. AKT3 expression is 
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only detectable in basal-type15 breast cancer cell lines while AKT1 and AKT2 are 
found in all types, but are expressed at higher levels in luminal-type cell lines[222]. 
Mutation of the AKT isoforms occurs at a relatively low frequency in breast 
cancer (3.48%, 1.45% and 6.13% for AKT1, AKT2 and AKT3, respectively)[215,223]. 
A single oncogenic hotspot mutation E17K, which accounts for 96% of all AKT1 
point mutations in breast cancer, changes the conformation of the PH domain and 
alters the surface charge near the PI-binding pocket from negative to neutral[31,215]. 
This AKT1 mutant has a 100-fold higher affinity for PI(4,5)P2, a seven-fold higher 
affinity for PI(3,4,5)P3 and localizes to the membrane even in the absence of GF 
stimulation. This results in higher levels of activated AKT1 (approximately five-fold 
increase) in serum-starved cells. Additionally, expressing this AKT1 mutant in cells 
suffices to induces transformation[31,224,225]. The corresponding mutation has also 
been detected in AKT2 and AKT3, though at a very low frequency[31]. 
1.5.2 Isoform-specific roles of AKT in breast cancer 
There is no doubt that the PI3K/AKT pathway is involved in cancer, but the exact 
contribution of each AKT isoform to tumorigenesis and metastasis is highly 
controversial. Most of the isoform-specific functions of AKT were observed in 
cancer models, and it quickly became clear that results obtained in one cancer 
model do not necessarily translate to other cancer models. Therefore, I will limit the 
discussion on AKT isoform-specific functions to a single cancer type, breast cancer. 
This is the cancer type that was used throughout this project to characterize the 
AKT Nb sets and to study the role of AKT2. All things considered, the PI3K/AKT 
pathway is dysregulated in up to 70% of human breast cancers and the 
upregulation in AKT activity is correlated with poor prognosis[226,227].  
As this is a still growing field, with inconsistent and conflicting reports on AKT 
isoform-specific functions, the mechanisms discussed below represent what is 
currently the greatest consensus.  
 
In breast cancer, AKT1 and AKT2 both promote cell proliferation. Ablation of 
either isoform has been shown to reduce Cyclin D1 levels, but the signalling 
mechanism through which each isoform exerts its effect is different[163,228–230]. For 
 
                                           
15 Basal-type or triple-negative breast cancer cells generally have low expression levels of hormone 
receptors (estrogen and progesterone) and HER2 receptors but display high expression of basal 
markers, such as keratins and proliferation-related genes. This is an aggressive type of tumour with 
worse prognosis compared to luminal type tumours, which express hormone receptors and respond well 
to hormone therapy[522]. 
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AKT1 this is quite straightforward: it regulates Cyclin D1 through phosphorylation 
of GSK3. Ablation of AKT2 on the other hand does not affect GSK3 phosphorylation 
levels, but this isoform probably regulates Cyclin D1 levels through isoform-specific 
phosphorylation of FOXO transcription factors[231–233]. Furthermore, AKT2 also 
regulates CDK2 levels, another kinase that regulates RB1 and promotes G1- to S-
phase transition[234,235]. 
The two CDK inhibitors, p21Cip1/WAF1 and p27Kip1, are both AKT substrates and 
their transcription is also regulated by AKT. In fibroblasts p21Cip1/WAF1 is 
phosphorylated by AKT1 to stimulate cell cycle progression, while AKT2 binds but 
does not phosphorylate p21Cip1/WAF1 and prevents phosphorylation by AKT1[203]. 
Experiments in mice showed that AKT1 expression is required to maintain p27Kip1 
expression, whereas another study shows that AKT1 activity causes degradation 
of p27Kip1 through phosphorylation of SKP2. AKT2 ablation does not directly affect 
p27Kip1 phosphorylation but up-regulates the transcription of its gene[204,231,234]. The 
influence of AKT3 on proliferation is less clear, it either has a small positive effect 
or no significant effect on cell proliferation[233]. 
So far no studies have conclusively implicated AKT2 in apoptosis, this process 
appears to be regulated by AKT1 and, to a lesser extent, by AKT3[236]. AKT1 inhibits 
apoptosis through the FOXO3-BIM axis and AKT3 affects apoptosis by regulating 
BCL-2 and BAX[229,232,236–239]. Again, AKT3’s role is unclear, studies agree that 
AKT3 regulates BCL-2 and BIM expression levels, just not on whether the final 
effect is pro-survival or pro-apoptosis[239–241]. 
 
Although AKT2 could not be linked to apoptosis, it does regulate cell survival by 
inhibiting autophagy. In breast cancer cells with AKT2 knockdown, the mTORC1-
P70S6K signalling axis is inhibited, limiting protein synthesis. At the same time, the 
lack of PGC-1 Ser570 phosphorylation by AKT2 stimulates mitochondrial 
biogenesis. This imbalance in protein demand and production induces a 
pathological autophagy that specifically targets mitochondria. Initially, salvaging 
mitochondria could increase survivability, but a prolonged and uncontrolled 
autophagy would eventually result in cell death[157,158,160,234,242]. 
 
Observations in mice and cell cultures show that AKT1 suppresses migration 
and invasion of breast cancer cells, while AKT2 promotes these 
processes[229,233,237,243]. AKT1 down-regulation induces an EMT-like phenotype by 
down-regulating E-cadherin expression, up-regulating N-cadherin and VIMENTIN 
expression, and activation of the ERK pathway. AKT2, on the other hand, does not 
regulate the ERK pathway, has no effect on E-cadherin expression levels but does 
stimulate VIMENTIN expression. Remarkably, AKT2 expression is required for the 
phenotypic changes induced by an AKT1 down-regulation[234,244]. 
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AKT1 also downregulates FAK and Integrin β1 expression, whilst AKT2 activity 
increases Integrin β1 expression. In line with these observations, the expression of 
constitutively active AKT1 (indirectly) induces the phosphorylation of PAXILLIN 
Tyr118, displacing it from focal contacts thereby reducing the formation of focal 
adhesions[99,163,231,245]. 
The regulation of the actin-bundling protein PALLADIN is an interesting example 
of an isoform-specific function of AKT. This protein localizes to FAs and stress 
fibers. It was found that AKT1, but not AKT2, interacts with and phosphorylates 
PALLADIN Ser507. The phosphorylation of PALLADIN by AKT1 induces cross-
linking of actin filaments into bundles, which increases the rigidity of the actin 
cytoskeleton, decreases formation of invadopodia and reduces the migration of 
breast cancer cells. These effects are negated by silencing PALLADIN. 
Additionally, reintroduction of a non-phosphorylatable PALLADIN mutant in 
PALLADIN-/- cells does not restore the organized actin cytoskeleton phenotype 
whereas the wild-type PALLADIN does[35,246]. AKT2 on the other hand upregulates 
PALLADIN levels by increasing protein stability and gene transcription. Exactly how 
PALLADIN upregulation fits into the invasive phenotype promoted by AKT2 is 
unclear. In addition to its role in Actin-bundling, PALLADIN also acts as a molecular 
scaffold for proteins (profilin, VASP, EZRIN and α-actinin) that localize to actin 
fibers. One theory is that the upregulation of PALLADIN by AKT2 causes an 
imbalance in protein complexes, of which PALLADIN is a participant, that favours 
remodeling of the actin cytoskeleton to promote migration[174,246]. Where increased 
AKT1 activity promotes an organized and rigid actin cytoskeleton through 
PALLADIN, AKT2 activity is associated with the remodeling of the actin 
cytoskeleton and an AKT2 knockdown results in the loss of structured stress 
fibers[163,237]. 
 
Succinctly put, AKT1 activity facilitates tumor initiation by promoting cell cycle 
progression and inhibiting apoptosis. On the other hand, this isoform opposes 
cancer cell migration and invasion, reducing a cancer’s metastatic potential. 
The role of AKT2 in proliferation is less clear as, like AKT1, it regulates Cyclin 
D1, but opposes AKT1 in the regulation of CDK inhibitors. However, the positive 
effect of AKT2 activity on cell migration and invasion is not to be contested. AKT2 
clearly promotes an invasive phenotype by inducing an EMT-like phenotype and 
through the remodeling of the Actin cytoskeleton. 
The scant information available on the role AKT3 in breast cancer does not yet 
enable us to pin down the function of this isoform. So far, the effects that have been 
attributed to AKT3 depend, by and large, on which breast cancer model was used 




Ever since the discovery that the PI3K/AKT pathway promotes cell survival in 
response to GFs, it has been a prime target for cancer therapy. Nowadays, an 
enormous number of various inhibitors are available that target various proteins in 
the pathway. There are PI3K- (ATP-competitive, pan-PI3K and isoform-specific), 
mTORC1-, dual-specificity mTORC1 and PI3K-, mTORC1&2-inhibitors and ATP-
competitive and allosteric AKT inhibitors[247]. Some PI3K (Idelalisib, Copanlisib and 
Duvelisib) and mTOR (Everolimus and Temsirolimus) inhibitors have already been 
approved by the FDA and are used to treat divergent types of cancer[64,247]. Due to 
the presence of extensive feedback mechanisms in the pathway, simultaneous 
inhibition at several levels appears to be the optimal approach for cancer therapy, 
and AKT remains an essential target. 
 
ClinicalTrials.gov reports 325 clinical trials (recruiting, active and completed) to 
evaluate the efficacy of AKT inhibition in various cancer types[64,221,247–252]. In 
general, results from completed trials are not encouraging and, as a result, none of 
the existing AKT inhibitors have been approved for use as cancer 
therapeutic[64,247,249,253–256]. This has not stopped pharmaceutical companies 
(Abbott, Amgen, Array, Bayer, Chiron, Eli Lilly, Genentech and Merck to name a 
few) from researching and patenting diverse small-molecule AKT inhibitors[251]. 
So, it is clear that the currently available AKT inhibitors have 
shortcomings. There are two main types of AKT inhibitors: ATP-competitive and 
allosteric inhibitors. As the name implies, ATP-competitive inhibitors compete with 
ATP for binding the kinase domain. For this type of inhibitor, the lack of specificity 
for AKT is a major issue. This comes as no surprise given the high degree of 
similarity of the AKT kinase domain with such domains from other kinases of the 
AGC kinase family. Off-target effects are such a serious problem that ATP-
competitive AKT inhibitors have largely fallen out of use as a research tool and 
should no longer be considered valid therapeutics. As such, they are not worth 
discussing in detail. 
 
The allosteric inhibitors, on the other hand, show greatly increased specificity for 
AKT over closely related kinases and have less off-target effects[221,249]. This type 
of inhibitor targets an interdomain region between the PH- and Kinase-domain, and 
prevents the activation of AKT by stabilizing the kinase in the PH-in conformation 
(Figure 13)[257]. The AKT amino acid residue Trp80, that plays an important role in 
maintaining the PH-in conformation, was revealed to be essential for the function 
of this type of inhibitor, and mutation of this site is detected in vivo at an extremely 
low frequency[25,215,258–260]. Of these allosteric inhibitors MK-2206 is the most 
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promising candidate[253]. Based on this chemical scaffold, further improvements are 
being made through structure-based drug design and the introduction of functional 
groups that result in covalent-allosteric inhibitors that permanently bind and inhibit 
their target (Table 3) [33,257,261,262]. 
 
Although the development of allosteric inhibitors was a leap forward in 
targeting AKT, these suffer from the drawback that they affect all three AKT 
isoforms. The isoform-specific, and sometimes opposed roles of the AKT isoforms 
in the regulation of certain cellular processes could explain the lack of effect of 
allosteric inhibitors in clinical trials and, perhaps the dose-limiting adverse 
effects[249,253,258]. 
 
Table 3 Allosteric AKT inhibitors. The therapeutic effect of both Mk-2206 and ARQ 
092 has been evaluated in several clinical trials. Cell-free assays were used 
to determine IC50 values[24,33,261,263]. 
 AKT1 IC50 AKT2 IC50 AKT3 IC50 Phase CAS number 
AKTi-1/2 58 nM 210 nM 2200 nM N/A 612847-09-3 
MK-2206 8 nM 12 nM 65 nM II 1032350-13-2 
ARQ 092 4.5 nM 5 nM 16 nM II 1313883-00-9 





Figure 13 Allosteric inhibition of the AKT kinases. A: Chemical structure of MK-
2206. B: Mechanism for allosteric inhibition of AKT. C: Crystal structure of 
AKT1 with an allosteric inhibitor. The PH domain interacts with both the N-
lobe (near the ATP-binding site) and C-lobe. The allosteric inhibitor (AKTi-
1/2, cyan) forms noncovalent interactions with the N-lobe, C-lobe and PH 
domain, particularly with the aromatic side chain of Trp80 (magenta). 
Allosteric inhibitors stabilize the PH-in conformation, characterized by a 
disordered activation loop, disordered and displaced αC-helix, and a blocked 
ATP-binding site. Structure from PDB 3O96, created in PyMOL.
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Chapter 2  
Nanobodies: one size fits all 
“I swear to god, I had something for this.” 
-Archer 
 The discovery of nanobodies 
To combat pathogens, such as viruses and bacteria, the adaptive immune system 
produces Antibodies (Abs). These are large proteins that bind with high affinity and 
specificity to proteins and peptides from those pathogens. Since the introduction of 
the hybridoma technology in 1975, Abs have been widely used as research tool, 
diagnostic or therapeutic. Due to their large size (150 kDa), high-production cost 
and low stability, several attempts have been made to optimize the Ab format 
resulting in what are called “next-generation antibody fragments” such as the 
Fragment antigen-binding (Fab) or Single-chain Variable Fragment (ScFV) 
(Figure 14)[264,265]. These smaller fragments ameliorated some of the issues 
encountered when working with Abs, but their production proved to be troublesome, 
in part due to stability issues, and in certain cases the functionality was lost. 
Sometimes, nature does it better. 
 
In 1993 the Hamers-Casterman group reported the serendipitous discovery of 
Heavy-chain Antibodies (HcAbs) in dromedary serum. This type of Ab completely 
lacks Light-chains and, in contrast to the HcAbs produced by malfunctioning B cells, 
are fully functional (Figure 14A)[266–268]. Later on, it was discovered that these 
HcAbs are characteristic for several members of the camelidae species including 
Bactrian camels, llamas and alpacas but also occur in certain types of sharks[269]. 
That this type of Ab has evolved independently in different species hints towards a 
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unique role or an advantage over conventional Abs. We do not know exactly what 
this role or advantage is in vivo, but that has not stopped us from making good use 
of the unique biochemical and biophysical properties of the antigen-binding 
fragments of these HcAbs. 
 Structure and properties 
2.2.1 Structure of a HcAb and nanobody 
A conventional Immunoglobulin-γ (IgG) Ab is composed of two identical Heavy-
chain (HC) and Light-chain (LC) polypeptides (Figure 14A). The LC contains two 
domains: one variable (VL) and one constant domain (CL), and the HC folds into 
one variable (VH) and three constant domains (CH). One VL-VH pair constitutes 
the antigen-binding fragment. 
As the name implies, an HcAb has no LCs but the HCs also lack the first constant 
domain, CH1. The result is that the antigen-binding fragment of an HcAb is a single 
domain, referred to as Variable domain of the Heavy-chain of HcAbs (VHH). This 
domain retains its antigen-binding capacity when isolated and is also called a 
Nanobody (Nb). 
 
A Nb is shaped more or less like a rugby ball, measures 2.5 nm by 4 nm and is 
approximately 15 kDa in size. The protein adopts a typical immunoglobulin fold with 
two antiparallel β-sheets, one with four strands and one with five strands, and a 
disulfide bond that connects both β-sheets (Figure 14B). The loops that connect 
the β-strands contain three Hypervariable (HV) regions that cluster at the N-
terminal side of the domain where they form the Complementarity-Determining 
Region (CDR) or the paratope1. The loops are enclosed by four Framework (FR) 
regions which have a more conserved sequence (Figure 14C)[268,270,271]. 
 
                                           
1 The Paratope is the part of an Ab or Nb that interacts with an antigen, the Epitope is the part of the 








Figure 14 (Previous page). Schematic representation of a camelid HcAb and its 
antigen binding fragment, the VHH or nanobody. A: Unlike conventional 
Abs, an HcAb lacks light chains and the first constant domain of the heavy 
chain (CH1). A VHH or Nb is derived from the antigen-binding fragment of 
such an HcAb. This corresponds to the single chain variable fragment 
(ScFV) which is a fusion protein of the variable domains of the heavy and 
light chains of a conventional Ab. The Fab, another antibody fragment, 
contains an entire light-chain, and VH1 and CH1 of the heavy-chain. Figure 
adapted with modifications from[271] B: Crystal structure of Gelsolin Nb 13. 
FR regions are shown in orange, HV1 in blue, HV2 in green and HV3 in 
magenta. VHH specific amino acid substitutions in FR2 are shown, with side 
chains, in red. HV regions cluster at the N-terminal side of the Nb. Structure 
from PDB 2X1O created in PyMOL[272]. C: A Nb is composed of three HV 
regions, each sandwiched between two FR regions. The HV1 and HV3 loops 
of a Nb are generally longer than the HVs of conventional Abs. Red triangles 
denote amino acid substitutions in FR2 that render a Nb more hydrophilic. 
Adapted with modifications from[271]. 
In conventional Abs, the VL and VH each contribute three hypervariable loops to 
construct the paratope, Nbs only have the three loops from the VHH. This means 
that, in theory, the Nb has only half the antigen-interacting surface of a VL-VH pair, 
but also that the diversity introduced by combining a VH and VL domain into a 
single paratope is lost. Although the VH and VHH share a high degree of sequence 
identity, evolution has introduced subtle structural changes to adapt the VHH to the 
absence of a light chain and the VL[270]. 
The HV1 loop of the VHH is extended towards the N-terminus and the HV3 loop 
is, on average, longer and more solvent exposed than that of a VH, creating a larger 
surface area (Figure 14C)[270]. VHHs often have an additional disulfide bond 
between those loops to constrain their flexibility. Additionally, the HV1 and HV2 
loops adopt conformations that are not found in VH domains where the 
conformational variability of the HV loops is restricted to a set of what are called 
‘canonical structures’[273]. The alternative loop structures and longer CDR loops 
introduce diversity into the structural repertoire and increase the surface area of the 
VHH paratope[270,273]. Another difference lies in the functional distinction of amino 
acid residues as ‘scaffold’ or ‘antigen-binding’. Although the same methods (such 
as KABAT numbering) are used to discriminate between paratope and non-
paratope residues for both Abs and Nbs, this difference is less clear in Nbs where 
certain FR residues can form contacts with the antigen and not all loops contribute 
equally to antigen-binding. 
 
Based on a structural analysis of over 100 Nb:antigen crystal structures, the size 
of a Nb’s paratope was determined to range from 570-950 Å2, quite a bit larger than 
that of a VH (350-750 Å2) and not much smaller than that of a VH-VL pair (680-
1160 Å2). Nbs also have a much higher pairwise residue-residue contact density 
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(0.454 for a Nb versus 0.262 for a VH-VL pair), thus despite the smaller paratope, 
they form almost as much contacts with their antigen as a VH-VL pair[268,270,274–278]. 
Because it does not interact with a VL domain, the framework of a VHH has a 
larger solvent exposed area[270]. The exposed hydrophobic patch of about 700 Å2 
is the main reason why VH domains are prone to aggregate in the absence of a VL 
domain. The VHH has evolved to function without VL and has specific amino acid 
substitutions in this region that increase hydrophilicity (Figure 14B and C). Mutation 
of these residues in a VH to amino acids found in a VHH (Val34->Phe, Gly44->Glu, 
Leu45->Arg and Trp47->Phe), also known as ‘camelising’ a VH increases the 
solubility, vice versa, substitution of these residues in a VHH to mimick a VH leads 
to dimerization of the humanized VHH[279,280]. It should be noted that ‘camelising’ a 
VH introduces deformations in the amino acid backbone. This hydrophobic patch 
is, in VHHs, also partially shielded from the solvent by the HV3 loop which folds 
over this region and buries amino acids that would otherwise participate in the 
interaction with a VL. 
2.2.2 Nanobody properties and characteristics 
Nbs are small. With a molecular weight of only 15 kDa they are, to date, the smallest 
naturally-occurring2 antigen-binding fragments[281–284]. Their small size is an 
advantage for binding epitopes where the steric hindrance of the larger 
conventional Abs forms an obstacle. Moreover, the HV loops of a Nb can form a 
convex paratope which makes them particularly suited for targeting cavities on the 
surface of an antigen, such as the active site of enzymes[285,286]. Other types of 
paratope architecture such as a flat surface or a cavity have also been observed[287–
289]. Nbs mainly bind conformational epitopes, those that interact with linear 
epitopes have also been reported but they are more rare[272,286,290–292]. 
 
Apart from their small size and unique paratope architecture, Nbs have several 
other favourable characteristics. The in vivo affinity maturation of HcAbs ensures 
that Nbs (at least those from immune libraries) interact with their targets with high 
specificity and affinity. Affinities in the nano- or picomolar range are frequently 
obtained[268,274,293]. Stability is another hallmark of Nbs. They are resistant to both 
heat-induced unfolding and denaturation by chaotropic agents with a reported Tm 
 
                                           
2 Synthetic binding proteins or antibody mimetics are proteins that can specifically bind proteins but 
are not structurally related to antibodies. These are derived from naturally occuring scaffolds and range 
in size from 6 to 20 kDa. Although they have similar characteristics as Nananobodies concerning stability 
and production, they do not benefit from in vivo affinity maturation. 
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ranging from 60 to 80 °C and Cm values of 2.3 to 3.3 M for guanidinium 
hydrochloride and ≥ 6 M for urea. Although this is more likely to be the exception 
than the rule, certain Nbs can even recover their fold and functionality after 
denaturation[294–297]. Generally, Nbs do not suffer from the reducing cytoplasmatic 
environment and retain functionality in the absence of disulfide bonds[293,298–300]. In 
our experience, there are only a few examples where a Nb can no longer bind its 
target when expressed as an intrabody, but this could also be due to aggregation 
of the Nb, low affinity or that the antigen exists in a state (protein complex or PTMs) 
that is not recognized by the Nb[284,290,301–305]. 
 
Furthermore, the fact that Nbs are encoded by single exon of ±350 base pairs, 
enables easy cloning and engineering. Although Nbs already have a low 
immunogenicity due to the high sequence homology with the human VH, they can 
be ‘humanized’ through directed mutation of specific FR amino acid residues to 
more closely resemble a human VH. The same technique can also be used to 
modify the Nb sequence to further improve on their affinity and stability. These 
modifications are not always without risk, as attempting improving one 
characteristic can negatively affect another[297,306–310]. Nbs can be linked to tags, 
made into bi-specific interactors, linked to a fluorescent moiety, or one can 
introduce functional groups for downstream modification[301,311–313]. 
 
Because of their single-domain structure, the recombinant production of a Nb is 
much easier and cheaper compared to that of conventional Abs or next generation 
Ab fragments. Nbs can be produced in E. coli with yields up to 100 mg/L culture or 
in yeast where the yield can be up to 250 mg/L. Another advantage of Nbs over 
conventional Abs is their long shelf life. Under physiological conditions, Nbs remain 
soluble at high concentrations (>30 mM), at 37 °C they remain stable for a few 
weeks, they can be stored at 4 °C for several months or for much longer at -20 
°C[314,315]. 
 Nanobody generation and characterization 
The creation of new Nbs is a straightforward procedure, yet it has some labour-
intensive parts and is time consuming[316]. In capable hands, the whole procedure 
can be completed in under three months. 
For the generation of an immune library, a camelid is subjected to weekly 
injections with the antigen(s) for a duration of six weeks (Figure 15). This ensures 
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the production of affinity-matured HcAbs. Five to ten antigens can be injected 
simultaneously. The desired function of a Nb is an important factor in the choice of 
antigen. Immunizing a camelid with a natively folded protein will result in Nbs that 
can bind conformational epitopes, a denatured protein on the other hand, has a 
higher probability of generating Nbs that can serve as detection reagent in Western 
blotting or immunohistochemistry of fixed samples. If the antigen is a 
transmembrane protein, a DNA-based immunization can be performed or the 
protein should be reconstituted into lipid vesicles prior to immunization. By 
alternately injecting orthologues proteins, species cross-reactive Nbs can be 
obtained[317–321]. 
After this immunization, blood is collected from which lymphocytes can be isolated. 
Following RNA extraction and RT-PCR, the Nb gene fragments coding for the 
antigen-binding domain of the HcAbs can be amplified using PCR and cloned into 
a phagemid vector. After this, multiple rounds of phage display and panning are 
performed to enrich specific binders. The positive clones are then screened by 
ELISA and sequenced[316]. Alternative techniques such as bacterial/yeast two-
hybrid and lentiviral screening are suboptimal for handling large libraries but will 
only enrich Nbs that are stable in a reducing environment and that can still interact 
with their antigen when expressed intracellularly[320,322]. 
 
Figure 15 Generation of nanobodies. Schematic representation of the Nb generation 
process which is used at the Nanobody lab (UGent), and was used at the 
VIB/VUB Nanobody Core to generate the Nb sets used throughout this 





When immunization of an animal is not an option, for example when the antigen 
has low immunogenicity or is toxic, naïve or synthetic libraries can be used. Naïve 
libraries are derived from lymphocytes of a non-immunized animal and synthetic 
libraries are generated by randomizing amino acid residues of the HV loops on a 
fixed framework. The upside is that one does not need to immunize an animal which 
makes the process a lot faster, the downside is that the resulting Nbs are not 
affinity-matured and may require substantial engineering to improve their 
affinity[324,325]. 
 
After obtaining the Nb cDNA, an arduous screening has to be performed to 
winnow down a (sometimes extensive) Nb set to a manageable number of 
candidates for functional experiments. Although the criteria for retaining a Nb differ 
from project to project, a good starting point is to select Nbs that can interact with 
the endogenous antigen in a relevant context, for example, expressing the Nbs 
intracellularly followed by immunoprecipitation for intrabody applications or 
evaluating antigen binding through flow cytometry in case the antigen is a cell 
surface protein. The next step would be to determine the affinity of the Nbs for their 
antigen. Techniques such as isothermal titration calorimetry, surface plasmon 
resonance, biolayer interferometry and microscale thermophoresis are all viable 
options, but the low throughput and high sample consumption of isothermal titration 
calorimetry makes it less optimal for large Nb sets. A Nb set is subdivided into 
groups based on the sequence homology and length of their HV3, and Nbs from 
the same group bind to the same epitope on the antigen[320]. After measuring the 
affinity of a Nb, this grouping can be used to select the strongest interactors within 
a group. 
For projects where protein function is investigated, the specific epitope that is 
bound by a Nb is an important factor. It is advisable to perform an epitope mapping 
prior to functional experiments. If the antigen consists of several distinct protein 
domains, a simple pull-down or ELISA strategy can be employed[290,326]. Other 
techniques, such as cross-linking mass spectrometry or determining a 3D-structure 
of the Nb:antigen complex, are much more intensive but will also yield more 
detailed information[276,327]. These guidelines should enable the selection of a few 




One could say that nanobodies are a ‘jack of all trades’ but, the second half of this 
figure of speech, ‘master of none’ is not applicable. The potential of Nb-based 
applications is illustrated by the number of (start-up) companies that are based on 
nanobody technology. As there are plenty of very well written reviews on this 
subject I will try (but probably fail) to be succinct and focus on a few examples which 




Figure 16 (Caption on next page). 
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Figure 16 (Previous page). Nanobody applications. A: The delocalization of 
endogenous proteins to the mitochondria by genetically fusing a Nb to a 
mitochondrial outer membrane (MOM)-tag[290]. B: Targeted degradation of 
an endogenous protein by the proteasome through AdPROM. A Nb that 
binds a protein of interest (antigen) is genetically fused to the substrate 
recognition domain of the Cullin-RING E3 Ubiquitin ligase complex, resulting 
in ubiquitylation and proteasomal degradation of the Nb’s antigen[333]. C: 
SPECT/CT imaging of amyloid deposits using a 99Tc-labeled FAF Nb[334]. D: 
Visualization of invadopodia in cells that were fixated after photoporation 
with Cortactin Nb2-AF488 (Green) compared to a conventional Cortactin Ab 
(Red)[335]. E: Crystal Structure of the Nb-stabilized active state of GPCRs. 
Such structures can aid in the rational design of more efficient 
therapeutics[318]. F: A Nb interacts with and prevents the EGF-induced 
phosphorylation of Cortactin[301]. 
2.4.1 The use of nanobodies in diagnostics and therapy 
Nbs’ low immunogenicity, high stability, superior tissue penetration, fast clearance 
and unique epitopes make them well suited for diagnostic and therapeutic 
applications. 
 Diagnostics (it’s just a flesh wound) 
Nanbodies have been applied as tracers for in vivo PET/SPECT imaging 
(Figure 16C). Their rapid tissue penetration and high specificity allows imaging as 
early as 1 h after injection. This enables the use of radionuclides with short half-
lifes, without sacrificing image contrast[281]. Using this technology, radiolabeled Nbs 
(99Tc, 68Ga, 18F or 111In) have been used to detect atherosclerotic plaques, amyloid 
deposits and tumours[281,334,336–338]. However, their rapid clearance results in high 
tracer intensity in the kidneys and bladder, which makes imaging nearby targets 
next to impossible, and Nbs are still somewhat more expensive to produce than 
peptide-derived tracers. 
 
A Nb can replace conventional antibodies when used in diagnostic tests such as 
antibody-based slides or arrays and have already been used as biosensors to 
detect HIV and Trypanosoma[312,339]. In this case the high specificity and, 
particularly, high yield/low cost production is considered a huge boon[340–343]. 
 Therapeutics 
Nbs possess most of the characteristics that make an Ab a good therapeutic. One 
drawback is that, due to the lack of an Fc-region, Nbs are unable to trigger antibody-
dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. 
Purely as immunotherapeutic their efficacy is inferior to that of Abs, although the 
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lack of an Fc-region could also reduce unwanted immune-mediated effects. Yet, 
the size of an Ab is limiting for tissue penetration and the high production cost puts 
a huge strain on public healthcare systems[293]. Nbs on the other hand have 
excellent tissue penetration and can be manufactured at a relatively low cost. Abs 
are administered by injection, but Nbs can also be administered through inhalation 
and there is even an example of a protease-resistant Nb that can be 
ingested[293,332,344,345]. Add to that their improved stability and long shelf life, and it is 
not surprising that Nbs are being investigated for therapeutic purposes.  
 
The ease by which Nbs can be modified enables their use as a targeting module 
for therapeutics. In a similar strategy as is used for imaging, a radionuclide labeled 
Nb can also be used to deliver cytotoxic radiation to cancer cells. Camel-IDS, a 
VUB spin-off company, developed CAM-H2 (an 131I-conjugated anti-HER-2 Nb) for 
treatment and imaging of advanced/metastatic HER-2 positive cancers. A Phase 
I/II clinical trial (NCT04467515) for this radiopharmaceutical is expected to be 
completed by 2025[346]. Apart from radionuclides, Nbs can also be used for targeted 
pro-drug delivery or the directed delivery of toxins or nano-sized drug carriers to 
tumours [282,293,347–351]. By using Nbs that bind tumour associated antigens that are 
expressed on the surface of cancer cells, the damage to healthy tissues is greatly 
reduced[352–354]. 
There are also Nbs with ‘intrinsic therapeutic activity’ (Figure 16F). Such Nbs 
can, for example, act as antagonists for extracellular receptors, block their function 
and suppress downstream signalling. Nbs against both EGFR and c-MET show 
anti-proliferative effects in vitro and a modified EGFR Nb inhibits tumour growth in 
vivo[350,355,356]. In addition to cell-surface targets, Nbs are also being investigated to 
target intracellular proteins such as CapG, but this a novel approach that will take 
much longer before it can be implemented as a form of therapy[305,357]. The modular 
nature of Nbs allows simultaneous targeting of distinct tumour-related proteins 
which could prevent tumours from acquiring resistance to inhibition of a single 
pathway. Also, bispecific Nbs where one Nb targets the Fc-receptor, can trigger 
antibody-dependent cell-mediated cytotoxicity[358,359]. 
 
Apart from cancer, clinical trials are ongoing to investigate Nbs as a means to 
combat various infections and diseases such as psoriasis, rheumatoid arthritis, 
inflammatory bowel disease, thrombocytopenic purpura and respiratory syncytial 
virus[350,360]. Highly relevant today are Nbs that target the SARS-CoV-2 spike 
protein. Although these have not yet reached clinical trials, they could be of great 
value as therapeutics to combat the coronavirus pandemic[361–365]. 
Caplacizumab, which is the first EMA- and FDA-approved Nb-based therapeutic, 
deserves special mention. This Ablynx – Sanofi product that targets and inhibits the 
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von Willebrand factor to treat a rare blood-clotting disorder (acquired thrombotic 
thrombocytopenic purpura), was approved in 2018 and 2019 in Europe and the 
USA, respectively. Although it has taken a while, this illustrates that it’s all about 
finding a niche that plays to the Nbs’ strengths, and has opened the door (or 
floodgates) for renewed interest in Nb-based therapeutic applications[366,367]. 
2.4.2 Nanobodies as tool for fundamental research 
Although the therapeutic applications show great promise, the success stories have 
been few and far between. Where Nbs truly shine (so far) is in their application as 
a research tool[274,332]. Nbs can be used as an alternative to conventional Abs in 
many applications including, but not limited to ELISA, Co-immunoprecipitations and 
immunocytochemistry[311]. Several companies exist that develop and 
commercialize Nb-based tools or offer custom-made Nbs (Creative Biolabs, 
ChromoTek, GenScript, Gulliver Biomed BV, ProSci Inc., ...). There are 
applications where a Nb is simply a (superior) alternative to a conventional Ab, but 
in many cases the use of a Nb offers a specific advantage. 
 Nanobodies to unravel protein function (whodunnit?) 
Ever since we obtained the tools to do it, the go-to technique for studying protein 
function has been to remove a protein of interest (POI) and look for the resulting 
phenotype (what did we break?). 
Gene knockdown techniques such as RNAi and knockout techniques such as 
CRISPR-Cas9 are commonly used to achieve this in in vitro settings[368,369]. As no 
technique is perfect, these also come with their disadvantages. RNAi suffers from 
off-target effects: the seed sequences can downregulate mRNAs unrelated to the 
gene of interest[370,371]. This technique is also inconvenient for depleting proteins 
with a long half-life or proteins of which the mRNAs have a high turnover rate[372]. 
Furthermore, the results are variable and, in most cases, one does not reach a 
complete knockdown of the target protein[373–377]. 
Due to its higher efficacy, simplicity and specificity, CRISPR-Cas9 has rapidly 
become the most used genome editing technology[378]. This technique is derived 
from a prokaryotic defense mechanism against foreign genetic elements, and also 
suffers from off-target effects[378–381]. This is particularly concerning since CRISPR-
Cas9 permanently modifies the genome[377].The genes that can be targeted by 
CRISPR-Cas9 are somewhat limited by the need for a Protospacer-Adjacent Motif 
(PAM) sequence next to the target. This is partly ameliorated by the different PAM 
sequence selectivity of Cas orthologs, and efforts are ongoing to engineer Cas 
variants that further expand the targeting potential[377,382]. CRISPR-Cas9 is much 
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more versatile than RNAi as it allows gene knockout, targeted mutation, transient 
silencing and can even be used to induce transcription of genes[368,377,383]. Of all the 
available methods CRISPR-Cas9 is the most efficient and it is still being improved 
upon[378,381]. The discovery of this revolutionary tool was awarded with the Nobel 
Prize in Chemistry in 2020. 
 
In the case of enzymes, small-molecule inhibitors are a valid alternative to study 
protein function without dowregulation of expression levels. Here, off-target effects 
can (again) be a serious issue. This is particularly troublesome for kinases, a 
subclass of enzymes that plays a prominent role in many (patho)physiological 
processes, which have ATP as a common substrate[384]. Off-target effects are 
believed to be the main reason for the 90% attrition rate of small-molecule inhibitors 
in late stage clinical trials. For AKT, even an inhibitor with little off-target effects is 
no good as, despite the serious efforts made to develop an isoform-specific 
inhibitor, the best candidate still affects all three isoforms[385]. Furthermore, if one 
can only inhibit enzyme activity, one is seriously restricting the range of proteins 
one can investigate[386]. Structural proteins and protein-protein interactions are 
much more difficult to target using small-molecules[272,387]. 
An elegant solution to this problem is the use of targeted proteolytic degradation 
to deplete a POI. This technique relies on Proteolysis Targeting Chimeras 
(PROTACs), molecules that bind to both a POI and an E3 ubiquitin ligase, resulting 
in the ubiquitylation and proteasomal degradation of the POI. The PROTAC itself 
is not degraded and can initiate the degradation of several POI molecules[388–390]. 
Nonetheless, one does not easily achieve a full knockdown, and there is no clear 
relation between the affinity of a PROTAC for its target, and its efficacy[388]. 
PROTACs incorporate small molecules for targeting the POI and will suffer from 
the same off-target effects as that small-molecule[390–392]. 
 
Nbs are high-affinity interactors that, unlike genetic approaches, can target 
proteins directly and, unlike small-molecule inhibitors, can be used to target 
structural proteins. As intrabodies, they can induce a protein functional knockout by 
directly inhibiting the function of a protein or they can block protein-protein 
interactions, either directly by occupying a part of the target protein needed for the 
interaction or by locking their antigen in a conformation unsuited for binding 
interaction partners. This can result in a fully intact protein that is no longer able to 
perform a specific function, without affecting the expression levels of the whole 
protein[272,301,302,304,305,393]. This molecular scalpel that allows specific modulation of 
a protein function stands in contrast to the downregulation of a protein and all its 
functions in a knockdown or knockout. 
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A well-known example of this is the use of Nbs to study GPCR function. Nbs 
have been used as chaperones to stabilize the active conformation of the β2AR, 
M2R and μOR and have aided in the crystallization of the first GPCR-G protein 
complex[317]. The same Nbs, coupled to EGFP, allowed tracking of GPCR activation 
dynamics in living cells[394]. Moreover, Nbs that were generated for an antagonist-
bound GPCR were able to selectively inhibit distinct downstream signalling 
pathways, demonstrating their value as tools to study GPCR function[393,395]. The 
same is true for p53 Nbs developed by our lab. A Nb that binds the p53 DNA binding 
domain and interferes with p53 transcriptional activities, without perturbing 
conformation or DNA-binding was characterized. This Nb can target a single p53 
function, something which has not yet been achieved using other tools[396]. Our 
group has also used Nbs for the actin binding proteins N-WASP, Fascin, Cortactin 
and L-Plastin to study podosome or invadopodia formation dynamics. These actin-
rich membrane protrusions are involved in (cancer) cell migration and invasion. For 
L-Plastin, two Nbs were characterized that bind distinct domains and exert different 
effects. L-plastin Nb5 blocks actin bundling and Nb9 locks L-Plastin in an inactive 
conformation. Not only did these Nbs allow the researchers to determine the 
precise contribution of these proteins and specific domains to the formation and 
function of podosomes and invadopodia, they could also be used to downregulate 
these structures[301,302,304,397–401]. 
2.4.2.1.1 Nanobody-enabled drug design 
Although the main goal is to better understand the function of a protein or study 
signalling pathways, Nbs can also be instrumental in drug discovery. Functional 
Nbs can be used to validate a signalling pathway, a protein, a specific interaction, 
a protein domain or even a specific epitope as a therapeutic target[402]. When 
sufficiently characterized, these Nbs show which ‘therapeutic epitopes’ are worth 
pursuing for drug design. The convex paratope of Nbs is particularly suited to define 
pockets which could be targeted by small-molecules[403]. This method of structure-
based drug design requires detailed three-dimensional structures of the protein-Nb 
complex. Alternatively, screening can also be performed by finding small molecules 
that bind pockets that are only accessible when the protein structure is stabilized 
by the Nb, or that compete with the Nbs for binding their target[395,404]. 
 
Nbs can be used as chaperones to enable crystallography of target proteins 
(Figure 16E). The stabilized structure of an (in)active GPCR that was obtained 
through use of conformation-specific Nbs (ConfoBodies®) is a superior starting 
point for the discovery of new agonists or antagonists[395,402,405,406]. Intracellular Nbs 
that lock GPCRs in a specific conformation allow screening for conformation-
specific small molecules[395]. For example, Nbs that target the κ-opioid receptor 
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could accelerate the rational design of safer opioid medications[406]. Confo 
Therapeutics is a drug discovery company dedicated to rational drug design based 
on Nb-stabilized GPCR protein structures. 
Key conformational intermediates of β2-microglobulin amyloidogenesis could be 
determined through X-ray crystallography by trapping the protein in these 
conformations using Nbs. This research discovered protein-protein interactions that 
are potential targets for small molecules[407]. 
 
A publication by Overington et al. from 2006 stated that all approved small-
molecule drugs with a known mode-of-action exert their effect through only 207 
human protein targets, which is slightly over one percent of all coding genes[408,409]. 
Those protein targets are not equally distributed over the complete proteome. 
Certain gene families such as GPCRs, nuclear receptors, ligand-gated ion 
channels and kinases are over-represented. The same goes for protein domains: 
all current drugs target only 130 ‘druggable domains’ while there are over 10,000 
known protein folds[409,410]. The innovation rate for novel drug targets is rather low, 
with most ‘new’ drugs being an improvement on an existing one but targeting the 
same protein. This could indicate that we have already picked the ‘low hanging 
fruits’ and that new technological developments are needed to improve our ability 
to tackle new targets such as structural proteins or difficult targets that were 
previously considered undruggable. Nbs could be one of the tools that causes a 
paradigm shift in drug discovery and development. 
 Engineering nanobodies 
Not all Nbs affect protein function. There are examples of Nbs that efficiently bind 
their target, yet have no measurable effect on protein function[290,303,411]. Luckily, 
Nbs are easily engineerable, meaning that those Nbs (but also functional Nbs), can 
be modified to expand their use as a research tool.  
Nbs can be linked to localization tags and used to displace their target from its 
natural environment (Figure 16A). This can restrict a protein’s access to interaction 
partners or substrates and trigger a loss-of-function[290,303,400]. Delocalization of 
Fascin-1 to the Mitochondrial Outer Membrane (MOM) using MOM-localization 
tagged Nbs led to the discovery of its role in MMP-9 secretion. This effect is 
independent of Fascin-1-induced F-Actin bundling, a process that is inhibited by 
the untagged Nb[400]. 
To overcome the shortcomings of RNAi in targeting long-lived proteins, 
alternative techniques that trigger protein degradation have been developed 
(Figure 16B and paragraph 2.4.2.1). Just like a PROTAC, the Nb-based 
techniques exploit the ubiquitin proteasome pathway. But, in this case, Nbs are 
used as the substrate recognition domain of an E3 ubiquitin ligase complex. This 
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induces ubiquitylation and proteasomal degradation of the target protein. This 
approach does not require small molecules and results in less off-target effects but 
requires transfection/transduction or internalization of the Nb-constructs. These 
techniques (deGradFP, Protein-i and AdPROM) have been used to degrade GFP-
tagged proteins and ASC[333,412–414]. 
 
Nbs are also suited as a primary detection reagent in fluorescence microscopy 
(Figure 16D)[274,290]. This does not sound groundbreaking at first, and when used 
in conventional microscopy it does not offer much benefits, apart from a cheaper 
and more straightforward protocol[274]. However, with the development of super-
resolution microscopy techniques (STED, STORM and PALM), the use of labelled 
Nbs as nanoscale detection tools has gained traction. When using indirect 
immunohistochemistry (a primary and secondary Ab) for protein detection there is 
quite some distance between the protein and the dye used for detection (12 – 15 
nm per Ab). This increases the apparent size of the visualized structure by up to 
24-30 nm[274]. This ‘linkage error’ can be reduced four- to seven-fold by using a 
fluorophore labeled Nb[335,415,416]. To put this in numbers: a microtubule is known to 
have a diameter of 25 nm. Using conventional methods (primary and secondary 
Ab) a microtubule has an apparent diameter of 45 ± 5.8 nm, but using AF647-anti-
GFP Nbs to detect YFP-Tubulin Ries et al. were able to resolve the diameter to 
26.9 ± 3.7 nm[417]. Nbs in combination with site-specific labeling will likely have a 
big role in super-resolution microscopy. 
As Nbs remain stable in the reducing cytoplasm they can also be used for live-
cell imaging. Staining with conventional Abs requires fixation, which is incompatible 
with the study of dynamic processes[418]. The genetic fusion of a protein with a 
fluorescent protein (GFP, YFP,...) is also an option, through CRISPR-Cas9 gene 
editing this can even be done while maintaining near to endogenous expression 
levels[419,420]. This reduces the artefacts induced by protein overexpression, but the 
fusion to a fluorescent protein changes a protein’s properties and can still lead to 
mislocation, loss of function and self-oligomerization[311,335,418,420,421]. A recombinant 
Nb with a fluorescent tag can bind and track its target under native conditions when 
it is introduced into a cell[311,335]. Chromobodies®, which are Nbs genetically fused 
to fluorescent proteins, are a ChromoTek product. This method requires 
transfection and, in light microscopy, EGFP is seen as a 400 nm haze which makes 
Chromobodies® unsuitable for high-resolution techniques[422]. Manduhai Nbs, a 
Gulliver Biomed BV product, can be easily and efficiently labeled through click-
chemistry. This allows customizable, site-specific modification of Nbs, including 
linkage to Alexa Fluor fluorescent tags[293,311,335]. Manduhai Nbs are potentially 
superior for microscopy applications but require internalization when they are to be 
used in live cell imaging[311,335]. 
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 Nanobodies: buyer beware 
The previous paragraphs illustrate that Nbs have an enormous potential as a tool 
to study protein function. But this is by no means an argument for the exclusive use 
of Nbs. Each technique has its own advantages and disadvantages, and different 
techniques should be considered complementary. We need not sugarcoat the fact 
that Nbs also come with their disadvantages. 
 
The main one is that unmodified Nbs cannot cross the cell membrane[274]. Since 
one obtains a Nb’s cDNA, which can be cloned into a new vector backbone, the 
most straightforward solution is the use of transfection or transduction to obtain 
intrabodies. In the case of an inducible expression system one can even tune the 
expression levels of a Nb to those of its target. 
Multiple research groups are looking into ways to pilot proteins through the cell 
membrane, these methods can also be applied to Nbs. Certain techniques such as 
cell squeezing, electroporation or microinjection are only feasible when the protein 
has to be delivered to a limited number of cells. For microinjection up to 25 
injections per minute was achieved for adherent cells, electroporation is more high-
throughput but detrimental to cell viability[423]. Most proteins can be fused to a cell 
penetrating peptide (TAT-PTD, Penetratin, 8R, ...), these have a length from 8 to 
20 amino acids, at least 5 of which are positively charged[424]. There is no 
consensus on the mechanisms that are responsible for the cellular uptake of 
proteins that were linked to these peptides and the efficiency is generally low due 
to endocytic entrapment and cell toxicity[423,424]. Recombinant p53 Nbs that were 
linked to a cyclic arginine-rich cell-penetrating peptide are efficiently delivered into 
cells. However, these types of peptide (and the linked protein) accumulate in the 
nucleolus[425]. As a positive charge appeared to be a determining factor on uptake, 
research groups have edited the Nb framework to generate Nbs with a theoretical 
charge of up to +15 that can access the cytosol of mammalian cells[426]. Such a high 
net charge at physiological pH is not common for proteins and it is unclear what 
effects these mutations in the Nb framework have on the detailed 3-D structure, 
intracellular localization and antigen-binding[427]. Another group is exploiting the E. 
coli type III secretion system to inject proteins into cells[305,357]. 
A recent, and very interesting development in this field is photoporation, where 
proteins, including Nbs, can be introduced into live cells by laser light and gold 
nanoparticles or graphene quantum dots. The laser light heats the nanoparticles or 
quantum dots which causes a phase transition in the lipid bilayer when using low-
intensity laser light or form a vapour nanobubble in the case of high-intensity laser 
light[311,335,428,429]. Both cause local perforation of the membrane and allow the 
diffusion of proteins from the surrounding medium into the cells. The pores close 
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within seconds to minutes. Gold nanoparticles tend to shatter after a single laser 
pulse while graphene quantum dots are more resistant and form larger pores 
through vapour nanobubbles. Photoporation combines speed, high throughput, 
delivery efficiency and low toxicity in a single technique and has already been 
proven to be effective for the introduction of fluorescently-labeled Nbs into cells for 
live-cell imaging[311,335]. 
 
Another flaw is that Nbs themselves are also susceptible to off-target effects, as 
is the case for every type of interaction between biomolecules. Although the 
occurrence of off-target interactions can be investigated by screening for interaction 
with closely-related proteins or a cellular thermal shift assay, one is hard pressed 
to find examples of this in the literature[430]. 
 
A third drawback when using Nbs is that, although this is quite exceptional, some 
Nbs can lose their functionality in a reducing environment[290]. The fourth catch is 
the investment, both in time and financially, involved in Nb production. Although the 
materials needed for panning and library construction are relatively inexpensive, 
animal housing and immunization is quite costly. Of course, so is the generation of 
novel monoclonal Abs or a CRISPR-Cas9 knockout. There is also no guarantee 
that an immunization will yield Nbs with an intrinsic effect on the function of the 
antigen. Given the options for Nb engineering this is not a serious issue, but it does 




Aim and scope 
“I’ll be honest, we’re throwing science at the 
wall here to see what sticks. No idea what it’ll 
do. Probably nothing.” 
-Cave Johnson 
Cancer is the second leading cause of death worldwide, with the highest incident 
rates in developed countries[431,432]. There are over 100 types of cancer and the 
characteristics that confer a proliferative advantage, also known as hallmarks of 
cancer, are shared by most types of human cancers (Figure 17)[161,433]. 
Unfortunately this does not mean that two types of cancer that possess the same 
characteristics will respond to the same treatment, as the cellular mechanisms 
through which a hallmark is acquired often differ. The characterization of 
dysregulated cellular mechanisms and their effects on tumour progression are 
integral to the identification and validation of molecules for targeted cancer therapy, 
a strategy that has gained in importance over the last years. 
 
The AKT protein kinase family regulates several cancer hallmarks, and AKT 
hyperactivation is a common molecular characteristic in human cancer 
(Figure 17)[6]. The discovery that the AKT isoforms can have opposing effects on 
certain cellular processes has made it abundantly clear that we cannot view AKT1, 
AKT2 and AKT3 as a single entity concerning signalling pathways. However, 
figuring out the exact contribution of each isoform to malignant progression, or 
targeting a single AKT isoform for cancer therapy is easier said than done. There 
are currently no small-molecule inhibitors that enable the specific targeting of a 
single AKT isoform. Despite this, certain inhibitors are being marketed as isoform-
specific, while in reality they only have a slight preference for a specific isoform at 
best, or no selectivity whatsoever at worst. This illustrates the necessity of such 
isoform-specific inhibitors. As the conventional methods used so far have not 
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yielded the desired result, it was high time to explore new approaches. A high 
degree of interaction specificity is required to enable a molecule to selectively bind 
a single AKT isoform, as it happens, this is something that Nbs excel at. 
Furthermore, a Nb is more likely to mimic the effect of a small-molecule inhibitor 
and can assist in the design or evaluation of novel therapeutics[284,395,404]. 
 
 
Figure 17 The hallmarks of cancer and AKT. This classification of cancer hallmarks 
represents an effort to bring some order to the chaos and complexities of 
human cancer. The inner ring of six hallmarks that include evading 
apoptosis, sustaining proliferative signalling, evading growth 
suppressors, sustained angiogenesis, invasion and metastasis, and 
replicative immortality are distinct, but complementary capabilities that are 
acquired progressively by incipient cancer cells as they progress to full-
blown malignant tumor cells. The outer ring contains two emerging 
hallmarks; deregulating cellular energetics and avoiding immune 
destruction, and also the two enabling characteristics (genome instability 
and tumor-promoting inflammation) that lie at the base of all other 
hallmarks and, in a way, are to blame for the dysregulation of cellular 
processes that lead to the emergence of a cancer hallmark. The hallmarks 
highlighted in orange are those that depend on cellular processes regulated 
by one of the AKT isoforms. The design of this figure was shamelessly stolen 
from Anneleen Steels and the hallmarks of cancer are based on[161,433]. 
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The primary objective was to generate Nbs that selectively interact with a single 
AKT isoform (Chapter 3). The allosteric inhibitors have shown that targeting the 
PH domain is a valid approach for inhibition of AKT. Therefore, in the first part of 
this research project we have used Nb technology to obtain isoform-specific 
interactors that interact with the AKT PH domains, including the oncogenic AKT1 
mutant, but also for full-length AKT2. As Nbs (generally) remain stable in the 
reducing cytoplasm, these tools can then be applied to study the function of 
individual AKT isoforms in a relevant cellular context without resorting to the 
downregulation of protein expression.  
 
Due to its effect on the migration and metastasis of breast cancer cells, the AKT2 
isoform deserves extra attention (Chapter 4). As we obtained several isoform-
specific Nbs that interact with distinct domains of the AKT2 kinase, this was a great 
opportunity to study the function of these individual AKT2 domains. Functional Nbs 
can be more than just a research tool; as is being explored for GPCRs, these Nbs 
could be used for structure-based drug design and be a stepping stone towards the 
first isoform-specific AKT inhibitor[395]. AKT2 Nb9 interacts with the PH domain and 
interfered with the PH-PIP3 interaction in vitro, Nb5 binds the protein kinase domain 
and has the potential to interfere with the catalytic activity of AKT2. But Nb8, which 
binds the AKT2 regulatory domain, is particularly interesting. It has been shown 
that this domain plays a role in fine-tuning AKT activity but has not yet been 
explored as a therapeutic target[82,86,175]. By using these Nbs as research tools we 
can study AKT2-specific signalling pathway and determine the contribution of 










Chapter 3  
Development and characterization of 
Protein Kinase B/AKT isoform-specific 
Nanobodies 
“Dear Reviewer 2: Go Fuck Yourself” 
-David A.M. Peterson[434] 
 Aim of the study 
As stated in Chapter 1, the AKT kinases are a promising and high-profile target for 
cancer therapy. However, the distinct, and sometimes opposed roles of the AKT 
isoforms have demonstrated that the tools which are available today to target AKT 
are inadequate. As there is still much room for improvement, we developed and 
characterized new tools, these being anti-AKT nanobodies, with the primary goal 
of obtaining isoform-specific interactors. These tools are complementary to gene 
knockdown techniques, represent a novel approach to target individual AKT 




 Research article 
Merckaert T, Zwaenepoel O, Gevaert K, Gettemans J (2020) Development and 
characterization of protein kinase B/AKT isoform-specific nanobodies. PLoS 
ONE 15(10): e0240554. https://doi.org/10.1371/journal.pone.0240554. 
 Abstract 
The serine/threonine protein kinase AKT is frequently over-activated in cancer and 
is associated with poor prognosis. As a central node in the PI3K/AKT/mTOR 
pathway, which regulates various processes considered to be hallmarks of cancer, 
this kinase has become a prime target for cancer therapy. However, AKT has 
proven to be a highly complex target as it comes in three isoforms (AKT1, AKT2 
and AKT3) which are highly homologous, yet non-redundant. The isoform-specific 
functions of the AKT kinases can be dependent on context (i.e. different types of 
cancer) and even opposed to one another. To date, there is no isoform-specific 
inhibitor available and no alternative to genetic approaches to study the function of 
a single AKT isoform. We have developed and characterized nanobodies that 
specifically interact with the AKT1 or AKT2 isoforms. These new tools should 
enable future studies of AKT1 and AKT2 isoform-specific functions. Furthermore, 
for both isoforms we obtained a nanobody that interferes with the AKT-PIP3-
interaction, an essential step in the activation of the kinase. The nanobodies 
characterized in this study are a new stepping stone towards unravelling AKT 
isoform-specific signalling. 
 Introduction 
The PI3K/AKT/mTOR pathway is one of the most frequently dysregulated pathways 
in cancer, up to 30% of human cancers have obtained mutations in one or several 
members of this pathway[53,435]. One of its central nodes, the Ser/Thr protein kinase 
AKT (also known as Protein Kinase B), regulates multiple cellular processes, 
among them cell survival, metabolism, growth and proliferation[435]. Although AKT 
itself is rarely mutated, the proteins that regulate AKT such as PI3K, PTEN and 
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PHLPP are frequently mutated, resulting in increased AKT activity, tumour cell 
growth and survival[436]. This made AKT an attractive target for the treatment of 
tumours with PI3K/AKT/mTOR pathway mutations[25,249]. However, the 
development of small-molecule AKT inhibitors has long been hampered by the 
structural similarity of the AKT catalytic domain to that of other kinases of the AGC 
kinase group[25,39,221]. In addition, there are several known cases of ATP-competitive 
inhibitors that induce AKT hyperphosphorylation and activity[252]. To overcome such 
issues, the focus shifted towards the development of allosteric inhibitors (such as 
MK-2206, miransertib and AKT1/2), which show highly improved specificity towards 
AKT[25,437,438]. 
 
In recent years however, it has become clear that specificity for the AKT family 
is not sufficient[439]. The AKT kinase comes in three isoforms (AKT1, AKT2 and 
AKT3) each encoded by a separate gene[440]. All AKT isoforms share the same 
basic building blocks: an N-terminal Pleckstrin homology (PH) domain, a linker, 
catalytic domain and C-terminal regulatory domain[440]. In unstimulated cells the 
PH-domain keeps AKT in an inactive conformation (PH-in) through interaction with 
the catalytic domain. In response to upstream signalling – the interaction of the PH-
domain with phosphatidylinositol (3,4,5)-trisphosphate (PIP3) produced by PI3K – 
AKT shifts to an open conformation (PH-out) enabling activation by phosphorylation 
on a threonine residue in the catalytic domain and a serine residue in the C-terminal 
regulatory domain[23–25,441]. The isoforms are highly homologous with 82% 
sequence identity for AKT1 vs AKT2, 83% for AKT1 vs AKT3 and 77% for AKT2 vs 
AKT3. Despite their homology, they have non-redundant and, in certain cases, 
opposed functions[86,163,207,229,234,243,246,439,442,443]. A striking example are the roles of 
AKT1 and AKT2 in breast cancer where AKT2 enhances migration and invasion, 
whereas AKT1 inhibits these processes[35,163,234,244,246]. This underlines the need for 
new tools to study AKT isoform-specific functions, which directly affect the protein, 
rather than the proteins’ expression levels. Such tools can aid in drug discovery or, 
through rational drug design, be the next step towards the development of an 
isoform-specific inhibitor[284]. Indeed, targeting a single AKT isoform to counteract 
the function of the drivers relevant to a specific type of cancer would alleviate the 
toxicity observed when using pan-AKT inhibitors and be beneficial for patient 
outcome[444]. 
 
The serum of alpacas and other members of the camelidae family contain 
Heavy-Chain-Only antibodies (HCAb). This subtype of IgG, discovered by the 
Hamers-Casterman group, completely lacks light chains (LC) and the first constant 
domain of the heavy chain (HC)[266]. The antigen-binding fragment of such a HCAb 
consists of a single domain that remains functional when isolated. This domain, 
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called a variable domain of the heavy chain of a HCAb (VHH) or a nanobody (Nb), 
is approximately 15 kDa in size and measures 2.5 by 4 nm[268,271]. Structurally, a Nb 
is composed of four well conserved framework regions (FR) and three 
hypervariable regions (HV), the latter forming loops that cluster at the N-terminal 
side of the folded Nb, where they form the antigen-binding surface or 
complementarity-determining region (CDR). The HV loops of a Nb are usually 
longer than those found in the variable domain of the heavy chain (VH), to 
compensate for the lack of the variable domain of the light chain (VL) which, in 
conventional Abs, forms the CDR together with the VH. The three HV loops of the 
Nb provide a CDR of 600-800 Å which, unlike the CDR of a conventional Ab, forms 
a convex surface[268,271,273,274]. In conventional Abs, the main chain atoms of the 
variable loops can only adopt a few different conformations, called canonical 
structures. However, the HV loops of a Nb are not limited to such canonical 
conformations[273] and therefore, Nbs can bind clefts on protein surfaces which 
cannot be targeted by conventional Abs[445]. As such, Nbs are small, stable, single-
domain and high-affinity binders that can access cryptic epitopes[271]. Nbs can be 
used to target intracellular proteins and block specific protein functions[274,284]. To 
achieve this, Nbs can be expressed intracellularly (intrabodies) using transfection 
or transduction. Alternatively, they can be introduced into the cell through 
photoporation, coupled to a cell-penetrating peptide or injected into cells by 
exploiting the E. coli T3SS[305,311,446]. 
 
To date there are no alternatives to genetic manipulation to study/interfere with 
the function of a single AKT isoform. The allosteric inhibitors, currently the most 
promising candidates for specific AKT inhibition, function by binding the PH domain 
and locking AKT in the PH-in conformation, preventing AKT activation[25,438]. To 
obtain isoform-specific AKT Nbs that interact with the AKT PH-domains, an alpaca 
was immunized with recombinant AKT1 PH-domain or the mutant form which 
confers constitutive membrane localization and activation of AKT1 (AKT1-E17K), 
full-length and activated AKT2 or the AKT3 PH-domain[441]. Using this approach, 
we obtained AKT1 and AKT2-specific binders, which can be expressed as 
intrabodies in mammalian cells. Furthermore, both for AKT1 and AKT2, a single 
specific Nb was obtained that interacts with the PH-domain and interferes with the 
AKT-PIP3-interaction in vitro. As AKT isoform-specific interactors, these Nbs offer 
new possibilities to study and interfere with the functions of these kinases at the 
protein level. As such, these new tools can be a step towards solving the complex 





3.5.1 Generation of AKT nanobodies 
The AKT1-, AKT1-E17K- and AKT3-PH domains were expressed in BL21 E. coli 
cells, purified using TALON®-immobilized metal affinity chromatography (IMAC) 
(Clontech) and subsequent anion-exchange chromatography (MonoQ, GE 
Healthcare). Purity of the eluted fractions was assessed by SDS-PAGE. Purified 
and active AKT2 was purchased from Active Motif (Figure 24). 
 
Three separate VHH libraries were constructed: one for AKT1, the second for 
AKT1-E17K and AKT3, and the third for AKT2. The libraries for AKT1 and AKT2 
were constructed using the pMECS phagemid vector and contained 5x107 
independent transformants (~87% with correct insert size) and 3x108 independent 
transformants (~80% with correct insert size) respectively. For AKT1-E17K and 
AKT3, the pHEN4 phagemid vector was used and a library with 7.7x107 
independent transformants (~93% with correct insert size) was obtained. Panning 
(2 rounds for AKT1 and 4 rounds for AKT1-E17K, AKT2 and AKT3), enzyme-linked 
immunosorbent assay (ELISA) on crude periplasmatic extracts and sequencing of 
positive colonies yielded 17 AKT1 Nbs, 8 AKT1-E17K Nbs, 10 AKT2 Nbs and 11 
AKT3 Nbs. 
3.5.2 Screening for AKT isoform-specific binders 
Nb expression was assessed though Western blot analysis of WK6 E. coli crude 
periplasmatic extracts (Figure 18). Almost all Nbs were successfully expressed at 
high levels, Nbs with low expression levels were denoted by an arrow in Figure 18. 
Only two Nbs (AKT1 Nb17 and AKT3 Nb 11) yielded no signal, which indicated no 
expression. In the pMECS vector, the His6 tag is cleaved off upon storage of the 
Nb at 4°C this resulted in a second band with lower molecular weight that was also 




Figure 18 Expression of AKT nanobodies in WK6 E. coli. Western blot detection of 
AKT Nbs in a crude periplasmatic extract on a 15% SDS gel. An anti-HA Ab 
was used to detect the Nbs. The vast majority of the Nbs had comparable 
and high expression yields. The expression of AKT1 Nb14 and Nb15, AKT1-
E17K Nbs5-8, AKT2 Nb10 and AKT3 Nb1 was low (denoted by an arrow) 
whereas only AKT1 Nb17 and AKT3 Nb11 could not be detected. Uncropped 
blots are available in paragraph 3.8.2.2. 
The AKT1, AKT1-E17K and AKT3 Nb sets were screened for both strength of 
interaction and specificity through ELISA (Figure 19). In contrast to the ELISA 
performed during panning, where each library was screened for interaction with the 
PH-domain used for immunization, each Nb was tested for cross-reactivity with 
each of the AKT PH-domains (AKT1, AKT1-E17K, AKT2 and AKT3). A Nb was 
considered to interact with a PH-domain when the measured optical density 
(OD)405 was at least three times higher than that of the EGFP Nb (negative control) 
for the corresponding PH-domain (OD fold change > 3, denoted as dashed line in 
Figure 19)[316]. 8 AKT1 Nbs met this OD fold change requirement, however the 
results clearly indicated these Nbs did not specifically interact with AKT1. AKT1-
E17K Nb7 interacted with both AKT1 and the oncogenic mutant AKT1-E17K, but 
showed no true preference for interacting with the mutant form of this PH-domain 
(p>0.05). AKT3 Nb7 interacted with AKT1, AKT1-E17K and AKT3, judging by the 
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OD fold change, this Nb bound more strongly with both the wild type and mutant 
form of the AKT1 domain than with AKT3 (p<0.05). AKT3 Nb8 and Nb9 both 
interacted with AKT3 but not with the other AKT isoforms. It should be noted that, 
for AKT3 Nb8, the measured OD405 for the other PH-domains almost reached the 
OD fold change requirement for being considered an interactor. 
 
Figure 19 ELISA screening of AKT pleckstrin homology domain nanobodies. The 
mean and 95% confidence interval (CI) of OD405 values are shown. 
Pleckstrin Homology domains were coated in wells of a 96 multiwell plate at 
1 µg/mL and incubated with the AKT Nbs (20µl from a crude periplasmatic 
extract). The EGFP Nb was used for background correction. A Nb was 
considered to interact with a PH domain when the OD405 fold change 
(normalized to the OD405 of the EGFP Nb for the same PH domain) was at 
least three (denoted by a dashed line). Nbs, which did not meet this criterion 
for any PH domain are not shown on this Figure and were not included in 
further analysis. ELISA data for the complete Nb sets are available in 
Figure 25. 
Results from this initial screening were used to select Nbs that have the greatest 
potential to be isoform-specific binders. The ELISA for the AKT1-, AKT1-E17K- and 
AKT3-Nbs indicated that we had obtained a single Nb specific for AKT1 (which 
binds both wild type and the E17K mutant) and two AKT3-specific Nbs. Additionally, 
AKT1 Nb8 was included in further screening experiments as pan-AKT Nb and AKT3 




Interaction of these Nbs with endogenous full-length AKT1, AKT2 and AKT3 
isoforms from MDA-MB-231 cells was determined through Co-Immunoprecipitation 
(Co-IP) using recombinantly produced hemagluttin (HA)-tagged Nbs. As the AKT2 
Nbs were produced using full-length AKT2, the entire AKT2 Nb set was included in 
this analysis. Anti-HA coated beads were incubated with whole cell lysate (WCL) 
as negative control. As shown by the clear band at ~15 kDa, all Nbs were efficiently 
produced in WK6 E. coli and enriched on the anti-HA-agarose beads (Figure 20). 
Western blot analysis of the Co-IP using AKT isoform-specific antibodies and 
quantification of the ECL signal showed AKT1 Nb8 to pull-down endogenous AKT1 
and AKT2, but not AKT3. AKT1-E17K Nb7 pulled-down only AKT1 (Figure 20). 
AKT2 Nbs 5, 6, 7, 8, 9 and 10 were able to pull-down AKT2. In addition to AKT2, 
AKT2 Nb7 cross-reacted with AKT1 and AKT2 Nb10 with both AKT1 and AKT3. 
Although AKT2 Nbs 1-4 were expressed to a similar extent, the signal for AKT was 
never higher than the control for any isoform. AKT3 Nb7 did not yield signal higher 
than the background for any AKT isoform. AKT3 Nb8 and Nb9 pulled-down AKT3 
to a similar extent but both Nbs also interacted with AKT1 and AKT2. 
 
Taken together with the ELISA screening, these results indicate immunization 
with the AKT1 PH domain did not yield Nbs specific for this isoform. We did, 
however obtain an AKT1-specific Nb that interacted with both the wild-type and 
E17K mutant. For AKT2, we obtained a set of 4 Nbs (AKT2 Nb5, Nb6, Nb8 and 
Nb9) that only interacted with AKT2 in a Co-IP and 2 Nbs (AKT2 Nb7 and Nb10) 
that interacted with several isoforms. Due to the low signal for AKT2, Nb6 was 
excluded from further experiments. No AKT3-specific Nbs were obtained as AKT3 





Figure 20 Co-IP of AKT isoforms using AKT1-, AKT1E17K-, AKT2- and AKT3-Nbs. 
Immunoprecipitation of endogenous AKT1, AKT2 or AKT3 from MDA-MB-
231 cells with recombinantly produced HA-tagged Nbs. Representative for 
three repeated experiments. For the AKT isoforms a pair of panels is shown 
for each isoform with a short exposure time and a long exposure time. The 
short exposure panel contains no saturated pixels. WCL= whole cell lysate, 
EGFP Nb = negative control of anti-HA-agarose incubated with the EGFP 
Nb and MDA-MB-231 lysate and LC= Light-Chain. Nbs were blotted using 
an anti-HA antibody, AKT1, AKT2 and AKT3 were detected using the 
C73H10, D6G4 and 62A8 isoform-specific Ab clones respectively. All Nbs 
(Nb-HA) were efficiently expressed in E. coli. Uncropped blots are available 
in paragraph 3.8.2.2. The graphs below the panels show signal intensity 




3.5.3 Epitope mapping of AKT2 nanobodies 
To narrow down the AKT2 domain(s) bound by the AKT2 Nbs, constructs were 
designed for recombinant expression of full-length AKT2 (FL-AKT2), the AKT2 PH-
domain (AKT2PH), AKT2 lacking the PH-domain (AKT2ΔPH) and the C-terminal 
regulatory domain (AKT2REG) (Figure 21A). Nb-protein interaction was 
determined by ELISA, the EGFP Nb was used as a negative control (Figure 21B). 
AKT2 Nbs 5, 8, 9 and 10 interacted with FL-AKT2 with a fold change in normalized 
OD of 6.66±0.8, 18.9±1.6, 18.1±0.7 and 18.69±1.7 respectively. This indicated that, 
even though the Nbs were produced by immunization with active (phosphorylated) 
AKT2, the Nbs can also bind unphosphorylated AKT2, this being AKT2 in its 
inactive conformation. AKT2 Nb9 was the only Nb that interacted with the AKT2 
PH-domain (OD fold change 19.1±0.6). AKT2 Nbs 5, 8 and 10 interacted with 
AKT2ΔPH (OD fold change of 4.02±0.27, 21.18±0.3 and 20.8±0.4 respectively). 
Both Nb8 and Nb10 also interacted with the regulatory domain (OD fold change of 
respectively 19.3±3.66 and 18.97±3.74) whereas Nb5 did not, suggesting Nb5s’ 
epitope to be located on the flexible linker, kinase domain or a region overlapping 
the boundary of the kinase- and regulatory domain. 
 
It was previously shown that Nbs can be used as the primary antibody for 
detection of proteins through Western blotting[301]. This depends on the type of 
epitope the Nb interacts with (linear vs. conformational). None of the AKT Nbs were 
able to detect AKT in crude lysates from MDA-MB-231 cells, indicating that the Nbs 





Figure 21 Epitope mapping of AKT2 Nbs. A: Illustration of the AKT fragments used 
for epitope mapping. B: ELISA: Mean and 95% CI of normalized OD plotted 
for full-length AKT2 (FL-AKT2), the AKT2 PH domain (AKT2PH), a fragment 
consisting of the flexible linker, kinase domain and regulatory domain 
(AKT2ΔPH) and the regulatory domain (AKT2REG). Target proteins were 
coated in wells of a 96 multiwell plate in quadruplicate for each AKT2 Nb 
and the EGFP Nb (negative control). All measured OD’s were normalized 
for the negative control. A Nb was considered to be an interactor when the 
average normalized OD was at least three times that of the negative control 
for the same AKT2 fragment (dashed line). 
3.5.4 AKT pleckstrin homology domain Nbs interfere with PIP3 
interaction 
Interaction of the AKT Pleckstrin Homology domains with PIP3 is responsible for 
the membrane recruitment of the AKT isoforms, where they can be activated[23]. 
Isoform-specific Nbs that interact with the PH-domain (AKT1-E17K Nb7 and AKT2 
Nb9) have the potential to interfere with this interaction, thereby inhibiting the 
activation of a single AKT isoform. A protein pull-down experiment using agarose 
beads coated with PIP3, recombinantly produced PH-domains and Nbs showed 
AKT1-E17K Nb7 interfered with the PIP3-PH-domain interaction for the PH-
domains of AKT1 and AKT1-E17K and AKT2 Nb9 for AKT2 (Figure 22). When 
compared to the control conditions where only PH-domain and PIP3-beads were 
incubated (CTRL) we found that a pre-incubation of PH-domain and Nb significantly 
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reduced (paired t-test) the amount of PH-domain pulled down by the PIP3-coated 
beads as determined by Western blot detection of the AKT PH-domains. 
 
Figure 22 AKT Nanobodies interfere with AKT-PH—PIP3 interaction. A: Western 
Blot of pull-down experiments using PIP3—coated beads and the AKT PH-
domains. For each PH domain a positive control (CTRL) was included where 
the PH-domains were incubated with the beads without Nb. When the PH-
domains were incubated with AKT1-E17K Nb7 or AKT2 Nb9 before PIP3-
coated beads were added we observe a reduction in the signal for AKT1 PH- 
and AKT1-E17K PH- or AKT2 PH-domain respectively. Representative for 
three repeated experiments. *p≤0.05, **p≤0.01 (paired t-test). The AKT1-, 
AKT1-E17K-– and AKT2-PH-domain were detected using an Ab specific for 
AKT1 (C73H10) and AKT2 (D6G4) respectively. Uncropped blots are 
available in paragraph 3.8.2.2. B: ImageJ quantification of western blots. 
All signal intensities were normalized for the appropriate control (CTRL). The 
mean (bar) and SD (whiskers) are shown. 
3.5.5 Transient expression of AKT Nbs in mammalian cells 
MDA-MB-231 cells were transfected for transient expression of the AKT Nbs and 
the EGFP Nb, which served as negative control throughout this experiment. 
Analysis of the crude lysate (Figure 23B) indicated that not all Nbs were expressed 
to the same extent: the EGFP Nb displayed the highest expression levels closely 
followed by AKT2 Nb5. AKT2 Nb8 and AKT3 Nb8 clearly had lower expression 
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levels (although the signal for the loading control for AKT3 Nb8 was lower as well), 
while AKT1-E17K Nb7 and AKT2 Nb9 could not be detected in crude lysate. 
Results from the Co-IP (Figure 23A) showed that AKT1-E17K Nb7 expression was 
detectable when enriched by the anti-V5-agarose, while the AKT2 Nb9 signal 
remained low under these conditions. The majority of the AKT Nbs was unable to 
pull-down any AKT, only AKT3 Nb8, which interacted with all three isoforms had a 
clear signal for AKT. 
 
Figure 23 Co-IP of endogenous AKT from MDA-MB-231 cells with Nbs transiently 
expressed as intrabodies. A: Co-IP of AKT and Nbs. WCL= whole cell 
lysate from EGFP Nb transfected cells, the negative control were cells with 
transient expression of the EGFP Nb. LC= Light Chain. B: Nb expression in 
crude lysate. 10µg crude lysate from transfected cells was analysed through 
SDS-PAGE and western blotting. GAPDH signal was used as loading 
control. AKT was detected using a pan-AKT antibody (C67E7), Nbs were 






Targeting the AKT PH-domain has shown to be a promising strategy for interfering 
with AKT function: allosteric inhibitors such as MK-2206 and miransertib show 
superior selectivity for AKT over related kinases when compared to ATP-
competitive inhibitors[25,253,438]. However, these inhibitors still target all AKT 
isoforms, which can be detrimental for cancer treatment considering the different 
and sometimes opposed functions of the AKT isoforms[163,249]. In this study, we 
report the generation and characterisation of Nbs specific for a single AKT isoform 
that interact with the PH-domain. Nb sets were generated by immunization of 
alpacas with the PH-domain of AKT1, AKT1-E17K (an oncogenic AKT1 mutant), 
the full-length and activated AKT2 and the AKT3 PH-domain. The obtained Nb sets 
were screened for specificity for a single AKT isoform through ELISA using 
recombinantly produced antigen and Co-IP using endogenous full-length AKT 
isoforms in crude lysate from MDA-MB-231 cells. 
 
Due to the high degree of sequence identity for the AKT PH-domains, most of 
the obtained Nbs did not specifically interact with a single AKT isoform. The AKT1 
Nbs interacted with all four PH-domains. A single representative (AKT1 Nb8) was 
included for the Co-IP where it pulled-down AKT1 and AKT2, but not AKT3. This 
deviation from the results observed in the ELISA could be explained by the much 
lower expression levels of AKT3 in MDA-MB-231 cells compared to AKT1 and 
AKT2 (unpublished results). The AKT3 Nb set did not yield any isoform specific 
Nbs. Even though the ELISA screening suggested AKT3 Nb9 to be AKT3-specific, 
Co-IP of the endogenous AKT isoforms did not corroborate this. It is possible that 
the particular epitope bound by these Nbs was no longer available when the AKT1-
PH-, AKT1-E17K-PH- or AKT2-PH-domains were coated on the multiwell plate. As 
the main goal of this study was to identify isoform-specific Nbs that interact with the 
PH-domain, the AKT1 and AKT3 Nbs were omitted from further experiments. 
 
AKT1-E17K Nb7 interacted with both the wild-type and mutant AKT1 PH-
domains. Co-IP on endogenous AKT confirmed the AKT1-specificity. Although the 
signal for AKT1 was consistently higher than background it was relatively weak, 
with a fold change vs the EGFP Nb ranging from two to five. This indicated that 
binding of this Nb to the AKT1 PH-domain was not influenced by the conformational 
changes induced by the E17K mutation whereas this is known to confer resistance 
to the PH-domain targeting allosteric inhibitor AKTi-1/2 and, although not linked to 
higher AKT1 activity, it decreased the effect of MK-2206 on the phosphorylation of 
AKT1 S473[31,447,448]. The AKT2 Nb set contained 6 Nbs that were able to pull-down 
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AKT2 from MDA-MB-231 cells, four of those (Nbs 5, 6, 8 and 9) were specific for 
AKT2. This set yielded a single Nb that interacted with the AKT2 PH-domain (Nb9), 
one that interacted with the regulatory domain (Nb8) and one that bound the linker 
or kinase domain (Nb5). 
 
Both AKT1-E17K Nb7 and AKT2 Nb9 could, for their respective AKT isoforms, 
interfere with the interaction between the recombinant PH-domain and PIP3-coated 
beads in an in vitro assay. For AKT1-E17K Nb7 this includes both the wild-type PH-
domain and the oncogenic mutant. These Nbs, when expressed as intrabodies in 
cells, can potentially interfere with the activation of AKT1 or AKT2: AKT bound by 
one of these Nbs would be stuck in an inactive ‘PH-in’ conformation[24]. 
 
However, when transiently expressed in mammalian cells, we observed 
relatively low expression levels for all of the AKT Nbs. In a Co-IP experiment of 
AKT and the transiently expressed Nbs, we were only able to detect AKT for AKT3 
Nb8, which interacted with all three isoforms and had already shown to be an 
exceptional binder in a Co-IP using recombinant Nb. It is highly likely that the low 
expression levels of the Nbs lie at the base of the lack of signal for the other tested 
Nbs. Although this is in our experience exceptional, it is also possible that the 
correct folding of the Nbs is affected by the reducing cytoplasmic environment, 
resulting in a loss-of-function. The low intracellular expression levels are a potential 
limitation to using these Nbs to study or interfere with specific AKT isoforms. These 
Nbs could benefit from alternative strategies to introduce the proteins into 
mammalian cells such as cell penetrating peptides, photoporation or 
electroporation[311]. 
 
Apart from interfering with AKT functions directly, an AKT isoform-specific Nb 
can be transformed into a tool to study protein function. Through the use of 
delocalization tags, a Nb can displace a target from its natural environment or when 
linked to a cullin-RING E3 ubiquitin ligase, the Nbs interaction with its target can 
trigger degradation of the target as an elegant alternative to RNAi[274,412]. A co-
crystal structure of the Nb and its target can also be used for structure-based drug 
design and lead to the first true AKT isoform-specific inhibitor[402,449,450]. 
 
In this study, we generated and characterized AKT1 and AKT2 isoform-specific 
binders (Table 4) that can be made into research tools to study the isoform-specific 
functions of the AKT kinase. Additionally, two of these Nbs have shown to interfere 




Table 4 Summary of characteristics for relevant AKT nanobodies. The Co-IP of 
AKT using recombinant Nbs was used as final criterium for specificity. For 
the AKT2 set the Nbs’ epitope was determined through ELISA, other Nb sets 
were generated by immunization with the PH-domain. Relative transient 
expression levels of the AKT Nbs in MDA-MB-231 cells was evaluated 
though Western blotting. AKT1-E17K Nb7 and AKT2 Nb2 interfere with the 
interaction the PH domain with PIP3 for the AKT1-, AKT1E17K- and 
AKT2PH-domain respectively. A summary of the characterization for the full 












1PHE17K Nb7 AKT1 PH Medium Yes 
2FL Nb5 
AKT2 
Linker/ catalytic High N/A 
2FL Nb8 Regulatory Medium N/A 
2FL Nb9 PH Low Yes 
3PH Nb8 AKT1,2,3 PH Low N/A 
 
The high prevalence of AKT over-activation in cancer makes this kinase a high-
profile target for cancer therapy. The Nbs obtained in this study are isoform-specific 
binders for AKT1 or AKT2. These can be made into research tools to investigate 
the isoform-specific functions of the AKT kinases in cells, offering alternatives to 
genetic approaches that will enable us to target a single AKT isoform. Additionally, 
two of these Nbs have shown to interfere with the AKT activation mechanism in an 
in vitro assay. These tools offer new opportunities to study the isoform-specific 




 Materials and methods (Stick it all in a bowl, baby) 
3.7.1 Immunization, library construction and panning 
 AKT-PH domain production 
Plasmids containing constructs coding for HA-AKT1, Myc-AKT1-E17K, HA-AKT2 
and HA-AKT3 were kind gifts from Donghwa Kim (H. Lee Moffit Cancer Center and 
Research Institute). 
cDNA encoding the PH-domains were isolated by PRC amplification using the 
following primers: Akt1PH Forward (Fwd) 5’ AGC GAA TTC ATG AGC GAC GTG 
GCT ATT GTG 3’, Akt1PH Reverse (Rev) 5’ GAA GCT TTC AGT TGT CAC TGG 
GTG AGC CCG ACC G 3’, Akt2PH Fwd 5’ AGC GAA TTC ATG AAT GAG GTG 
TCT GTC ATC 3’, Akt2PH Rev 5’ GAA GCT TTC ACA TCC ACT CCT CCC TCT 
CGT CTG G 3’, Akt3PH Fwd 5’ AGC GAA TTC ATG AGC GAT GTT ACC ATT 
GTG 3’ and Akt3PH Rev 5’ GAA GCT TTC AAT TCA TTC TCT CCT CTT CTT 
GCC TCT GC 3’. Constructs were inserted into a pHEN6 vector backbone using 
the Cold Fusion™ cloning kit (System Biosciences) according to the manufacturers’ 
protocol and proteins were expressed in BL21 E. coli. 
 Immunization and panning 
Nbs were generated in collaboration with the VIB Nanobody Core as described in 
‘Generation of single domain antibody fragments derived from camelids and 
generation of manifold constructs’ from Antibody Engineering: Methods and 
Protocols, second edition (2012). In short, alpacas were injected subcutaneously 
with the antigens on days 0, 7, 14, 21, and 35. Each injection contained 160 µg of 
protein for AKT1PH, 135 µg for AKT1PHE17K, 115 µg for AKT2FL and 250 µg for 
AKT3PH. Anticoagulated blood was collected on day 39. mRNA was extracted from 
lymphocytes, a VHH library was constructed and subjected to phage-display to 
select antigen-binding Nbs. 
All animal work was performed at the VIB Nanobody Core. Immunizations and 
animal handling was performed according to directive 2010/63/EU of the European 
parliament for the protection of animals used for scientific purposes and approved 
by the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussel 
(permit No. 13-601-1). The alpacas used in this study were not euthanized as part 
of the study. 
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3.7.2 In vitro nanobody characterization 
 Expression of recombinant AKT nanobodies 
Heat Shock-competent WK6 E. coli (strain created by Dr. Gholamreza 
Hassanzadeh-Ghassabeh Nanobody Service Facility, VIB) were transformed with 
the AKT Nb constructs in a pMECS-(AKT2 and AKT1) or pHEN4-vector backbone 
(AKT1-E17K and AKT3) and grown overnight (ON) at 37°C on a lysogeny broth (LB 
10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl)-agar plate containing 100 µg/mL 
Ampicillin. A single colony was picked and grown ON at 37°C in a shaking incubator 
in LB with 100 µg/mL Ampicillin. The next day, 1/100 (v/v) was transferred to Terrific 
Broth (TB 16.9 mM KH2PO4, 71.9 mM K2HPO4.3H2O, 2 mM MgCl2, 12 g 
Tryptone, 24 g yeast extract, 4% glycerol, 1% glucose pH 7.2), grown to 
OD600=0.6-0.9, induced with 1 mM isopropylβ-D-thiogalactoside (IPTG) and 
incubated ON at 28°C in a shaking incubator. The next day, cultures were 
centrifuged at 4°C, 3,000 x g for 20 min. 
Nbs constructs in the pMECS- or pHEN4-vector are equipped with an N-terminal 
PelB signal sequence resulting in export of the Nbs to the periplasmatic space of 
E. coli and can be extracted through osmotic shock. Periplasmatic extracts were 
prepared by re-suspending the pellet in Tris-EDTA-sucrose buffer (TES) (0.2 M 
Tris-HCl, 0.5 mM EDTA and 0.5 M sucrose pH 8) and incubating for 1 h on ice with 
gentle agitation after which TES buffer diluted 4x in Milli-Q grade water was added 
and incubated for an additional hour (with shaking). Extracts were centrifuged at 
4°C, 29,000 x g for 20 min and the supernatant (SN) was collected. 
 ELISA 
A 96-multiwell plate (Nunc Maxisorp, Sigma-Aldrich) was coated overnight (ON) at 
4°C with AKT1-, AKT1-E17K-, AKT2- or AKT3-PH-domains at 1 µg/mL in Coating 
buffer (100 mM NaHCO3, pH 8.4). In between each of the subsequent steps, the 
plate was washed three times with 0.1% Tween in Phosphate Buffered Saline 
(PBS) (-Ca2+/Mg2+). The remaining protein-binding sites were blocked by incubation 
with 0.1% (w/v) Casein in PBS for 1 h at room temperature (RT). Periplasmatic 
extract from WK6 E. coli containing a Nb was diluted in PBS (-Ca2+/Mg2+) and 100 
µl was added to a well in quadruplicate for each for each PH-domain. After 1 h 
incubation at RT, each well was incubated (1 h at RT) with 100 µl 0.5 µg/mL anti-
HA (#901502, BioLegend) antibody (Ab) and subsequently (1 h at RT) with 100 µl 
0.5 µg/mL alkaline phosphatase (AP)-linked anti-mouse Ab (A90-116AP, Bethyl 
Laboratories). The reaction was initiated by adding 2 mg/mL AP substrate (4-
nitrophenyl phosphate disodium salt hexahydrate, Sigma) in AP Blot Buffer (100 
mM Tris-HCl, 50 mM MgCl2.6H2O, 100 mM NaCl, pH 9.50). Absorbance was 
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measured at 405 nm. When the measured absorbance for an AKT Nb was at least 
threefold higher than for the EFGP Nb, the AKT Nb was considered to interact with 
that particular PH-domain. Significant differences in normalized OD405 were 
detected using a One-way ANOVA with Tukey’s test using GraphPad Prism V5.00. 
 Co-immunoprecipitation of endogenous AKT isoforms with 
recombinant nanobodies 
Nbs were produced and extracted as described above. Anti-HA-agarose beads 
(A2095, Sigma Aldrich) were incubated with 10 µg periplasmatic extract for 1 h at 
4°C with end-over-end rotation. The beads were washed with ice-cold Tris Lysis 
Buffer (20 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100 pH 7.5), 1mM phenyl-
metylsulfonyl fluoride (PMSF) and 200 μg/mL protease inhibitor cocktail) and 
incubated for 1 h at 4°C with end-over-end rotation with 1 mg crude lysate from 
MDA-MB-231 cells. A negative control where the EGFP Nb was added to the beads 
was included to determine non-specific binding of AKT to the agarose matrix and 
nanobody. The beads were washed three times with excess Tris Lysis buffer and 
heated to 95°C for 5 min in Laemmli Sample Buffer (5% SDS, 20% glycerol, 0,2% 
bromophenol blue, 5% β-mercaptoethanol, 65 mM Tris-HCl pH 6.8). 
Samples were analyzed by SDS-PAGE and Western blotting. The AKT isoforms 
were detected using isoform-specific Abs (AKT1 C73H10, AKT2 D6G4 and AKT3 
62A8 from Cell Signaling Technology®) and the Nbs with an anti-HA-tag Ab 
(11583816001, Merck). ECL signal for the AKT isoforms was recorded using the 
Amersham Imager AI680 and the signal was quantified using Image Studio Lite 
(v5.2). 
 Epitope mapping of AKT2 nanobodies 
Nbs were produced as described in “Expression of recombinant AKT Nbs”. The 
AKT2 PH-domain was produced as described above, the other AKT2 fragments 
were created through PCR amplification based on the HA-AKT2 template using the 
following primers: FL-AKT2 Fwd 5’ TGT ACA GAA TGC TGG TCA TAT GAA TGA 
GGT GTC TGT CAT C 3’and FL-AKT2 Rev 5’ TCA CCC GGG CTC GAG GAA TTC 
TCA CTC GCG GAT GCT GGC CGA GTA GG 3' for full-length AKT2, AKT2ΔPH 
Fwd 5’ TGT ACA GAA TGC TGG TCA TAT GAA GCA GCG GGC CCC AGG CG 
3’ and FL-AKT2 Rev for AKT2ΔPH and AKT2Reg Fwd 5’ GTA CAG AAT GCT GGT 
CAT ATG CTC AGC ATC AAC TGG CAG 3’ and FL-AKT2 Rev for the AKT2 
Regulatory domain. PCR product was cloned into the pTYB12 vector using the Cold 
Fusion™ cloning kit (System Biosciences) according to the manufacturers’ 
protocol. BL21 E. coli were heat-shock transformed with the AKT2 constructs in a 
pTYB12 vector backbone. A culture was grown in TB to an OD600>2, expression of 
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the constructs induced with 0.5 mM IPTG and the culture was incubated ON at 
20°C in a shaking incubator. The following day, the cultures were centrifuged (20 
min at 3000 x g, 4°C) and re-suspended in Chitin column buffer (20 mM Tris-HCl, 
500 mM NaCl and 1 mM EDTA, pH 8.5) with 1 mM PMSF and 200 μg/mL protease 
inhibitor cocktail. Cells were lysed using a French Press and sonication. Debris was 
pelleted by centrifugation (20 min at 29,000 x g, 4°C), supernatant was collected 
and loaded onto a column with Chitin beads (New England Biolabs) and allowed to 
empty by gravity flow at approximately 1 mL/min. Beads were washed with column 
buffer and incubated ON with column buffer containing 50 mM dithiothreitol (DTT). 
Elutions were collected and analysed by SDS-PAGE and Coomassie staining. The 
ELISA epitope mapping was performed as described above with the AKT2 
constructs coated in the wells and AKT2 Nbs (in crude periplasmatic extract) added 
in solution. 
 PIP3 pull-down 
Nbs from a periplasmatic extract were purified using TALON™-IMAC (Clontech) 
according to the manufacturers’ protocol. In short, periplasmatic extracts were 
incubated for 2 h at 4°C with end-over-end rotation with TALON™ resin pre-
equilibrated with wash buffer (50 mM NaH2PO4, 500 mM NaCl and 20mM 
imidazole, pH 8). The resin was washed three times with wash buffer and bound 
proteins were eluted with elution buffer (50 mM NaH2PO4, 500 mM NaCl and 500 
mM imidazole, pH 8). Purity of the proteins was evaluated using SDS-PAGE and 
Coomassie staining. 
For the pull-down experiment, a Nb was incubated at a 10X molar excess with 
PH-domain in Binding Buffer (10 mM HEPES, 150 mM NaCl and 0.25% NP-40, pH 
7.4) for 1 h at 4°C with end-over end rotation. Subsequently 50 µl PIP3-coated 
beads (P-B345A, Echelon Biosciences) were added to the mixture. A negative 
control containing only beads and a PH-domain was also included at this point. 
After a 3 h incubation at 4°C with end-over-end rotation, the beads were washed 
three times with Binding Buffer and bound proteins were eluted by adding Laemmli 
sample buffer and heating the beads to 95°C for 5 min. Proteins were separated by 
size through SDS-PAGE followed by Western Blot analysis. The recombinant PH-
domains of AKT1 and AKT2 were detected using an isoform-specific Ab (AKT1 
C73H10 and AKT2 D6G4, Cell Signaling Technology®). Signal intensity was 
quantified using ImageJ, values were normalized for the positive control (no Nb). A 




3.7.3 In vivo AKT nanobody properties 
 Subcloning Nbs for expression in mammalian cells 
Nbs were subcloned to the pcDNA3.1 V5/His6 vector for transient expression in 
mammalian cells. PCR amplification of the Nbs was performed using pcDNA3.1 
Fwd 5ʹ TTG GTA CCG AGC TCG GCC ACC ATG CAG GTG CAG CTG CAG GAG 
3ʹ and pcDNA3.1 Rev 5ʹ TAG ACT CGA GCG GCC GCT GGA GAC GGT GAC 
CTG 3ʹ. Cloning was performed with the Cold Fusion™ cloning kit (System 
Biosciences) according to the manufacturers’ protocol. 
 Cell culture, transfection and pull-down 
MDA-MB-231 (ATCC® HTB-26™) cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Gibco, Thermo Fisher Scientific) supplemented with 10% fetal 
bovine serum (Gibco, Thermo Fisher Scientific), 100 IU/mL penicillin and 10 μg/mL 
streptomycin (Gibco, Thermo Fisher Scientific)[451]. Cells were grown in a humidified 
incubator at 37°C and 10% CO2. This cell line was obtained from Prof. Dr. De 
Wever (University of Ghent) in October 2011. Prior to experiments, the cell line was 
tested and found negative for mycoplasma contamination using PlasmoTest™ 
(Invivogen). 
For transient expression of the AKT Nbs, the JetPrime® transfection reagent 
(Polyplus Transfection) was used according to the manufacturers’ 
recommendations. 24 h after transfection, the cells were collected using Trypsin 
Ethylenediaminetetraacetic acid (EDTA, 0.05%, Gibco, Thermo Fisher Scientific) 
and lysed in ice-cold Tris Lysis Buffer. 1 mg crude extract was incubated with 10 µl 
settled anti-V5-agarose beads (A7345, Sigma Aldrich) for 1 h at 4°C with end-over-
end rotation. The beads were washed three times with Tris Lysis Buffer and bound 
proteins were eluted by adding Laemmli sample buffer and heating the samples to 
95°C for 5 min. Proteins were separated using SDS-PAGE and analyzed by 
Western Blotting. AKT was detected using a pan-AKT Ab (C67E7, Cell Signaling 
Technology) and the Nbs through their V5-tag with an anti-V5 Ab (R960-25, 
Thermo Fisher Scientific). 
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 Supporting material 
3.8.1 Additional figures 
 
Figure 24 Antigens for immunization. Uncropped gels. From left to right 1 µg and 2 
µg of the AKT1 PH domain (AKT1), the oncogenic mutant AKT1 PH domain 





Figure 25 ELISA screening for AKT isoform-specific binders. Mean and 95% CI of OD405 values are plotted for the complete 
AKT1PH (A), AKT1PHE17K (B), and AKT3PH (C) nanobody sets. A dashed line shows the OD fold change requirement for 








Figure 26  Overview of the characterisation of the AKT1, AKT1-E17K, AKT2 and 
AKT3 Nb sets. Expression of the Nbs in WK6 E. coli was evaluated though 
SDS-PAGE & Western blot analysis of crude periplasmatic extracts. AKT 
isoform-specificity was assessed though both ELISA using recombinant 
AKT PH-domains (1 = AKT1 PH-domain, 1M = AKT1-E17K PH-domain, 2 = 
AKT2 PH-domain and 3 = AKT3 PH-domain) and a Co-IP using recombinant 
Nbs and the endogenous AKT isoforms from MDA-MB-231 crude lysates. A 
grey filled cell in the ‘ELISA specificity’ column indicates this Nb did not meet 
the OD fold change requirement for any PH-domain, these Nbs are not 
included in further experiments. The Co-IP was used as final criteria for 
specificity. Nbs that interact with an AKT PH-domain can interfere with the 
PIP3 interaction required for AKT activation. Using PIP3 coated beads, 
recombinant AKT PH-domains and Nbs we determined AKT1-E17K Nb7 
interferes with the interaction of the AKT1 PH-domain AND AKT1-E17K PH-
domain with PIP3. Using transient expression a selection of Nbs was 
expressed in mammalian cells (MDA-MB-231) and evaluated as intrabodies 
through a Co-IP of endogenous AKT. 
3.8.2 Online content 
All supporting information for the development and characterization of protein 
kinase B/AKT isoform-specific nanobodies can be found online at 
https://doi.org/10.1371/journal.pone.0240554 
 ARRIVE guidelines 
The ARRIVE guidelines checklist can be found online at 
https://doi.org/10.1371/journal.pone.0240554.s001 
 Raw images 
The original, uncropped images for all figures in the main manuscript can be found 
online at https://doi.org/10.1371/journal.pone.0240554.s002 
 Nb constructs 





Chapter 4  
An AKT2-specific nanobody that targets the 
hydrophobic motif induces cell cycle arrest, 
autophagy and loss of focal adhesions in 
MDA-MB-231 cells 
“Moeilijk gaat ook.” 
-Els Beghein 
 Aim of the study 
Our initial characterization of the AKT Nb sets yielded three AKT2-specific 
interactors that bound to distinct epitopes and domains. The obtained AKT2 Nbs 
represent a great opportunity to study the function of the individual AKT2 domains, 
which cannnot be done using genetic approaches. In this study, which could be 
considered the proof of concept for targeting AKT through isoform-specific 
nanobodies, we investigate the intrinsic potential of the nanobodies to modulate 
AKT2 in breast cancer cells. By performing a detailed investigation of the affected 
cellular processes we can unravel a part of AKT2’s signalling network.  
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 Research article 
Merckaert T, Zwaenepoel O, Gevaert K, Gettemans J (2021) An AKT2-specific 
nanobody that targets the hydrophobic motif induces cell cycle arrest, 
autophagy and loss of focal adhesions in MDA-MB-231 cells. Biomedicine & 
Pharmacotherapy (133). https://doi.org/10.1016/j.biopha.2020.111055. 
 Abstract 
The AKT kinase family is a high-profile target for cancer therapy. Despite their high 
degree of homology the three AKT isoforms (AKT1, AKT2 and AKT3) are non-
redundant and can even have opposing functions. Small-molecule AKT inhibitors 
affect all three isoforms which severely limits their usefulness as research tool or 
therapeutic. Using AKT2-specific nanobodies we examined the function of 
endogenous AKT2 in breast cancer cells. Two AKT2 nanobodies (Nb8 and Nb9) 
modulate AKT2 and reduce MDA-MB-231 cell viability/proliferation. Nb8 binds the 
AKT2 hydrophobic motif and reduces IGF-1-induced phosphorylation of this site. 
This nanobody also affects the phosphorylation and/or expression levels of a wide 
range of proteins downstream of AKT, resulting in a G0/G1 cell cycle arrest, the 
induction of autophagy, a reduction in focal adhesion count and loss of stress fibers. 
While cell cycle progression is likely to be regulated by more than one isoform, our 
results indicate that both the effects on autophagy and the cytoskeleton are specific 
to AKT2. By using an isoform-specific nanobody we were able to map a part of the 
AKT2 pathway. Our results confirm AKT2 and the hydrophobic motif as targets for 
cancer therapy. Nb8 can be used as a research tool to study AKT2 signalling events 
and aid in the design of an AKT2-specific inhibitor. 
 Introduction 
The phosphoinositide 3-kinase (PI3K)-AKT pathway is the most frequently over-
activated pathway in human cancer[210]. Multiple genetic aberrations have been 
identified in members of this pathway. Examples include the amplification or 
mutation of receptor tyrosine kinases (RTKs) such as EGFR and HER2, activating 
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mutations in PI3K and PDK1, and loss of PTEN[249,439]. These events result in 
increased activity of the serine/threonine protein kinase AKT (a.k.a. protein kinase 
B)[65,249]. AKT is activated by phosphorylation of threonine-309 in the activation loop 
of the catalytic domain and serine-474 in the C-terminal hydrophobic motif (HM) by 
PDK1 and mTORC2, respectively. Phosphorylation of both sites enhances AKT 
stability and is required for maximal catalytic activity[42,73,176]. Well over a hundred 
AKT substrates spanning several functional classes (protein and lipid kinases, 
regulators of the cell cycle, metabolic enzymes, transcription factors, …) have been 
identified. Some of these substrates (GSK3α/β, FoxO and mTORC1) are major 
signalling nodes on their own. 
 
By integrating a wide array of extracellular signals, AKT, as a master kinase 
regulates cell proliferation, survival, growth, migration and metabolism[176]. This 
relation of AKT to various hallmarks of cancer, together with the high incidence 
(>50%) of AKT hyperactivation in cancer have made this kinase a high-profile 
target. This has led to the development of several small-molecule inhibitors, some 
of which have already made it to clinical trials, albeit with limited 
success[64,247,249,253,254]. Both ATP-competitive and allosteric AKT inhibitors have 
been developed. For ATP-competitive inhibitors, the lack of specificity for AKT is a 
major issue, which comes as no surprise given the high degree of similarity of the 
AKT catalytic domain with such domains from other kinases of the AGC kinase 
family[38,39]. Allosteric AKT inhibitors, such as MK-2206, which target the PH-
domain, show more potential. However, these suffer from the drawback that they 
affect all AKT isoforms (AKT1/PKBα, AKT2/PKBβ and AKT3/PKBγ), testifying to 
the difficulty of developing specific AKT inhibitors[452]. 
 
The three AKT isoforms are encoded by separate genes and display up to 82% 
sequence identity[453]. Despite their highly similar sequences, the isoforms are non-
redundant. This was reported in studies using mice with individual knockouts (KO) 
of AKT isoforms and has been amply confirmed in in vitro 
studies[35,163,174,186,189,190,203,229,234,243,244,439,443,454–459]. To complicate matters further, 
their role is also context-dependent and in certain cases opposed to one another. 
The exact mechanisms that contribute to isoform-specificity have not been fully 
elucidated, but distinct subcellular localization, differences in relative expression 
levels and intrinsic kinetic properties, specific (in)activation and mutation of the 
isoforms are likely to play a role[34,42,86,439,460,461]. A striking example of isoform-
specific functions are the roles of AKT1 and AKT2 in breast cancer, where AKT2 




Such observations help to explain the limited success of AKT inhibitors in clinical 
trials and underline the need for a detailed study of the complex AKT signalling 
cascades. Mapping each isoform’s pathway and developing isoform-specific 
inhibitors could be the next step in tailoring cancer treatment to be most beneficial 
for the patient. 
In this study we focus on the role of AKT2 in the MDA-MB-231 breast cancer cell 
model. Instead of relying on genetic approaches to interfere with AKT2, we use 
nanobodies (Nbs) to target this isoform. Nbs are the antigen-binding fragment of 
heavy-chain-only antibodies. They consist of a single domain, are small (15 kDa) 
and highly stable proteins that interact with their antigen with high affinity and 
specificity[268]. Additionally, Nbs remain functional when expressed in the reducing 
cytoplasm of mammalian cells, which allows their use for modulating endogenous 
proteins in a relevant context[284,290,301–305,401]. The AKT2 Nbs were obtained by 
immunization of an alpaca with in vitro phosphorylated AKT2 and were previously 
shown to only interact with the AKT2 isoform[326].  
 
Here, we show that the AKT2 Nbs are high-affinity interactors, which interact 
only with the AKT2 isoform when stably expressed in MDA-MB-231 cells that 
express all three AKT isoforms. Nbs 8 and 9 have a cytotoxic/cytostatic effect that 
is unrelated to apoptosis. We show that Nb8 reduces phosphorylation of the AKT2 
HM in IGF-1 stimulated cells and use a (phospho)proteomics approach to map the 
downstream effects. Our results indicate that AKT2 is a major regulator of the cell 
cycle, organization of the actin cytoskeleton and autophagy. Nb8 has allowed us to 
map a part of the AKT2-specific signalling pathway, identified the HM as a 
therapeutic epitope and further strengthened AKT2 as a bona fide target for cancer 
therapy. This Nb is thus a promising new tool which can be applied, as a 
complementary approach to genetic approaches, in various contexts to study the 
function of this AKT isoform and could be used in the rational design of the first 





4.5.1 The AKT2 Nbs are high-affinity interactors 
To further characterize the obtained Nbs we determined detailed binding 
characteristics with AKT2 (stoichiometry, kon & koff) through Bio-layer Interferometry 
(Figure 27A-C). The obtained binding curves, for all Nbs, were fit using a 1:1 
binding kinetic model. X² and R² values were < 3 and > 0.95, respectively, which 
indicated that this was a good fit. All AKT2 Nbs interacted with recombinantly 
produced AKT2 with (sub)nanomolar affinity: Nb5 KD= 5.5 nM ± 64.9 pM, Nb8 KD= 
118 nM ± 3.03 nM and Nb9 KD= 583 pM ± 13.8 pM. 
 
Figure 27 Bio-layer interferometry for AKT2 Nbs. A-C: association and dissociation 
curves for the interaction of AKT2 Nbs 5, 8 and 9 with FL-AKT2. Nbs with a 
C-terminal HA-His6-tag, obtained from an E. coli periplasmatic extract were 
loaded onto biosensors coated with an anti-penta-His Ab. After measuring 
the background in the buffer, the tips were dipped into buffer solution 
containing AKT2 at various concentrations (association) and subsequently 
into a well containing only buffer for dissociation. The binding and release of 
AKT2 produced a shift in the interference pattern of reflected light, which 
was measured in real-time, resulting in the shown binding curves. D: SDS-
PAGE and Western blot of human FL-AKT2 (UniProt P31751) which was 
produced as an intein fusion protein in BL21 E. coli and purified using the 
IMPACT™ system followed by anion-exchange chromatography. Column 
fractions 28-30 are shown. Purity was assessed by SDS-PAGE and Western 
blotting using an AKT2 specific Ab. The uncropped gel and blot are available 
in the supporting material (paragraph 4.9.3). 
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4.5.2 Modulation of AKT2 in cancer cells 
 Generation of stable cell lines expressing the AKT2 Nbs as 
intrabodies 
Previous experiments indicated that AKT2 Nb5, 8 and 9 only interact with the AKT2 
isoform[326]. Using these Nbs as intrabodies (Nbs expressed intracellularly) would 
allow us to study the function of AKT2 without perturbing the other two isoforms. 
The AKT2 Nbs and EGFP Nb were subcloned into the lentiviral, tetracycin-inducible 
pLVX-Tight-Puro expression vector and transduced into MDA-MB-231 human 
breast cancer cells. Stable MDA-MB-231 cell lines with doxycycline (Dox)-inducible 
expression of the AKT2 Nbs or the EGFP Nb were generated (Figure 28A). 
 
All Nbs were successfully expressed in the stable cell lines. Co-
immunoprecipitation (Co-IP) experiments to assess the intrabody-AKT2 interaction 
showed that all AKT2 Nbs were able to pull-down AKT2 (Figure 28B). The EGFP 
Nb-expressing cell line was used as control. Using the same procedure, no AKT1 
or AKT3 could be detected in a Co-IP experiment (Figure 36). 
 
Figure 28 (Caption Opposite). 
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Figure 28 (Opposite). AKT2 Nbs as intrabodies in MDA-MB-231 cells. A: Stable and 
inducible expression of the EGFP Nb and AKT2 Nbs in MDA-MB-231 cells. 
Representative epifluorescence images of stable MDA-MB-231 cells with 
Dox-inducible Nb expression. Nb expression was induced with 500 ng/mL 
Dox (+Dox), uninduced cells (-Dox) were included to assess leakage 
expression. Merged images are shown, nuclei were visualized by DAPI 
(blue) and Nbs with an anti-V5 Ab (green). Scale bar, 10 µm. B: Co-IP of 
endogenous AKT2 from stable MDA-MB-231 cells with V5-tagged 
intrabodies using anti-V5 agarose. Nb expression was induced with 500 
ng/mL Dox. WCL= whole cell lysate, The EGFP Nb-expressing stable cell 
line was used as control. HC= Heavy-Chain, LC= Light-Chain. All Nbs were 
expressed in the stable cell lines and only the AKT2 Nbs pulled-down AKT2. 
AKT2 was detected using an isoform-specific Ab, Nbs were detected 
through their V5-tag. Co-IPs for AKT1, AKT3 and uncropped blots are 
available in the supporting material (paragraph 4.9.1 and 4.9.3). 
 Nb8 and Nb9 negatively regulate MDA-MB-231 cell viability or 
proliferation 
Several cellular processes regulated by AKT2 directly affect cell viability or 
metabolism. XTT and clonogenic assays were performed to determine whether the 
Nbs have a cytostatic/cytotoxic effect on MDA-MB-231 cells (Figure 29A and 
Figure 37). Both the parental cell line and the stable cell line expressing the EGFP 
Nb were used as controls. The effect of Nb expression was measured for up to 72 
h at intervals of 24 h. 
A 2-way ANOVA showed that there was significant interaction (F(8,44) = 5.78, 
p≤0.0001) between Nb and expression time (a time-dependent effect of Nb 
expression on OD475 of the formazan dye). Simple effects analysis by one-way 
ANOVA showed, that for all measured time points (24, 48 and 72 h), cells 
expressing either Nb8 or Nb9 had significantly (p<0.05) lower mean OD475 when 
compared to the parental cell line and EGFP Nb- or Nb5-expressing cell lines. Cells 
expressing Nb5 did not exhibit a significant (p>0.05) shift in mean OD475 compared 
to the controls indicating that, at any of the measured time points, Nb5 did not affect 
viability or cell division. Both Nb8 and Nb9 had a time-dependent effect on OD475 
with significantly lower values after 48 h compared to 24 h. However, the effect of 
these Nbs appeared to reach a maximum after 48 h. Additionally, Nb8 and Nb9 
elicited a comparable effect on the cells as their mean OD475 was not significantly 
different at any time point. 
These results indicate that the interaction of Nb8 or Nb9 with AKT2 negatively 
affects its function, possibly through different mechanisms as they bind separate 
epitopes[326]. 
Although it has been shown that pan-AKT inhibition induces apoptosis, our 
results indicated that this was not the case for Nb8 or Nb9 (Figure 29B)[437]. No 
reduction in full length caspase-3 nor the presence of cleaved Caspase-3 could be 
 
104 
detected in cells expressing Nb8 or Nb9 for up to 72 h whereas staurosporine, the 
positive control, induced both. Considering that caspase-3 is activated at the end 
of both intrinsic and extrinsic apoptotic pathways, these results strongly argue 
against the involvement of this cell death mechanism in the effects observed in the 
XTT-assay. Additionally, we did not observe the typical changes in cell shape nor 
detachment of cells from substrate, signs of apoptosis, in Nb-expressing cells. This 
was however the case in staurosporine (Sts)-treated cells. 
 
Figure 29 Cytotoxic and cytostatic effect of AKT2 intrabodies on MDA-MB-231 
cells. A: XTT-assay of the Parental (PAR) and stable MDA-MB-231 cell 
lines expressing the EGFP Nb or AKT2 Nb5, 8 and 9. Both the Parental and 
EGFP Nb-expressing cell lines were used as negative control. Values shown 
are the mean and SD of OD475 values normalized for the EGFP Nb for three 
repeated experiments. A one-way ANOVA with Tukey’s multiple comparison 
test was used to compare mean OD475 values. * p<0.05, ** p<0.01, 
***p<.001. Full statistical analysis can be found in Table 6. B: Western blot 
detection of caspase-3 processing in an untreated control, Sts-treated cells 
(10 µM) or AKT2 Nb8- or Nb9-expressing MDA-MB-231 cells (500 ng/mL 
Dox). The 17 and 19 kDa fragments of caspase-3 could not be detected in 
cells expressing Nb8 or Nb9, indicating that the observed reduction in cell 
count was not a consequence of apoptosis. Vinculin was used as loading 
control. Uncropped blots are available the supporting material (paragraph 
4.9.3). 
 Nb8 affects AKT2 HM phosphorylation in IGF-1-stimulated 
cells 
Epitope mapping experiments showed that Nb8 interacts with the AKT2 HM and 
Nb9 with the pleckstrin homology (PH) domain[326]. Both Nbs can potentially 
interfere with AKT2 activation: Nb8 by shielding the modification site in the HM and 
Nb9 by interfering with the PH-phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)P3) interaction[42,73,326]. 
The effect of the AKT2 Nbs on phosphorylation of the AKT2 HM was determined 
through Western blotting (Figure 30A). In cells expressing Nb8 we observed a 
clear and significant reduction (one-way ANOVA, p<0.0001) in pAKT2 S474 levels 
after 1, 5 and 30 min IGF-1 stimulation but not after 15 min IGF-1 stimulation 
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(Figure 30B). Such an effect was not observed in Nb5-, Nb9- or EGFP Nb-
expressing cells. Total AKT2 levels were unchanged at any of the measured time 
points (one-way ANOVA, p<0.05). 
 
Figure 30 Nb8 expression attenuates IGF-1 response in MDA-MB-231 cells. A: 
Western blot detection of HM-phosphorylated AKT2 (pAKT2 S474). 
Untreated cells were grown in standard growth medium, IGF-1-stimulated 
cells (5 ng/mL) were serum starved for 48 h prior to stimulation and Nb 
expression was induced with Dox (500 ng/mL) for 24 h. Vinculin was used 
as loading control and Nb8 was detected through its V5-tag. AKT2 and 
pAKT2 S474 were detected using isoform-specific Abs. Uncropped blots are 
available in the supporting material (paragraph 4.9.3). B: ImageJ 
quantification of AKT2 and pAKT2 S474 levels. Values were normalized for 
vinculin. The fold change of AKT2 and pAKT2 S474 levels between Nb8-
expressing cells and uninduced cells was calculated. A one-way ANOVA 
indicated there was a significant reduction in pAKT2 S474 levels for Nb8-
expressing cells after 1, 5 and 30 min IGF-1 stimulation. Total AKT2 levels 
did not significantly differ for any time point. 
 Nb8 expression resulted in significant changes in the 
(phospho)proteome 
The AKT kinases are part of a large signalling cascade involving downstream 
kinases and transcription factors. AKT2’s phosphorylation status determines its 
catalytic activity and, possibly, which substrates can be phosphorylated by the 
kinase[82,175]. 
To obtain a comprehensive view of Nb8’s effects on AKT2 signalling, the 
proteome and phosphoproteome of MDA-MB-231 cells expressing Nb8 or the 
EGFP Nb were compared. Using a label-free approach we were able to reliably 
quantify 2,509 proteins and 7,677 phosphosites on 1,998 proteins. A student’s t-
test and filtering by difference in intensity resulted in the identification of 151 down- 
and 38 up-regulated phosphosites (Figure 31A). 
As changes in regulation of a protein modification (phosphosite) can reflect 
changes in regulation of the whole protein, protein expression levels in the same 
samples were quantified (shotgun proteome (SG) analysis) prior to phosphoprotein 
enrichment. Fold change values of phosphosites, for which the whole protein could 
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be quantified, were normalized. This was possible for 74 phosphosites (39% of all 
identified phosphosites).The SG proteome analysis identified 37 differentially 
regulated proteins (20 down- and 17 up-regulated proteins) in Nb8-expressing cells 
(Figure 31B). The full list of differentially regulated phosphosites and proteins can 
be found in paragraph 4.9.3. Both PCA analysis of all quantified phosphosites or 
proteins and hierarchical clustering of differentially regulated proteins/phosphosites 
clearly grouped the replicate samples by ‘treatment’ i.e. Nb8 or EGFP Nb 
expression (Figure 38). 
AKT2 protein expression was not differentially regulated between EGFP Nb- and 
Nb8-expressing cells, but no phosphorylated AKT2 peptides were identified. For 
both AKT1 and AKT3, phosphopeptides were identified, none of which met the 
criteria for different regulation. The site identified for AKT3 (S472) is the HM site, 
corresponding to S474 in AKT2. A total of 20 known AKT substrates were 
quantified, none of these were differentially regulated between Nb8- and EGFP Nb-
expressing cells (Table 7). These sites include BAD S99, GSK3β S9 and, a known 
AKT1 substrate, PALLADIN S1118. A NetPhos motif search identified three 
potential AKT substrate sites: TRA2A (T88), SRRM1 (S551) and IRS1 (S270), all 
of which were down-regulated in Nb8-expressing cells[463]. 
 
To identify the cellular processes influenced by Nb8 expression, all differentially 
regulated proteins (phosphorylation and expression) were subjected to PANTHER 
Gene Ontology (GO) term enrichment and KEGG pathway mapping[464]. A selection 
of enriched terms is shown in Figure 31C. Fold enrichment and P-values for all 
significantly enriched GO terms can be found in paragraph 4.9.3. For cellular 
component, both ‘nucleoplasm’ and ‘cytosol’ were enriched while ‘integral 
component of membrane’ was underrepresented. This could indicate that our 
analysis did not equally cover the whole proteome. Interestingly, given the results 
from the XTT and clonogenic assays, ‘mitotic cell cycle’ was an enriched biological 
process term and five proteins were mapped to the KEGG ‘cell cycle’ pathway. 
AKT2 inactivation has been linked to autophagy. Proteins involved in autophagy, 
mitophagy and phagophore assembly site were overrepresented in the significantly 
regulated proteins. Additionally, seven proteins were mapped to the ‘KEGG 
autophagy – animal’ pathway[234,465]. Several terms pertaining to the cytoskeleton 
and cell motility were enriched including, but not limited to, stress fiber, basement 
membrane, cell-cell adherens junction, focal adhesion and cytoskeleton. 
Furthermore, mapping the protein list to KEGG pathways identified seven hits to be 
part of the ‘focal adhesion’ pathway and five hits were mapped to the ‘actin 
cytoskeleton’ pathway. 
These results prompted us to investigate the effects of Nb8 on the cell cycle, 




Figure 31 (Caption on next page).  
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Figure31 (Previous page). Differential (phospho)proteome analysis of Nb8- vs 
EGFP Nb-expressing cells. Relative phosphopeptide (A) or protein (B) 
intensities (Log2LFQ(Nb8/EGFP Nb)) are plotted versus statistical 
significance (-Log10(P value, two-sided student’s t-test)). Quantified peptides 
were filtered by significance (permutation-based false discovery rate 
calculation, FDR=0.05 S0=0) and a difference ≥1 or ≤-1. Hits which were up-
regulated in Nb8-expressing cells are indicated in red, down-regulated hits 
in blue. C: A selection of enriched GO terms with fold change and p-value 
are plotted, divided into three categories: ‘cellular component’, ‘biological 
process’ and ‘molecular function’. 
 Nb8 interference with AKT2 results in a G0/G1 cell cycle arrest. 
The AKT family was previously established as a regulator of the cell cycle[123]. In 
total, the GO enrichment and KEGG pathway mapping yielded 26 proteins 
(Figure 31C and Table 8) involved in various stages of the mitotic cell cycle or 
regulation of DNA metabolic processes. 
 
Retinoblastoma-associated protein (RB1), a tumour suppressor and regulator of 
the cell cycle, was hypophosphorylated on multiple sites. These phosphosites were 
not down-regulated to the same extent and RB1 expression was not significantly 
(p>0.05) down-regulated in Nb8-expressing cells. With the exception of S37, the 
identified RB1 phosphosites are regulated by Cyclin D1-CDK4/6 complexes or 
Cyclin A/E-CDK2 complexes[118]. 
 
The localization and degradation of Cyclin D1 is regulated by phosphorylation on 
T286, downstream of AKT and AKT also regulates Cyclin D1 activity through 
CDKN1A and CDKN1B[101,122,466]. Immunofluorescence (IF) and Western blotting 
were used to determine the effect of Nb8 expression on Cyclin D1. IF experiments 
showed that Cyclin D1 was enriched in the nucleus (Figure 39) (co-localization with 
DAPI according to Mander’s Colocalization Coefficient quantified using ImageJ)[467]. 
This was still the case in MK-2206 (pan-AKT inhibitor)-treated cells and EGFP Nb- 
or Nb5-expressing cells (Figure 32A). In cells expressing Nb8, the nuclear 
enrichment of Cyclin D1 was lost as these cells had a significantly lower overlap 
between DAPI and Cyclin D1 (one-way ANOVA, p<0.001) (Figure 32B). 
No (phospho)peptides for Cyclin D1 were found in the proteomics analyses. 
Western blotting was used to determine changes in Cyclin D1 protein expression 
levels. Nb8-expressing cells showed a significant (Wilcoxon signed rank test, 
p<0.001) reduction in Cyclin D1 levels when compared to the un-induced control 
(Figure 32C and D). Again, we found that MK-2206 treatment had no effect on 
Cyclin D1 even though it strongly reduced AKT2 S474 phosphorylation. A one-way 
ANOVA with Dunnett’s test indicated that there were no significant differences in 
Cyclin D1 levels between the EGFP Nb-, Nb5- and Nb9-expressing or MK-2206-
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treated cells. In addition, we found that CDK2 levels were also significantly down-
regulated in Nb8-expressing cells (Wilcoxon signed rank test, p<0.05). 
 
A cell cycle analysis showed that, compared to the EGFP Nb-expressing cells, 
the Nb8-expressing cell line had a significantly (one-way ANOVA with Tukey’s 
multiple comparison test, p<0.001) higher proportion of cells in the G0/G1 phase 
(+19.36 ± 3.43%) at the expense of cells in both the S (-10.22 ± 1.77%) and G2 
phase (-8.77 ± 2.77%) (Figure 32E). The cell cycle profile of Nb5- and Nb9-
expressing cells was similar to that of EGFP Nb-expressing cells. With the 
exception of the G2 phase of cells expressing Nb9, which showed a very small (-
3.08 ± 3.06%) but significant (p<0.05) decrease, there were no significant 
differences in population for any cell cycle phase. Full data for the one-way ANOVA 
with Tukey’s post-test can be found in Figure 39. 
 
Although the experiments above focused on signalling events downstream of 
Cyclin D1-CDK4/6 complexes, CDK2 and the cell cycle entry of MDA-MB-231 cells, 
there were indications of reduced activity of other cyclin-dependent kinases (CDKs) 
and reduced phosphorylation of proteins which function in later stages of the cell 
cycle (Table 8). 
NIFK, an interaction partner of Ki-67, phosphorylation was down-regulated on 
T234 and T238, substrate sites for GSK3α/β and CDK1, respectively. Although this 
infers reduced GSK3α/β activity, T234 can only be phosphorylated after CDK1 has 
phosphorylated T238[468]. Reduced CDK1 activity would thus result in a reduction 
of phosphorylation for both these sites. Phosphorylation of both sites is required for 
the NIFK-Ki-67 interaction. Both proteins are recruited to the chromosome 
periphery during mitosis[469]. Ki-67, a biomarker for proliferating cells, 
phosphorylation on S1937, S2223 and T2231 were also reduced. TPX2, a protein 
involved in cell cycle progression, phosphorylation was down-regulated on S738, 
another CDK1 substrate site and RRM2, which regulates the synthesis of DNA 
precursors, was down-regulated on S20 which is a CDK2 substrate site. 
 
Taken together, our other results show that Nb8 expression affected cell cycle 
progression through inhibition of the AKT2/CyclinD1-CDK2/RB1 signalling 
cascade. The final result was a reduction in RB1 phosphorylation on several CDK-
dependent sites allowing this protein to exert its tumour suppressive function, i.e. 





Figure 32 (Caption opposite). 
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Figure 32 (Opposite). Nb8 expression affected cell cycle progression through 
Cyclin D1 regulation. A: Representative epifluorescence images of MDA-
MB-231 cells treated with 5 µM MK-2206 or stably expressing AKT2 Nb5, 
Nb8 or the EGFP Nb (500 ng/mL Dox). The Nbs were distributed equally 
throughout the cells (red). In cells treated with MK-2206 or expressing Nb5 
or the EGFP Nb, the signal for Cyclin D1 (green) coincided with the signal 
for DAPI (blue), indicating a nuclear enrichment of Cyclin D1. In Nb8-
expressing cells this nuclear staining pattern was lost. Scale bar, 10 µm B: 
Plotted mean and 95% CI of Manders’ Colocalization Coefficient after 
Costes thresholding (tM1) for DAPI and Cyclin D1 for at least 85 cells. A 
one-way ANOVA with Tukey’s multiple comparison test indicated tM1 for 
Nb8-expressing cells was significantly (p<0.0001) lower compared to tM1 of 
the EGFP Nb- or Nb5-expressing cells and MK-2206-treated cells. 
Colocalization coefficients for all other treatments (MK-2206, EGFP Nb and 
Nb5) were not significantly different. C: Western Blot detection of Vinculin 
(loading control), AKT2 phosphorylated on S474 (pAKT2 S474), Cyclin D1, 
CDK2 and Nb8. Nb expression was induced with Dox (500 ng/mL) or  the 
cells were treated with MK-2206 (5 µM) for pan-AKT inhibition. 
Representative for at least six repeated experiments. D: Quantification of 
Cyclin D1 and CDK2 using ImageJ. Values were normalized for vinculin. The 
fold change for Dox-treated versus untreated cells is plotted. All data points 
are shown with their mean (dashed line) and a 95% CI (Whiskers). * 
p<0.05 and *** p<0.001, Wilcoxon signed rank test. Repeats are available 
in paragraph 4.9.3. E: Cell cycle phase distribution of Nb-expressing MDA-
MB-231 cells. Cells were gated to exclude debris, doublets and to include 
Nb-expressing cells. Values shown are the mean and SD of at least 3 
repeated experiments. The proportion of cells in the G0/G1-, S- and G2-
phase is shown as a percentage. Note that the y-axis has a break between 
10% and 60%. 
 Nb8 activates autophagy 
Previous studies indicated that ablation of AKT2 induces autophagy[234]. Autophagy 
(and mitophagy) were enriched biological processes identified in our proteomics 
analysis along with the cellular component ‘phagophore assembly site’. Pooling the 
hits from these GO keywords yielded 12 proteins with 14 differentially regulated 
phosphosites and four proteins with significant changes in expression levels 
(Figure 31C, Table 9). 
 
One of those proteins, Transcription factor EB (TFEB), controls expression of 
autophagy-related and lysosomal genes, among which are MAP1LC3B (LC3B) and 
ATG9A. TFEB is phosphorylated by mTORC1 on S122 and S142, resulting in the 
cytoplasmatic retention and inactivation of TFEB[154,155]. Both of these sites were 
down-regulated in Nb8-expressing cells along with S109, S114 and S138, the 
former two of which have also been shown to regulate TFEB localization. 
Additionally, RBC1CC1/FIP200, an integral part of the ULK complex, 
phosphorylation on S222 was up-regulated as were phosphorylation sites of 
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MAP1B (S541, S1785, T1788 and S2211), while both ATG2B (S497) and ATG9A 
(S656) phosphorylation were down-regulated. The effect of these PTMs for 
RB1CC1, MAP1B, ATG2B and ATG9A is unknown, but these proteins are involved 
in autophagosome formation, ATG2B and ATG9A in the early stages and 
RB1CC1/FIP200 in both early and late stages. Phosphorylated MAP1B interacts 
with LC3B and links autophagosomes to microtubuli[470,471]. 
To determine whether these changes induced autophagy in Nb8-expressing cells 
we analysed the levels of LC3B-II. The precursor protein LC3B is cleaved to form 
LC3B-I which, on induction of autophagy, is lipidated (phosphatidylethanolamine 
conjugation) to LC3B-II. This lipidated form migrates faster in SDS-PAGE and can 
be used as a marker for autophagy (Figure 33A)[472]. 
LC3B-II levels were significantly up-regulated in Nb8-expressing cells and MK-
2206-treated cells (p<0.05, Wilcoxon signed rank test) when compared to the un-
induced or untreated cells(Figure 33B). The fold change in LC3B-II levels 
(normalized for their respective control) of Nb8-expressing cells or MK-2206-
treated cells was not significantly different (p=0.84). An additional control, where 
NH4Cl is added to the medium of treated cells, was included to ensure LC3B-II up-
regulation was due to increased autophagy and not inhibition of autophagic flux 
(downstream processing of autophagic cargo). NH4Cl prevents lysosomal 
acidification and the further increase of LC3B-II in doubly-treated (Dox+NH4Cl or 
MK-2206+NH4Cl) cells indicated that MK-2206-treatment or Nb8 expression did not 
block autophagic flux(Figure 33C). 
 
The increased presence of autophagosomes in Nb8-expressing cells was 
confirmed though confocal microscopy using the Cyto-ID® dye (Figure 33D). 
Mitochondria were stained using MitoTracker® Orange CMTMRos and Nb8 was 
visualized through its V5-tag. The average amount of autophagic vesicles per cell 
was determined through ImageJ quantification. A Mann Whitney test indicated that 
Nb8-expressing cells contained significantly more autophagic vesicles (p<0.0001) 
(Figure 33E). 
 
Nb8 expression affected the phosphorylation status and expression levels of 
several proteins involved in autophagy. The observed LC3B-II upregulation and the 
higher amount of autophagic vesicles clearly shows the activation of autophagy as 








Figure 33 (Previous page). Nb8 induced autophagy. A: Western blot detection of 
LC3B-II in untreated cells, MK-2206 (5 µM)-treated cells or AKT2 Nb 
expressing cells (500 ng/mL Dox) and doubly-treated (Dox or Mk-2206) with 
NH4Cl (10 mM) added 4 h prior to cell lysis. Actin was used as loading 
control. The LC3B Ab detected both LC3B-I and LC3B-II. Nbs were detected 
through their V5-tag. B: ImageJ quantification of signal intensity. Values 
were normalized for the loading control (Actin) and experimental control 
(uninduced cells). All data points, their mean (dashed line) and a 95% CI 
(whiskers) are shown. Both MK-2206-treated and Nb8-expressing cells 
showed a significant (*p<0.05, Wilcoxon signed rank test) fold change 
increase in LC3B-II levels. C: Further increase in LC3B-II levels in NH4Cl-
treated cells, indicating that an up-regulation of autophagy rather than 
inhibition of autophagic flux lies at the base of LC3B-II increase in MK-2206-
treated and Nb8-expressing cells. Repeats are available in paragraph 4.9.3. 
D: representative confocal images of MDA-MB-231 cells. Cells expressing 
Nb8 contained significantly more autophagosomes (as green dots, Cyto-ID). 
Mitochondria were stained using Mitotracker® Orange CMTMRos (red). 
Autophagosomes were located near the mitochondrial network in both Nb8-
expressing and un-induced cells. Scale bar, 20µm. E: Average amount 
(mean and 95% CI) of autophagic vesicles per cell from at least 200 cells 
spread over three repeated experiments. Nb8-expressing cells had 
significantly (*** p<0.0001) more autophagic vesicles per cell. 
 Nb8 reduces focal adhesion count and CD29 expression 
In breast cancer cells, AKT1 and AKT2 have opposing effects on cell migration and 
metastasis, AKT1 activity reduces, while AKT2 enhances these processes. Our 
data indicated that Nb8 expression changes phosphorylation and/or expression 
levels of multiple proteins involved in cell adhesion and motility (Figure 31C, 
Table 10 and Table 11). Cell motility requires the dynamic remodeling of the 
cytoskeleton, including actin stress fibers and focal adhesions[167]. Focal adhesions 
(FA) are large protein complexes that link the extracellular matrix to the actin 
cytoskeleton through transmembrane integrins. In total, 17 and 7 differentially 
regulated proteins were quantified that localize to FAs and stress fibers, 
respectively. 
 
The effect of these changes in protein expression and phosphorylation on FAs 
in MDA-MB-231 cells was determined through IF, using Vinculin as a marker for 
FAs and labelled phalloidin to visualize F-actin (Figure 34A)[473]. FAs were 
quantified using ImageJ, the data are representative for three repeated 
experiments with at least 100 cells for each treatment. A one-way ANOVA (with 
Dunnett’s multiple comparison test) indicated that cells expressing Nb8 had 
significantly fewer FAs (p<0.01 for EGFP Nb vs Nb8 and p<0.001 for untreated and 
MK-2206-treated cells vs Nb8) (Figure 34B). Peptides from Vinculin were identified 
in the SG proteomics analysis. Label-free quantification (LFQ) indicated that 
Vinculin expression levels were unchanged for Nb8- vs EGFP Nb-expressing cells, 
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suggesting that Vinculin is displaced from FAs. Additionally, Nb8-expressing cells 
contained fewer structured actin filaments.  
The expression of Integrin β1 (CD29), an integral part of FAs, is up-regulated by 
AKT2 and promotes breast cancer cell migration[174,442]. WB detection of CD29 
showed CD29 levels were reduced in MDA-MB-231 cells after 48 h of Nb8 
expression (Figure 34C) (one-way ANOVA with Dunnett’s multiple comparison 
test, p<0.05) (Figure 34D). For the EGFP Nb-expressing cells no significant 
differences in CD29 levels were found for any time point. 
 
Figure 34 (Caption on next page).  
 
116 
Figure 34 (Previous page). Nb8 reduced the number of focal adhesions present in 
MDA-MB-231 cells. A: representative confocal images of MDA-MB-231 
cells. Vinculin was used as a marker for Focal adhesions, actin filaments 
and Nbs were visualised using fluorescent phalloidin and an anti-V5 Ab, 
respectively. Focal adhesions are visible as green vinculin streaks at the 
ends of actin filaments. Nb8-expressing cells contained both less vinculin 
streaks and fewer structured actin filaments when compared to the control 
conditions. Vinculin image insets are after background subtraction and 
thresholding[474]. Scale bar, 20 µm. B: ImageJ quantification of FAs for at 
least 100 cells. ** p<0.01, ***p<0.001. C: Western blot detection of CD29 in 
MDA-MB-231 cells expressing the EGFP Nb-(control) or Nb8. Nb expression 
was induced by 500 ng/mL Dox for up to 48 h. GAPDH was used as loading 
control, the Nbs were detected through their V5-tag. D: ImageJ 
quantification of signal intensity for CD29, normalized for GAPDH. Repeats 
are available in paragraph 4.9.3. A one-way ANOVA with dunnett’s multiple 
comparison test showed that, after 48 h of Nb8 expression, CD29 levels 
were significantly reduced (p<0.05). 
 Discussion 
In a previous study, we obtained and characterised three AKT2 specific Nbs (Nb5, 
Nb8 and Nb9) which interact with the catalytic, HM and PH domain of AKT2, 
respectively[326]. Nbs can knock out specific protein functions without reducing 
protein expression levels[272,290,301–305,401]. This makes Nbs complementary tools to 
RNAi for studying protein function. However, a function-blocking Nb seems to be a 
better indicator of the effects of a conventional inhibitor and such Nbs (or their 
therapeutic epitope) can be used in the discovery or design of new inhibitors. Here, 
we present high-affinity AKT2-interactors that can be used in living cells. Through 
lentiviral transduction, the AKT2 Nbs were stably integrated into the genome of 
MDA-MB-231 cells and can pull-down endogenous AKT2.  
Nb9 has been shown to interfere with the interaction of the AKT2 PH-domain with 
PtdIns(3,4,5)P3 which, in theory, could affect AKT2 activation. However, despite 
the results from cell-free experiments, we did not observe a reduction in AKT2 HM 
phosphorylation in IGF-1 stimulated cells expressing Nb9. The cell-free 
experiments did use a high molar excess of Nb9 over PH-domain. Nb9 has a higher 
affinity for the AKT2 PH-domain when compared to PtdIns(3,4,5)P3 (583 pM vs 590 
nM), but perhaps Nb9 expression levels were too low to overcome the sudden spike 
in local PtdIns(3,4,5)P3 concentration[29,67]. 
We found that Nb8 expression reduces phosphorylation of AKT2’s HM (S474) in 
IGF-1-stimulated cells. As Nb8 binds the HM and reduces, but not abolishes, 
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phosphorylation of that domain it is likely that Nb8 does not completely inhibit AKT2 
function. Phosphorylation of the AKT HM has been shown to ‘fine tune’ AKT 
signalling, a reduction in phosphorylation of this site only affects a subpopulation of 
AKT substrates[82,86,175]. Nb8’s effect is not necessarily limited to reducing the 
catalytic activity of AKT2. The interaction of Nb8 with the AKT2 HM could block 
‘structural’ AKT2 functions. It could restrict access to specific AKT2 substrates or 
interfere with the interaction of AKT2-regulating proteins[21,272,301,302,304,305]. 
 
A phosphoproteome analysis reliably quantified 7,677 phosphosites, 189 of 
which were differentially regulated between Nb8- and EGFP Nb-expressing cells. 
The shotgun proteome analysis of the same samples quantified 2,509 proteins, 37 
of these had significant changes in expression levels. The AKT3 HM phosphosite 
(S472) was quantified but not down-regulated in Nb8-expressing cells, which was 
expected as Nb8 does not interact with this isoform. The corresponding 
phosphosites for AKT1 and AKT2 were not quantified, nor was the phosphosite in 
the catalytic domain identified for any isoform. That several AKT substrate sites 
were quantified but not differentially regulated indicates that these are either not 
AKT2-specific substrates or that their phosphorylation is not affected by a reduction 
of AKT2 HM phosphorylation. The phosphorylation status of T309 and S474 
(residues for AKT2) has been suggested to determine substrate accessibility. 
Singly phosphorylated AKT at T309 would retain most of its functions, while doubly 
phosphorylated AKT (T309 and S474) adds additional substrates to its 
repertoire[82,175]. It remains to be seen whether this additional level in AKT regulation 
is also isoform-specific[39,82,86]. 
That no known AKT substrates were differentially regulated also means that we 
were unable to find a direct link between AKT2 and the differentially regulated 
phosphosites or proteins based on previously identified AKT substrates 
(PhosphoSitePlus®). That the novel potential AKT substrates identified by a 
NetPhos sequence motif search were all down-regulated could indicate these are 
regulated by AKT2 and that they are affected by Nb8. 
BAD S99 is an example of an AKT substrate site that is unaffected by Nb8 
expression. This is in line with our observation that Nb8 did not induce apoptosis, 
as shown by the lack of caspase-3 processing. This shows that AKT2 does not play 
a dominant role in the regulation of apoptosis in the breast cancer model used here. 
However, the roles of the AKT isoforms in regulating apoptosis are most likely 
context-dependent. There are reported cases where knockdown of a single isoform 
was sufficient to induce apoptosis, but also where a combined knockdown of all 
isoforms was required to obtain a similar effect[203,249]. 
The AKT kinases are part of a large network that includes multiple kinases 
downstream of AKT[6]. We expected that the majority of the identified phosphosites 
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would be indirectly regulated by AKT2. A Fisher exact test on substrate motifs for 
differentially regulated phosphosites showed consensus phosphorylation sites for 
CHEK1, CAMK2, CAMK4, PKA and PKC were enriched. The AKT pathway also 
includes several transcription factors, 17 differentially regulated proteins have 
‘transcription regulation’ as UniProtKB keyword (Supplementary Proteomics Data). 
Proteins of which the expression levels were significantly altered add another layer 
of information to the effect of AKT2 modulation by Nb8. 
GO term analysis and KEGG pathway mapping linked the differentially regulated 
proteins (both phosphorylation and expression levels) to specific functions 
regulated by AKT2. Indeed, the vast majority of our protein hits are involved in 
processes known to be regulated by the AKT family[163,174,242,443,460,462,475]. 
 
Our results implicate AKT2 as the dominant isoform in cell cycle regulation. 
Phosphorylation levels of GSK3β, an AKT substrate that phosphorylates Cyclin D1 
on T286 inducing nuclear export, were unchanged. This indicates that GSK3β is 
not responsible for the reduction in Cyclin D1 expression levels which is in line with 
results from a study using AKT2 siRNA[234]. There are other kinases downstream of 
AKT, such as DYRK1B and IKKA, which can also phosphorylate this site[476,477]. 
Additionally, this effect could also be achieved by the inhibition of Cyclin D1-CDK4 
complexes by CDKN1A or CDKN1B, both direct AKT substrates. CDKN1B 
upregulation has been observed in MDA-MB-231 cells with AKT2 down-regulation 
through siRNA[101,234]. The downregulation of Cyclin D1 and CDK2 accounts for the 
hypophosphorylation of seven out of eight detected RB1 phosphosites. These 
changes enable RB1 to exert its tumour suppressive functions. That not all 
phosphosites were down-regulated to the same extent suggests that there may be 
other upstream elements involved in RB1 regulation that are also affected by Nb8. 
Ten RB1 transcription targets that play a role in the cell cycle were quantified by 
shotgun proteomics. Only three (MCM6, RRM1 and CDK1) were significantly down-
regulated, but the fold change was too low to be considered biologically relevant[118]. 
Treating cells with MK-2206, a pan-AKT inhibitor, did not reduce Cyclin D1 or 
CDK2 levels. Another study has shown that MK-2206 treatment does not affect cell 
cycle progression in MDA-MB-231 cells[437]. Our results show this cell type is 
sensitive to AKT2 inhibition, resulting in a G0/G1 cell cycle arrest. 
This raises the question why AKT2 inhibition affects cell cycle progression, but 
full inhibition of the AKT family does not. Both AKT1 and AKT2 have been shown 
to regulate Cyclin D1 expression levels in MDA-MB-231 cells, which makes it 
unlikely that regulation of this process is AKT2-specific[234]. It is possible that 
complete inhibition of the AKT family triggers feedback mechanisms which are not 
activated by a reduction in AKT2 activity alone[477,478]. 
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Contrary to the effects on cell cycle progression, both Nb8 and MK-2206 had 
equal effects on induction of autophagy in MDA-MB-231 cells, specifically LC3B-II 
up-regulation. This indicates that neither AKT1 nor AKT3 plays a significant role in 
this process as inhibition of these kinases along with AKT2 (in MK-2206-treated 
cells) did not have an additive effect on LC3B-II levels. 
Although this was not observed directly, the reduced phosphorylation of TFEB 
(and EEF2K) sites suggests reduced mTORC1 activity, the main regulator of 
autophagy downstream of AKT. This is supported by the reduced RPS6KA1 S363 
phosphorylation, an upstream activator of mTORC1. 
In addition to this, we observed increased phosphorylation of RB1CC1/FIP200 
and MAP1B, and reduced phosphorylation of ATG2B and ATG9A. We suggest 
these modifications play a role in autophagy regulation, although how these are 
linked to AKT2 remains to be elucidated. 
Autophagy in cancer is a double-edged sword as it can promote cell survival or 
cell death[479]. The uncontrolled autophagy induced by Nb8 can lead to cell death 
and contribute to the effect on cell viability/proliferation. Other studies have shown 
that AKT2 inhibition leads to targeted degradation of mitochondria by autophagy 
(mitophagy)[234]. However, we found that autophagosomes stained by Cyto-ID™ 
were localized to the mitochondrial networks regardless of Nb8 expression 
(although these were much fewer in number in uninduced cells) and were unable 
to confirm increased mitochondrial volume in these cells. However, these results 
were based on knock-down of AKT2 and the time points for evaluation of the effects 
differ greatly from our own. It is possible that the effect is not yet detectable or that 
Nb8 specifically blocks certain AKT2 functions and elicits different effects than an 
AKT2 knockdown. 
 
The role of AKT2 in breast cancer cell migration and metastasis has been well 
established[163,174,229,442,456,462]. GO term analysis of differentially regulated proteins 
identified several enriched cellular components, biological processes and 
molecular functions related to the actin cytoskeleton and cell migration. The 
phoshorylation of ZYX S308 and PARVA S4/8 is known to affect cell migration, but 
the function of the majority of the phosphosites identified in our experiments has 
not yet been elucidated[480,481]. 
Our results show AKT2 modulation by Nb8 affects FAs in MDA-MB-231 cells. 
Organized complexes of FAs and stress fibers, which are observed at the leading 
edge of migrating cells, are not found in Nb8-expressing cells but were still present 
in MK-2206-treated cells. 
Although the down-regulation of PALLADIN, as was observed in AKT2 ablated 
cells, could explain the loss of stress fibers, PALLADIN levels were unchanged in 
Nb8-expressing cells (Figure 40). This suggests that maintaining PALLADIN 
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expression does not require full AKT2 activity and that a full protein knockdown is 
required to elicit this effect. 
It also appears that a complete inhibition of the AKT family by MK-2206 does not 
have the same effect on the cytoskeleton in MDA-MB-231 cells, which is likely due 
to the opposite functions of AKT1 and AKT2 in breast cancer cell migration. These 
results help explain how AKT2-specific signalling promotes cell migration in breast 
cancer cells. 
 Conclusions 
In this study we have used a novel approach to interfere with AKT2. An isoform-
specific Nb, which targets the HM, enabled us to study the effect of AKT2 
modulation in cells without affecting AKT2 expression levels. 
The HM is, to our knowledge, a previously unexplored epitope for AKT inhibition. 
Here, we show the importance of the HM in AKT2 signalling and the cellular 
processes affected by blocking this domain (Figure 35). Using high-throughput 
proteomics approaches we were able to identify proteins regulated by AKT2 further 
downstream in the pathway and the cellular processes which were affected by 
Nb8’s modulation of AKT2 activity. 
We show that, in MDA-MB-231 cells, AKT2 is the dominant isoform in cell cycle 
regulation but, given the results from other studies, think it is unlikely that this 
process is regulated solely by AKT2. We confirmed AKT2’s role in autophagy and 
identified PTM events that occur on induction of autophagy. Finally, we identified 
an isoform-specific mechanism by which AKT2 regulates focal adhesions, which 
could affect the ability of cancer cells to migrate and metastasise. 
In summary, our results confirm AKT2 and the HM as a bona fide target for 
cancer therapy. In contrast to techniques that down-regulate protein expression, 
Nb8 or its epitope can aid in the rational development of an AKT2-specific inhibitor 




Figure 35 Summary of Nb8’s effects on AKT2 signalling. A proposed model for the 
effects of Nb8 in MDA-MB-231 cells based on the results from this study, 
KEGG, Reactome pathways and STRING interactions. A dashed line 
indicates events that were not detected in this study, but are known to be a 
part of the AKT signalling pathway. The box marked “X” indicates the 
missing link(s) between AKT and the differentially regulated proteins. An 
arrow and t-bar indicate activating and inhibiting modifications, respectively. 
Lines ending in dots indicate a protein-protein interaction. +p = 
phosphorylation, +exp = increased expression and loc = effects on 
localization. White boxes indicate proteins that were detected in our 
experiments but were not differentially regulated. Red and blue colored 
boxes indicate detected proteins with up- or down-regulated 
phosphorylation/expression levels, respectively. The effect of Nb8 on the 
pathways is shown in a green box at the bottom of the figure. Created using 




 Materials and methods (And stir it with a wooden spoon) 
4.8.1 Antibodies 
Table 5 Antibodies. The antibodies used in Western blotting (WB) and immunostain 
(IS) experiments in “An AKT2-specific nanobody that targets the 
hydrophobic motif induces cell cycle arrest, autophagy and loss of focal 
adhesions in MDA-MB-231 cells”. 
Target Clone Manufacturer Cat. Nr. Use Dilution 
AKT1 C73H10 Cell Signaling 2938 WB 1/1000 
AKT2 D6G4 Cell Signaling 3063 WB 1/1000 
pAKT2 (S474) D3H2 Cell Signaling 8599 WB 1/1000 
AKT3 62A8 Cell Signaling 3788 WB 1/1000 
V5-Tag  Invitrogen R960 WB 1/5000 
    IS 1/500 
Caspase-3  Cell Signaling 9662 WB 1/1000 
VINCULIN hVIN-1 Abcam V9131 WB 1/5000 
    IS 1/600 
Cyclin D1 SP4 Abcam Ab16663 WB 1/1000 
    IS 1/200 
LC3B  Cell Signaling 2775 WB 1/1000 
Actin  Abcam Ab8229 WB 1/2000 
CD29 P5D2 Abcam Ab24693 WB 1/1000 
4.8.2 Production and purification of recombinant FL-AKT2 
The production of recombinant FL-AKT2 was performed as described 
previously[326]. Briefly, BL21 E. coli were heat-shock transformed and a culture was 
grown in Terrific Broth (TB, 16.9 mM KH2PO4, 71.9 mM K2HPO4.3H2O, 2 mM 
MgCl2, 12 g Tryptone, 24 g yeast extract, 4% glycerol, 1% glucose pH 7.2) to 
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OD600≥2, expression was induced with 0.5 mM IPTG and the cultures were 
incubated ON at 20°C in a shaking incubator. Cells were lysed using a French press 
and sonication, debris was pelleted (11,000 x g for 20 min at 4°C) and the 
supernatant (SN) was loaded onto a column containing Chitin beads (New England 
Biolabs). After washing the beads, proteins were eluted by ON incubation with 50 
mM DTT and purified by anion exchange chromatography (GE Healthcare). Purity 
was assessed by SDS-PAGE and Coomassie staining. 
4.8.3 Production of recombinant AKT2 Nbs 
WK6 E. coli were heat-shock transformed with pMECS-Nb plasmids and grown in 
TB at 37°C until an OD600 of 0.6-0.8 was reached. Nb expression was induced by 
adding 1 mM IPTG and cultures were incubated ON at 28°C. Nbs in the pMECS 
vector are expressed with an N-terminal PelB signal sequence, resulting in 
periplasmatic localization. Cells were pelleted (11,000 x g for 20 min at 4°C) and 
Nbs were extracted through osmotic shock using Tris-EDTA-Sucrose (TES, 0.2 M 
Tris, 0.5 mM EDTA, 0.5 M sucrose, pH 8.00). Protein concentration of the resulting 
periplasmatic extract was measured using the Bradford assay (Bio-Rad 
Laboratories). 
4.8.4 Bio-layer interferometry and data processing 
All experiments were run on an Octet RED96 system (ForteBio) at 25°C. Anti-
Penta-HIS biosensors (HIS1K, ForteBio) were pre-wet in kinetics buffer (KB, PBS 
(Gibco, Thermo Fisher) with 0.1% (w/v) BSA) for at least 10 min. Loading solutions, 
containing 10 µg/mL protein, were prepared by diluting the Nb-containing 
periplasmatic extracts in KB. All samples were dispensed into a 96-wellplate 
(Greiner Bio-One, 655209) at a volume of 200 µl. A single kinetics run entailed the 
following steps: Biosensor Regeneration (5 s in 0.5 M H2SO4 followed by 5 s in 
KB, for three cycles), Baseline (60 s in KB), Loading (300 s in loading solution), 
Baseline (60 s in KB), Association (300 s in KB containing purified FL-AKT2) and 
Dissociation (600 s in KB). Flow rate was set to 1000 for all steps. For Association, 
four FL-AKT2 concentrations were included (twofold dilutions starting at 25 nM FL-
AKT2 for Nbs 5 and 9 or starting at 800 nM for Nb8) and a single reference well 
without FL-AKT2 for background subtraction. 
Data was processed (software version 9.0.0.4) using the reference well for 
subtraction, the baseline was aligned to the y-axis (last 5 seconds of the Baseline 
step) and Savitzky-Golay filtering was used to reduce noise. KD values were 
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generated by fitting (global fit using curves from all AKT2 concentrations) the full 
association and dissociation steps to a 1:1 kinetic model. 
4.8.5 Cell culture and transduction 
For maintenance, MDA-MB-231 (ATCC® HTB-26™) cells were grown at 37°C in a 
humidified 10% CO2 incubator. The cells were cultured in DMEM supplemented 
with 10% foetal bovine serum and 100 IU/mL penicillin and 10 µg/mL streptomycin 
(medium and supplements from Gibco, Thermo Fisher Scientific). Prior to 
experiments, all cell lines were tested and found negative for mycoplasma 
contamination using PlasmoTest™ (InvivoGen). Stable cell lines expressing the 
AKT2 Nbs and the EGFP Nb were generated using the Lenti-X Tet-On Advanced 
Inducible Expression System (clontech) as described previously[301].  
4.8.6 Immunofluorescence and microscopy 
Coverslips were coated with 50 µg/mL rat tail type I collagen (BD Biosciences) in 
PBS (with Ca2+ and Mg2+) for 1 h at 37°C. MDA-MB-231 cells were seeded at a 
density <50% for Cyclin D1 detection and 60-80% for all other experiments. 24 h 
post-seeding, Nb expression was induced with 500 ng/mL Dox (Duchefa 
Biochemie, D0121) or the cells were treated with 5 µM MK-2206 (Selleckchem). 
Immunostaining was performed 24 h later. For visualization of autophagic vesicles 
and mitochondria, cells were treated with 10 µM Chloroquine for 4 h and incubated 
with Cyto-ID® green detection reagent (Enzo Life Sciences, ENZ-KIT175) and 0.1 
µM MitoTracker™ Orange CMTMRos (Thermo Fisher Scientific, M7510) according 
to the manufacturer’s instructions. Cells were fixed with 3% paraformaldehyde for 
25 min, permeabilized with 0.2% Triton X-100 for 5 min and incubated with 100 mM 
glycine for 20 min. Each incubation step was followed by at least three washing 
steps with PBS (with Ca2+ and Mg2+). Coverslips were incubated with primary and 
secondary antibodies (1 h at 37°C or 30 min at room temperature (RT) for primary 
Ab and secondary Ab, respectively), nuclei were stained with 0.4 µg/mL DAPI 
(Sigma Aldrich, D9542) and Acti-stain 670 Phalloidin (Cytoskeleton, PHDN1-A) 
was used to visualise F-actin. Coverslips were mounted onto microscopy slides 
using Vectashield antifade mounting medium (Vector Laboratories, H-1000) and 
sealed using nail polish. 
Images were captured using a Zeiss Axiovert 200 M fluorescence microscope 
with Apotome module (Zeiss x63 1.4-NA Oil Plan-Apochromat objective, Carl 
Zeiss) and Axiovision 4.5 software (Zeiss) or an Olympus IX81 Fluoview 1000 
confocal laser scanning microscope (Olympus x60 1.36-NA Oil UplanSApo 
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objective, Olympus, Tokyo, Japan) with FluoView FV 1000 software (Olympus). 
Images were analyzed using ImageJ. 
For quantifying Cyclin D1 co-localization with DAPI, the Coloc2 plugin was used. 
A one-way ANOVA with tukey’s multiple comparison test (GraphPad Prism v5.00) 
was used to compare Manders colocalization coefficient with costes thresholding 
between cell lines. Representative for 85 cells per cell line collected over three 
repeated experiments. Autophagic vesicles were counted using ImageJ. Focal 
Adhesion count was determined according to Horzum et al[474]. A one-way ANOVA 
with dunnett’s multiple comparison test (GraphPad v5.00) was used to determine 
significant differences in the average number of focal adhesions present in cells. 
4.8.7 Co-immunoprecipitation of AKT2 using intrabodies 
Stable cell lines expressing the AKT2 Nbs and EGFP Nb were seeded in T75 cell 
culture flasks and Nb expression was induced by adding 500 ng/mL Dox. After 24 
h, cells were lysed in ice-cold Tris Lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1% 
Triton X-100, 1 mM PMSF, 200 µg/mL protease inhibitor cocktail pH 7.5). Cell 
debris was pelleted and protein concentration determined using the Bradford 
assay. 1 mg WCL was incubated with 10 µl settled anti-V5-agarose beads (A7345, 
Sigma Aldrich) for 1 h at 4°C with end-over-end rotation. 
The beads were washed three times and proteins were eluted in Laemmli SDS 
sample buffer (5% SDS, 20% glycerol, 0,2% bromophenol blue, 5% β-
mercaptoethanol, 65 mM Tris-HCl pH 6.8) by heating the beads to 95°C for 5 min. 
Eluates were analysed by SDS-PAGE and Western blotting. D6G4 was used to 
detect AKT2 and Nbs were detected using an anti-V5 Ab (Invitrogen, 1296025). 
4.8.8 XTT-assay 
Stable MDA-MB-231 cell lines expressing the AKT2 Nbs or EGFP Nb were 
detached using Trypsin-EDTA (Gibco, Thermo Fisher Scientific) and re-seeded at 
6,000 cells per well in 96-wellplates (Greiner Bio-One, 655160). A separate plate 
was used for each time point (24 h, 48 h and 72 h). 500 ng/mL Dox was added to 
induce Nb expression. An internal control condition without Dox and background 
correction wells containing only medium (no cells) were also included. 
After incubation (24-72 h), 50 µl of activated XTT solution (XTT cell proliferation 
kit II, Roche) was added to all wells and the OD was measured at 475 nm and 660 
nm, immediately (background), 4 h and 6 h after adding the solution. Specific 
absorbance was obtained by subtracting the values from background wells and 
non-specific readings (OD at 660 nm). Values were normalized for the internal 
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control and the EGFP Nb-expressing cells. Data was gathered from three 
independent experiments. A one-way ANOVA with tukey’s multiple comparison test 
(GraphPad Prism v 5.00) was used to compare all time points within a single cell 
line or a single time point between all cell lines. 
4.8.9 Caspase-3 detection 
Stable MDA-MB-231 cell lines expressing AKT2 Nbs or the EGFP Nb were seeded 
in 6-wellplates at a density of 75,000 cell per well and Nb expression was induced 
by adding 500 ng/mL Dox. Cells were lysed with ice cold Tris Lysis buffer, 
immediately, 24 h, 48 h and 72 h after adding Dox. Staurosporine-treated (10 µM, 
24 h) cells were included as positive control. 
Protein concentration in the WCL was determined by Bradford assay and a 10 
µg sample was analysed by SDS-PAGE and Western blotting. The Caspase-3 Ab 
used (Cell Signaling Technology, 9662) detected both full-length Caspase-3 and 
the 17/19 kDa fragments. Vinculin (hVIN-1, Sigma Aldrich) was used as loading 
control and Nbs were detected through their V5-tag. 
4.8.10 AKT2 hydrophobic motif detection 
MDA-MB-231 cell stably expressing Nb8 were seeded in a 6-wellplate. Cells were 
serum starved for 48 h and Nb expression was induced with 500 ng/mL Dox for 24 
h. A control condition of serum starved cells without Dox was included. Cells were 
stimulated with 5 ng/mL IGF-1 for 1 min, 5 min, 15 min or 30 min and lysed using 
ice cold RIPA lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS, 1 mM PMSF, 200 μg/mL protease inhibitor cocktail mix, 
pH 7.6) with phosphatase inhibitors (PhosSTOP™, Roche, 1 tablet/10 mL buffer). 
A 10 µg sample was analysed by SDS-PAGE and western blotting. AKT2 and p-
AKT2 S474 were detected using D6G4 and D3H2, respectively. Vinculin was used 
as loading control and Nb8 was detected using an anti-V5-tag Ab. Signal intensity 
was quantified using ImageJ. A one-way ANOVA (GraphPad Prism v5.00) was 




4.8.11 (Phospho)proteomics analysis 
 Sample preperation 
Stable MDA-MB-231 cells expressing Nb8 or the EGFP Nb were serum-starved for 
48 h and treated with Dox (500 ng/mL) for 24 h prior to IGF-treatment (5 ng/mL, 5 
min) and lysis. Cells were scraped and lysed in a urea lysis buffer containing 9 M 
urea, 20 mM HEPES pH 8.0 and PhosSTOP™ phosphatase inhibitor cocktail 
(Roche, 1 tablet/10 mL buffer). The samples were sonicated with 3 pulses of 15 s 
at an amplitude of 20% using a 3 mm probe, with incubation on ice for 1 minute 
between pulses. After centrifugation for 15 minutes at 20,000 x g at RT to remove 
insoluble components, proteins were reduced by addition of 5 mM DTT and 
incubation for 30 minutes at 55˚C and then alkylated by addition of 10 mM 
iodoacetamide and incubation for 15 minutes at RT in the dark. The protein 
concentration was measured using a Bradford assay and, from each sample, 4 mg 
protein was used to continue the protocol. 
Samples were further diluted with 20 mM HEPES pH 8.0 to a final urea 
concentration of 4 M and proteins were digested with 40 µg LysC (Wako) (1/100, 
w/w) for 4 hours at 37°C. Samples were diluted to 2 M urea and digested with 40 
µg trypsin (Promega) (1/100, w/w) overnight at 37˚C. 
The resulting peptide mixture was acidified by addition of 1% trifluoroacetic acid 
(TFA) and after 15 minutes incubation on ice, samples were centrifuged for 15 
minutes at 1,780 x g at room temperature to remove insoluble components. Next, 
peptides were purified on SampliQ SPE C18 cartridges (500 mg, Agilent). Columns 
were first washed with 5 mL 100% acetonitrile (ACN) and pre-equilibrated with 15 
mL of solvent A (0.1% TFA in water/ACN (98:2, v/v)) before samples were loaded 
on the column. After peptide binding, the column was washed again with 5 mL of 
solvent A and peptides were eluted twice with 700 µl elution buffer (0.1% TFA in 
water/ACN (20:80, v/v)). The eluted peptides were divided in two parts: 100 µl was 
dried completely in a speedvac vacuum concentrator for shotgun analysis, while 
the remainder was used for phosphopeptide enrichment. 
Phosphopeptides were enriched with MagReSyn® Ti-IMAC beads according to 
the manufacturer’s instructions with slight modifications. Briefly, 100 µl 
MagReSyn® Ti-IMAC beads (per sample) were washed twice with 70% EtOH, once 
with 1% NH4OH and three times with a mixture of water/ACN/TFA (14:80:6, v/v/v). 
Next, the digested sample was incubated with the washed beads for 30 min at room 
temperature, the beads were washed once with a mixture of water/ACN/TFA 
(14:80:6, v/v/v) and three times with a mixture of water/ACN/TFA (19:80:1, v/v/v). 
Phosphopeptides were eluted from the beads by adding 80 µl 1% NH4OH three 
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times. 60 µl 10% formic acid (FA) was added to the combined eluate and the 
samples were dried completely in a speedvac vacuum concentrator. 
 LC-MS/MS analysis 
LC-MS/MS analysis was performed at the VIB Proteomics Core. 
Purified peptides for shotgun analysis were re-dissolved in 20 µl solvent A and 
2 µl of each sample was injected for LC-MS/MS analysis on an Ultimate 3000 
RSLCnano system (Thermo) in line connected to a Q Exactive mass spectrometer 
(Thermo). Trapping was performed at 10 μl/min for 4 min in loading solvent A on a 
10 mm µPACTM trapping column (PharmaFluidics) with C18-endcapped stationary 
phase and the samples were loaded on a 50 cm long micro pillar array column 
(PharmaFluidics) with C18-endcapped functionality mounted in the Ultimate 3000’s 
column oven set at 35°C. For proper ionization, a fused silica PicoTip emitter (10 
µm inner diameter, New Objective) was connected to the µPAC™ outlet union and 
a grounded connection was provided to this union. Peptides were eluted by a non-
linear increase from 1 to 50% MS solvent B (0.1% FA in water/ACN (2:8, v/v)) over 
159 minutes, first at a flow rate of 750 nl/min, then at 300 nl/min, followed by a 5-
minutes wash reaching 95% MS solvent B and re-equilibration with MS solvent A 
(0.1% FA in water). 
The mass spectrometer was operated in data-dependent, positive ionization 
mode, automatically switching between MS and MS/MS acquisition for the 5 most 
abundant peaks in a given MS spectrum. The source voltage was 2.9 kV, and the 
capillary temperature was 275°C. One MS1 scan (m/z 400−2,000, AGC target 3 × 
106 ions, maximum ion injection time 80 ms), acquired at a resolution of 70,000 (at 
200 m/z), was followed by up to 5 tandem MS scans (resolution 17,500 at 200 m/z) 
of the most intense ions fulfilling predefined selection criteria (AGC target 5 × 104 
ions, maximum ion injection time 80 ms, isolation window 2 Da, fixed first mass 140 
m/z, spectrum data type: centroid, intensity threshold 1.3xE4, exclusion of 
unassigned, 1, 5-8, >8 positively charged precursors, peptide match preferred, 
exclude isotopes on, dynamic exclusion time 12 s). The HCD collision energy was 
set to 25% Normalized Collision Energy and the polydimethylcyclosiloxane 
background ion at 445.120025 Da was used for internal calibration (lock mass). 
 
Peptides resulting from phosphopeptide enrichment were re-dissolved in 20 µl 
solvent A and 10 µl was injected for LC-MS/MS analysis on an Ultimate 3000 
RSLCnano system in-line connected to a Q Exactive HF mass spectrometer 
equipped with a Nanospray Flex Ion source (Thermo). Trapping was performed at 
10 μl/min for 4 min in solvent A on a 20 mm trapping column (made in-house, 100 
μm internal diameter (I.D.), 5 μm beads, C18 Reprosil-HD, Dr. Maisch, Germany) 
and the samples were loaded on a 50 cm long micro pillar array column 
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(PharmaFluidics) with C18-endcapped functionality mounted in the Ultimate 3000’s 
column oven set at 35°C. For proper ionization, a fused silica PicoTip emitter (10 
µm inner diameter) (New Objective) was connected to the µPAC™ outlet union and 
a grounded connection was provided to this union. Peptides were eluted by a non-
linear increase from 1 to 50% MS solvent B (0.1% FA in water/ACN (2:8, v/v)) over 
159 minutes, first at a flow rate of 750 nl/min, then at 300 nl/min, followed by a 5-
minutes wash reaching 95% MS solvent B and re-equilibration with MS solvent A 
(0.1% FA in water). 
The mass spectrometer was operated in data-dependent, positive ionization 
mode, automatically switching between MS and MS/MS acquisition for the 5 most 
abundant peaks in a given MS spectrum. The source voltage was 2.6 kV, and the 
capillary temperature was 275°C. One MS1 scan (m/z 400−2,000, AGC target 3 × 
106 ions, maximum ion injection time 80 ms), acquired at a resolution of 70,000 (at 
200 m/z), was followed by up to 5 tandem MS scans (resolution 17,500 at 200 m/z) 
of the most intense ions fulfilling predefined selection criteria (AGC target 5 × 104 
ions, maximum ion injection time 80 ms, isolation window 2 Da, fixed first mass 140 
m/z, spectrum data type: centroid, intensity threshold 1.3xE4, exclusion of 
unassigned, 1, 5-8, >8 positively charged precursors, peptide match preferred, 
exclude isotopes on, dynamic exclusion time 12 s). The HCD collision energy was 
set to 25% Normalized Collision Energy and the polydimethylcyclosiloxane 
background ion at 445.120025 Da was used for internal calibration (lock mass). 
QCloud was used to control instrument longitudinal performance during the 
project[482]. 
 Data processing 
Data processing was performed at the VIB Proteomics Core. 
Data analysis of the shotgun and phosphoproteomics data was performed with 
MaxQuant (version 1.6.10.43) using the Andromeda search engine with default 
search settings including a false discovery rate set at 1% on PSM, peptide and 
protein level. Spectra were searched against the human proteins in the UniProt 
Reference Proteome database (database release version of June 2019 containing 
20,960 human protein sequences, (http://www.uniprot.org) supplemented with the 
sequences of AKT2 Nb8 and the EGFP Nb. The mass tolerance for precursor and 
fragment ions was set to 4.5 and 20 ppm, respectively, during the main search. 
Enzyme specificity was set as C-terminal to arginine and lysine, also allowing 
cleavage at proline bonds with a maximum of two missed cleavages. Variable 
modifications were set to oxidation of methionine residues, acetylation of protein N-
termini and phosphorylation of serine, threonine or tyrosine residues, while 
carbamidomethylation of cysteine residues was set as fixed modification. Matching 
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between runs was enabled with a matching time window of 0.7 minutes and an 
alignment time window of 20 minutes. 
Only proteins with at least one unique or razor peptide were retained leading to 
the identification of 3,805 proteins and 9,999 phosphorylated sites. Proteins were 
quantified by the MaxLFQ algorithm integrated in the MaxQuant software. A 
minimum ratio count of two unique or razor peptides was required for quantification. 
 Data analysis 
Further data analysis of the shotgun results was performed with the Perseus 
software (version 1.6.2.1) after loading the proteingroups file from MaxQuant. 
Reverse database hits, potential contaminants and proteins that were only 
identified by site were removed, LFQ intensities were log2 transformed and 
replicate samples were grouped. Proteins with less than three valid values in at 
least one group were removed and missing values were imputed from a normal 
distribution (width 0.3 and down shift 1.8) around the detection limit leading to a list 
of 2,509 quantified proteins that was used for further data analysis. Then, a t-test 
was performed (FDR=0.05 and s0=0) and significant hits were filtered for 
Log2LFQ(Nb8/EGFP Nb) difference of <-1 or >1 to compare differences in protein 
levels between Nb8- and EGFP Nb-expressing cells. A volcano plot was generated. 
37 proteins were found to be significantly regulated.  
For the analysis of the phosphoproteome data, the phospho(STY)sites file was 
loaded in the Perseus software (version 1.6.2.1). Reverse hits and potential 
contaminants were removed, the site table was expanded and the intensity values 
were log2 transformed. Replicate samples were grouped, phosphosites with less 
than three valid values in at least one group were removed and missing values 
were imputed from a normal distribution (width 0.3 and down shift 1.8) around the 
detection limit leading to a list of 7,677 quantified phosphopeptides that was used 
for further data analysis. Then, a t-test was performed (FDR=0.05 and s0=0) and 
significant hits were filtered localization probability ≥0.75 and for 
Log2LFQ(Nb8/EGFP Nb) difference of <-1 or >1 to compare Nb8- and EGFP Nb-
expressing cells. A volcano plot was generated. 189 phosphopeptides were 
significantly regulated.  
The Panther classification system was used to determine statistical 
overrepresentation of GO-terms in the list of significantly regulated proteins. The 
whole Homo sapiens gene set was used as reference list, a Fisher’s exact test with 
Bonferroni correction for multiple testing was used to determine significantly 
enriched (p<0.05) terms. 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
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identifier PDX020637 (login username: reviewer19716@ebi.ac.uk and password: 
iJKACkge). 
4.8.12 Detection of cyclin D1 expression levels 
MDA-MB-231 cell lines (parental, EGFP Nb, Nb5, Nb8 and Nb9) were seeded in 6-
wellplates at 80,000 cells / well. Nb expression was induced by Dox (500 ng/mL). 
A control condition of untreated cells and cells treated with 5 µM Mk-2206 were 
also included. 
After 24 h incubation, cells were lysed using RIPA lysis buffer and 10 µg WCL 
was analysed through SDS-PAGE and western blotting. P-AKT2 S474 was 
detected using D3H2, Cyclin D1 using Ab16663, Vinculin by hVIN-1 and Nbs 
through their V5-tag. Vinculin was used as loading control. Signal intensity was 
quantified using ImageJ and a Wilcoxon signed rank test (GraphPad Prism v5.00) 
was used to compare treated cells with control conditions. 
4.8.13 Cell cycle analysis 
180,000 cells were seeded in 25 cm2 culture flasks and treated with Dox (500 
ng/mL) for 24 h. Cells were detached, fixed with ice cold 70% ethanol for 30 min 
and permeabilized with 0.2% Tween-20 and 0.2% saponin in PBS. After blocking 
in 5% (w/v) BSA and 0.2% Tween-20 in PBS cells were incubated for 1 h at RT 
with 1 µg/mL anti-V5-AF645 (Thermo Fisher Scientific, 451098). Cells were washed 
twice with PBS between incubation steps. Finally, the cells were incubated with 100 
µg/mL RNase A (Roche) for 5 min at RT and subsequently with 50 µg/mL Propidium 
Iodide (Sigma Aldrich, P4170). 
Samples were run on an Attune NxT Flow Cytometer (Invitrogen). The obtained 
data was analysed with FlowJo™ (v10). Samples were gated to exclude cellular 
debris and doublets. A one-way ANOVA with Tukey’s multiple comparison test 
(GrahPad Prism v5.00) was used to determine significant changes in the proportion 
of cells in each cell cycle phase. 
4.8.14 Detection of LC3B-II 
MDA-MB-231 cells (parental, EGFP Nb, Nb5, Nb8 or Nb9) were seeded in 6-
wellplates at 100,000 cells/well. After ON incubation cells were treated (5 µM Mk-
2206 for the parental cells and 500 ng/mL Dox for stable cell lines) and incubated 
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for 24 h. untreated cells were included as a control, as well as cells which were, in 
addition to Mk-2206 or Dox, also treated with 100 mM NH4Cl for 4 h. 
Cells were lysed using ice cold RIPA lysis buffer and a 25 µg sample was 
analysed by SDS-page and western blotting. The LC3B Ab (Cell Signaling 
Technology, 2775) detected both LC3B-I and LC3B-II. Actin (Abcam, Ab8229) was 
used as loading control, Nbs were detected using their V5-tag. Signal was 
quantified using ImageJ and a Wilcoxon signed rank test (GraphPad Prism v5.00) 
was used to detect significant differences between treated cells and control. 
4.8.15 Quantification of CD29 levels 
MDA-MB-231 cells expressing Nb8 or the EGFP Nb were seeded in 6-wellplates. 
Nb expression was induced by Dox (500 ng/mL) and cells were lysed 
immediately,after 24 h and 48 h using ice cold RIPA lysis buffer. 
A 10 µg sample was analysed by SDS-page and western blotting. CD29 was 
detected using P5D2 (Abcam, 24693) and Nbs using an anti-V5 Ab. GAPDH 
(Abcam, Ab8245) was used as loading control. Signal intensity was quantified using 
ImageJ and a one-way ANOVA with dunnett’s multiple comparison test (GraphPad 
v5.00) to analyse differences between time points. 
 Supporting material 
4.9.1 Additional figures 
 
Figure 36 Co-IP of AKT1 and AKT3 using intrabodies. Co-IP of endogenous AKT1 
or AKT3 from MDA-MB-231 cells with intracellularly expressed, V5-tagged 
AKT2 Nbs using V5-agarose. WCL= whole cell lysate, C= control using the 
EGFP Nb expressing stable cell line. HC= Heavy-Chain, LC= Light-Chain. 
All Nbs are expressed in the stable cell lines and—apart from the positive 





Figure 37 Cytotoxic and cytostatic effect of AKT2 intrabodies on MDA-MB-231 
cells. Clonogenic assay for stable cell lines expressing the EGFPNb, AKT2 
Nb5, Nb8 or Nb9. 25.000 cells were seeded in a multiwell dish on day1, Nb 
expression induced with 500ng/mL Doxycyclin on day2 and crystalviolet 




Figure 38 Differential (phospho)proteome of Nb8- vs EGFP Nb-expressing cells. Principal Component analysis of 
phosphoproteome (A) and proteome (B) data for the phosphoproteomics run and proteome data and heatmap showing the 
Log2-transformed, Z-scored values of LFQ intensity for differently regulated phosphosites (C) and proteins in the same 
experiment (D). Hierarchical clustering shows a clear distinction between treatment conditions (Nb8 expressing cells or EGFP 





Figure 39 Cyclin D1 localization and cell cycle analysis. A: representative 
epifluorescence images of the un-induced stable Nb8 MDA-MB-231 cell line. 
Nb-V5 is stained Red, nuclei were stained with DAPI (Blue) and Cyclin D1 
is stained green. No Nb expression could be detected and Cyclin D1 
localizes to the nucleus. B: A one-way ANOVA with Tukey’s multiple 
comparison test was performed to compare each pair of nanobody 
expressing cell lines. This shows the proportion of cells in the G0/G1, S and 
G2 phases are respectively higher, lower and lower when compared to any 
other nanobody (p≤0.001). With the exception of the G2 phase for EGFP Nb 
vs Nb9 (p≤0.05) no other significant differences were detected. 
 
 
Figure 40 Quantification of PALLADIN expression levels. A:1= -Dox, 2= +Dox, 3= 
+MK-2206 . All values were normalized for the fluorescent Cy5 total protein 
stain. B: A one-way ANOVA with Tukey’s multiple comparison test indicated 
the mean Palladin signal intensity did not significantly (p=0.57) differ 
between any of the treatment conditions. 
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4.9.2  Additional tables 





Table 7 Phosphoproteomics: quantified known AKT substrates. Known AKT 
substrates identified in the phosphoproteomics screening 
(PhosphoSitePlus®). A hit was only considered to be relevant when it was 
both significant (FDR<0.05) and had a Log2 difference vs the EGFP Nb ≥1 
or ≤-1. Positive values indicate higher phosphopeptide abundance in Nb8 











S570 - 0.14 
S588 - -0.34 
S751 - -0.96 
BAD S99 - -0.06 
CARHSP1 S52 - 0.33 
EPHA2 S897 + 0.54 
NIBAN1 S602 - 0.65 
FLNA S2152 - 0.51 
FLNC S2233 + 0.14 
GSK3Β S9 - 0.01 
NDRG2 S332 - -0.14 
PALLADIN S1118 - 0.44 
PDCD4 S457 - 0.46 
PEA15 S116 - 0.6 
PIKFYVE S307 - 0.13 
PKM S37 + 0.57 
PRAS40 T246 - -0.15 
RANBP3 S126 - -0.64 
RPS6 S236 - -0.06 
TIAM1 S231 - -0.2 
USP8 S718 - 2.4 




Table 8 Differentially regulated phosphosites and proteins involved in the 
mitotic cell cycle according to KEGG and Gene Ontology. Positive 
values indicate higher phosphopeptide/protein abundance in Nb8 










ZFYVE19 S354 +1.42 -2.11 
GAK 
S826 +1.12 -1.58 
S829 +1.12 
RB1CC1 S222 +1.16  
HSP90AA1 
S252 +1.01 +0.18 
S263 +1.01 
 
DIS3L2 S875 -1.01  
NUMA1 
S1991 -1.02 -0.08 
T2000 -1.02 
AHCTF1 S2226 -1.08  
NOCL1 
T607 -1.1  
T610 -1.1  
HMGA2 
S44 -1.19  
S105 -1.02  
FANCD2 S1435 -1.19  
CDCA8 S219 -1.22  
RIF1 S2144 -1.3  
TPX2 S738 -1.33  
MIS18BP S1008 -1.39  
RRM2 S20 -1.43  
RPS6KA1 S363 -1.46  
NEK9 S827 -1.5 -0.66 
PTTG1/2 S165 -1.52  
SUN2 S1084 -1.78 +0.23 
FLNA S1084 -1.78 0.23 
TXNIP S361 -1.78  
STAG2 S1061 -1.87 -0.13 
MKI67 
S1937 -1.22  
S2223 -1.98  
S2231 -1.83  
RB1 










WDR62 T1053 -3.86  
 
RRAG A/B   +2.63 





Table 9 Protein and phosphosite hits related to autophagy. Proteins grouped 
into autophagy-related GO terms or pathways. KEGG ‘autophagy’, 
‘autophagy – animal’ and GO BP autophagy and autophagosome assembly 
and GO CC ‘phagophore assembly site’ are included. Positive values 
indicate higher phosphopeptide/protein abundance in Nb8 expressing cells 









RB1CC1 S222 +1.16  
MAP1B 





S826 +1.12  
S829 
ADD2 
S693 +1.06  
S697 
HSP90AA1 









ATG9A S656 -1.99  
IRS2 
S388 -1.27  
S391 
ATG2B S497 -1.07  
 
RRAG A/B   +2.63 





Table 10 (Phospho)proteomics protein hits related to focal adhesion. Positive 
values indicate higher phosphopeptide/protein abundance in Nb8 
expressing cells vs EGFP Nb expressing cells wile negative values indicate 









TGFB1I1 S192 2.7 1.51 
DOCK7 S452 2.6 0.03 
GAK 
S826 +1.12 -1.58 
S829 
 
PDLIM1 S130 -1.04 -0.35 
ZYX S308 -1.05 0.27 
CAP1 S310 -1.23 0.16 
NUMB S361 -1.33 0.04 
PARVA 
S4 -1.52  
S8 -1.57  
FLNA S1084 -1.78 0.23 
AHNAK S41 -3.16 0.36 
 
FLNC   +2.49 
LCP1   +1.81 
 
HSPG2   -1.24 
JUP   -1.33 
ZNF185   -1.61 
LAMB1   -1.76 





Table 11 (Phospho)proteomics protein hits related to stress fibers. Positive 
values indicate higher phosphopeptide/protein abundance in Nb8 
expressing cells vs EGFP Nb expressing cells wile negative values indicate 







PDLIM1 S130 -1.04 -0.35 
ZYX S308 -1.05 +0.27 
LIMCH1 T215 -1.1  
FHOD1 S498 -1.17 -0.19 
PDLIM2 S124 -1.51  
S129 -1.49  
SIPA1L3 T1699 -1.65  
 
LCP1   +1.81 
4.9.3 Online content 
The supplementary material (uncropped images and proteomics data) related to 






General discussion and future perspectives 
“I’ve got a small query for you: What comes 
next? Do you have a clue what happens now?” 
-King George III 
AKT was discovered 33 years ago and has been the subject of tens of thousands 
of research papers, yet still remains a very relevant protein kinase for research 
today[10]. Over the years, the various events (GF stimulation, cytokines, cell-cell 
adhesion,…) that result in AKT activation and the downstream substrates through 
which AKT regulates cellular processes have been identified[6,46]. It has also 
become painfully clear that the AKT signalling cascade is part of a complex and 
convoluted network that processes a wide variety of stimuli. This is further 
complicated by the existence of three closely related AKT isoforms that differ in 
substrate specificity, subcellular localization and function, with much discord on the 
exact roles of these isoforms. 
The discovery that several members of the PI3K/AKT pathway can act as 
oncogenic drivers, and the observation that AKT is frequently hyperactivated in 
various kinds of cancer, has inevitably led to the evaluation of AKT inhibitors for 
cancer therapy. But perhaps this happened too rash, and with insufficient 
knowledge on the precise layout of the AKT signalling network. As a consequence, 
the results from clinical trials were rather disappointing: dose-limiting adverse 
effects, a general lack of efficacy, and after decades of research, not a single AKT 
inhibitor has been approved for cancer therapy. There is not even an inhibitor that 
has made it to phase III clinical trials[255–257,483,484]. 
Given what we know now about the isoform-specific, and sometimes opposed 
roles of the AKT isoforms in cancer, one could argue that the full inhibition of all 
three isoforms, the strategy used so far, is not the way to go. However, we lack 
inhibitors that show sufficient specificity for a single AKT isoform[257,261,262]. It is clear 
that new tools need to be developed with isoform-specificity as starting point. The 
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characterization of these tools goes hand in hand with unravelling the isoform-
specific functions of the AKT isoforms and the discovery or validation of therapeutic 
epitopes. 
Nbs are well-established as a research tool but have also found their way into 
diagnostics and therapy. Their characteristics make them an interesting new 
method to tackle the problem of AKT isoform-specificity. By nature, Nbs are a 
fundamentally different tool than gene knockdown techniques, and are therefore 
complementary. As is outlined in paragraph 2.4.2.1, I believe that a function-
blocking Nb could be a better indicator of the effects of a conventional inhibitor and 
this Nb or the therapeutic epitope can aid in the discovery and/or design of new, 
isoform-specific AKT inhibitors[284,406]. 
 
To achieve this, anti-AKT Nbs were generated by immunizing alpacas. That we 
started out with 45 unique Nb sequences and ended up with only four isoform-
specific Nbs (one for AKT1, three for AKT2 and none for AKT3) attests to the 
difficulty of obtaining (protein) molecules that only recognize a single AKT isoform. 
Despite the fact that the AKT linker regions have the lowest sequence identity 
by far, and at first glance appear to be the optimal antigen for obtaining isoform-
specific interactors, we chose not to use these linkers as antigens (Figure 1). While 
properly folded proteins or protein domains are highly antigenic for HcAbs, this is 
not the case for unstructured proteins or (oligo)peptides[320,485]. The linker region, 
being both a peptide and unstructured, is therefore an inherently unfit candidate for 
immunization. Furthermore, no function that offers opportunities for therapeutic 
intervention has been attributed to this region, which is the case for the PH domain 
(activation), protein kinase domain (catalytic activity) and regulatory domain 
(enhancing or inhibiting catalytic activity)[23–25,38,43,44]. Besides, the AKT PH domain 
is an attractive target due to its role in allosteric AKT inhibition, and we had 
previously observed that it is possible to obtain a Nb that specifically interacts with 
the Cortactin SH3 domain, which shares 71% sequence identity with the SH3 
domain of HS1[400]. 
In hindsight, an alternative strategy would have been to immunise multiple 
animals with the full-length AKT proteins. Unlike most lab animals, the camelidae 
used in the generation of an immune library are outbred animals and each will have 
a distinct immune response. This approach is more likely to yield affinity-matured 
Nbs that bind different epitopes[320]. But, the cost of the animals’ upkeep and the 
amount of antigen this approach would require, means that although such a 
strategy could have resulted in a more diverse set of Nbs, it is perhaps not a very 
realistic one. The results obtained with Nb8 show that there is still more to learn 
about the roles of the AKT domains, and it would be interesting to be able to 
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investigate the function of the regulatory domain of AKT1 and AKT3 using isoform-
specific Nbs. 
 
The problem we faced with intracellular expression of the Nbs through transient 
expression forced us to explore other options for obtaining intrabodies (Figure 18). 
The generation of stable cell lines with the Lenti-X™ Tet-On® system allowed for 
the selection of cells that have incorporated the Nb cDNA, and it is an inducible 
system, which is beneficial if the Nbs affect cell viability by interfering with AKT2. 
These stable cell lines allowed us to investigate if the Nbs modulate AKT2 
signalling in a relevant context. The MDA-MB-231 cell line represents a triple-
negative breast cancer model, an aggressive cancer subtype with limited treatment 
options and poor prognosis. Several members of the PI3K/AKT pathway are being 
investigated as candidates for targeted therapy to treat this type of cancer, including 
AKT[486,487]. However, the paucity of information regarding AKT isoform-specific 
functions and the lack of isoform-specific inhibitors has made validation of a single 
AKT isoform as a therapeutic target rather difficult. The MDA-MB-231 cell line 
expresses wild-type versions of AKT1, AKT2, AKT3 and many important 
downstream nodes in the pathway, and can therefore be used to map the specific 
downstream effects of interfering with AKT2 and to validate this isoform as a target 
for therapy[215,488]. 
It quickly became clear that Nb5, based on affinity, our second-best AKT2 
interactor, had no cytotoxic or cytostatic effect whatsoever when expressed in 
MDA-MB-231 cells (Figure 29A and Figure 37). 
Even though this is not something we have explored, Nb5’s high affinity for 
AKT2, and the efficiency of the Co-IP with endogenous AKT2, indicate that this Nb 
is a good candidate for the engineering techniques discussed in paragraph 2.4.2.2. 
Through click-chemistry, Nbs can be easily and efficiently labelled with 
fluorophores[335]. A fluorescently labelled Nb5 could act as an inert tracer for AKT2. 
Combined with photoporation and live cell imaging, such a tool can make it possible 
to track AKT2 in living cells and study the localization of this isoform, but also the 
changes that occur after activation of the AKT pathway[34,36,68]. This approach can 
be applied to a wide range of cell lines, but would require tuning of the Nb 
concentration to that of AKT2. When too much Nb is used, the unbound fraction 
would cause background signal and, worse, the excess Nb could bind to the wrong 
AKT isoform. 
 
The two other AKT2 Nbs, Nb8 and Nb9, had an impressive cytotoxic/cytostatic 
effect when expressed in MDA-MB-231 cells. We found that Nb8 induced a G0/G1-
phase cell cycle arrest and autophagy, effects which have been previously 
described upon AKT2 knockdown[234]. Although Santi et al. suggested that 
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autophagic cell death is an important part of the effect that occurs when interfering 
with AKT2, the small reduction in cell viability that we observed after 72 h clearly 
indicates that Nb8’s effect is predominantly cytostatic rather than cytotoxic 
(Figure 41). There is a downwards trend where viability is concerned, and it is 
possible that this parameter further decreases over time in cells expressing Nb8[234].  
 
Figure 41 Cell viability of MDA-MB-231 cells expressing Nb8. Stable cell lines were 
treated with Dox (500 ng/mL) for up to 72 h. A trypan blue exclusion assay 
with automated counting (Luna™ Automated Cell Counter) was used to 
discriminate between viable and dead cells. Values were normalized for the 
un-treated cell lines, the mean with a 95% CI is shown. A one-way ANOVA 
with Tukey’s multiple comparison test was used to compare mean cell 
viability between treatment and control. * p<0.05, ** p<0.01 and *** p<0.001. 
Only the Nb8-expressing cells had a significantly lower cell viability after 72 
h. 
AKT signalling often depends on cell context. Our low-throughput approach 
(stable cell lines) does not lend itself to studying AKT’s functions in a broad range 
of cell lines, but the tools (Nbs) we have characterized, do[440,489,490]. Keeping in 
mind the issues we encountered when expressing the Nbs in cells through transient 
transfection, photoporation, with an efficiency in excess of 80% and negligible 
toxicity, could be the technique that allows an accelerated evaluation of context-
dependent AKT2 functions and elucidate the factors that determine how an AKT 
isoform will behave in a particular cell type[311,335]. Perhaps, by consistently using 
the same AKT2 modulator we can filter out contrasting observations that result from 
the experimental approach used to probe AKT functions[234,235]. 
 
Our experimental approach enabled us to characterize some of the cellular 
processes and components that are affected by Nb8. But, due to the lack of a 3-D 
structure of the Nb8:AKT2 complex we can offer no conclusive evidence on the 
mechanism of action (MOA) of this AKT2 modulator. What we can do, is make an 
educated guess based on what is known from the literature, combined with the 
information gained from our own experiments. 
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The allosteric AKT inhibitors bind an interdomain region between the protein 
kinase- and PH-domain, and can only function if the PH domain is intact and Trp80 
is present[23,25,33,45,258,491,492]. Nb8, on the other hand, interacts with the C-terminal 
regulatory domain and can still bind to an AKT2 construct where the PH domain 
has been deleted (Figure 21B). It is therefore quite improbable that Nb8’s effects 
depend on the same allosteric pocket that is bound by the allosteric inhibitors, which 
means that Nb8’s MOA is distinct from that of the allosteric AKT inhibitors that exist 
today. The epitope mapping also excluded the possibility that Nb8 acts as a 
chaperone that locks the protein in the inactive conformation by binding the PH- 
and kinase-domain simultaneously, or that Nb8 mimics the PH domain’s inhibitory 
effect, as potential MOA. 
Nb8’s epitope, the C-terminal regulatory domain, allosterically regulates AKT 
catalytic activity. This effect depends on phosphorylation of the HM[24,44]. Our results 
show that Nb8 attenuates phosphorylation of the AKT2 HM in IGF-1-stimulated 
cells (Figure 30). Perhaps the steric hindrance from this Nb directly blocks 
mTORC2 from accessing this phosphorylation site, or Nb8 captures the regulatory 
domain in a conformation that is not suited for phosphorylation. This alone would 
prevent the full activation of the AKT2 kinase and limit the substrate repertoire to 
those substrates that can be modified by mono-phosphorylated (Thr309) 
AKT2[32,42,43,82,132]. It is also possible that Nb8 prevents binding of the regulatory 
domain to the kinase domain irrespective of HM phosphorylation, which could also 
have implications for the stabilization of the PH-in conformation.  
The regulatory domain participates in several protein-protein interactions, 
besides mTORC2, that could be likewise affected by Nb8[21]. Nb footprinting, an 
affinity purification-mass spectrometry (AP-MS) approach that compares the 
interactomes of several distinct Nb:AKT2 complexes, was performed in an attempt 
to identify true AKT2 interactors, and proteins that are displaced by the Nbs[274]. 
However, due to the low amount of AKT2 that was pulled-down we were unable to 
discriminate between such interactors and the non-specific background. To 
evaluate whether the Nbs affect the AKT2 interactome we most likely need to look 
at other techniques such as crosslinking prior to AP-MS, which would ‘freeze’ 
protein complexes, or BioID, which would label interactors of the Nb8:AKT2 
complex, providing a truthful representation of interactions that occur inside living 
cells[493,494]. 
Unlike the ATP-binding pocket, which is highly conserved across the entire 
kinome, there are no fixed rules that determine the structure of an allosteric 
regulation site. Therefore, allosteric sites such as the interdomain region targeted 
by MK-2206, are ideal for attaining selective inhibition of a kinase. But this also 
means that these sites are not easily discovered[495–497]. It is possible that Nb8’s 
epitope represents a second allosteric site, one that is sufficiently different between 
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the AKT isoforms to enable isoform-specific inhibition of AKT2. As it appears that 
most academic researchers and pharmaceutical companies are content to put all 
of their eggs in one basket by targeting the same allosteric site for AKT inhibition, 
there are no allosteric AKT inhibitors that target the hydrophobic motif, nor has it 
been considered as a target for therapeutic intervention. When compared to the 
screening of small molecules, the use of Nbs in the discovery of allosteric sites has 
a much lower throughput. Nonetheless, this approach has shown merit for the 
modulation of kinases whose inhibitors are known to have significant off-target 
effects, such as Aurora-A, EGFR and CDPK1[498–500]. Now, we can add AKT2 to this 
list. 
Even though Nb8 represents a novel method for AKT2 modulation, the fact that 
most unmodified Nbs cannot cross the plasma membrane means that the options 
for therapeutic application are limited. Several targeted approaches to deliver Nbs 
into cells are being explored, foremost among these are the use of lipid vesicles to 
deliver Nb RNA or exploiting the E. coli type III secretion system to inject functional 
Nbs into cells, but these approaches are still in an experimental stage[284,350,357]. 
However, the rational design of a small-molecule allosteric inhibitor based on the 
interaction interface of Nb8 and AKT2 or screening for small molecules that interact 
with the same epitope on AKT2 are more feasible options for therapeutic validation. 
The former strategy would require a detailed 3-D structure of the complex as can 
be obtained by X-ray crystallography, NMR, Cryo-EM or AI-based modelling, which 
is not an easy feat (2.4.2.1.1).  
 
Although we cannot exclude the involvement of other MOAs that rely on the 
regulatory domain, our results only support that Nb8 affects AKT2 signalling by 
reducing HM phosphorylation. With a total of 189 phosphosites on 140 proteins that 
were differentially regulated and 37 proteins with significant changes in expression 
levels, we have captured a snapshot of Nb8’s effects on the AKT2 signalling 
cascade[6,46,49]. For only a handful of these proteins (22%) the functional effect of 
the PTM is known, but the cellular processes that these proteins are involved in 
partially recapitulate those that are affected by an AKT2 knockdown in the same 
breast cancer model[49,233,234,440,456,501]. In contrast to Nb8, a knockdown abolishes 
all of AKT2’s functions, both catalytic and structural, and as a consequence, the 
effects of Nb8 and a knockdown are alike but far from identical[502–504]. 
In the same cancer model, an AKT2 knockdown reduced the stability and 
transcription of PALLADIN[174]. Contrarily, in cells expressing Nb8, PALLADIN 
levels remained stable (Figure 40). Although Chin et al. did not pin down the 
mechanism through which AKT2 regulates PALLADIN, the fact that Nb8 did not 
elicit the same effect suggests that this is either a structural AKT2 function, or that 
it depends on a downstream substrate that can still be modified by mono-
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phosphorylated (Thr309) AKT2. Strangely enough, AKT2 does not co-
immunoprecipitate with PALLADIN, nor did MK-2206 treatment have an effect on 
PALLADIN expression levels, which disproves both hypotheses[35]. 
Nonetheless, the modulation of AKT2 by Nb8 induced drastic changes in stress 
fibers and focal adhesions, which goes to show that PALLADIN is but one of several 
proteins through which AKT2 can regulate cytoskeletal remodeling (Figure 34). As 
PALLADIN expression and phosphorylation were unaffected by Nb8, all elements 
through which AKT1 stimulates an organized and rigid stress fiber network that 
opposes cell migration, are still in place[246]. Yet our results clearly show an almost 
complete loss of organised stress fibers, an indication that AKT2 trumps AKT1 in 
the regulation of stress fiber assembly. 
Integrin β1 is another example of a cytoskeletal protein that is regulated by AKT. 
While our results show a clear reduction in expression levels, this was not detected 
in an AKT2 knockdown[456]. However, Wang et al. focussed on short-term 
differences in phosphorylation and this discrepancy could be owed to the long half-
life of Integrin β1[505]. There are several other sources that support AKT’s role in 
Integrin β1 expression, but it appears that the final effect depends on the cellular 
context[163,443,490]. Given the importance of Integrin β1, FAs and stress fibers for 
cancer cell migration, our results imply that expression of Nb8 reduces a cell’s 
capacity to migrate and confirm the role of AKT2 in breast cancer cell migration. 
However, we can only offer indirect evidence and it remains to be seen what the 
functional effect of Nb8 on cell migration is. 
The different outcome of Nb8 expression and an AKT2 knockdown on 
autophagic cell death has already been mentioned[234]. Santi et al. also concluded 
that the ablation of AKT2 induces mitophagy, based on the presence of 
autophagosomes throughout the mitochondrial network. Our results do not agree 
with this claim as we observed that autophagosomes were also located near the 
mitochondrial network in the control conditions, although they were much fewer in 
number. 
The similarities between an AKT2 knockdown and the effects of Nb8 confirm that 
this Nb is an isoform-specific interactor. That a dowregulation of HM 
phosphorylation reproduces several of the effects observed in an AKT2 knockdown 
places a lot of importance on this phosphorylation site for AKT2 signalling and 
demonstrates the potential of the HM as a therapeutic target.  
A rather frustrating limitation of our analysis is that despite the identification of 
over twenty known AKT substrate sites, none were differentially regulated in Nb8-
expressing cells (Table 7). The result is that, when we reconstructed Nb8’s effects 
on the AKT2 signalling pathway, we were unable to establish a direct link between 
AKT2 and the differentially regulated proteins (Figure 35). A phosphoproteome 
analysis with a different phosphopeptide enrichment method, such as an Ab that 
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specifically binds the phosphorylated AKT substrate motif, rather than TiO2 beads, 
could shed more light on which AKT2-specific substrates are affected by Nb8[506]. 
However, that the identified AKT substrates were not affected by Nb8 was not a 
bad thing across the board. The phosphorylation of GSK3-β Ser9 only marginally 
depends on whether the AKT HM is phosphorylated or not, it is not affected by an 
AKT2 knockdown and is upregulated by knockdown of either PHLPP isoform. 
Together with our results this indicates that this GSK3-β site is not an exclusive 
AKT2 substrate and does not need full AKT activity to reach saturation[82,86,234]. 
PALLADIN Ser1118, another AKT substrate site that is unaffected by Nb8, can 
only be phosphorylated by AKT1 in vitro, which further strengthens our claim that 
Nb8 is an AKT2 isoform-specific modulator[246]. 
And, last but not least, that several AS160 phosphorylation sites were not 
affected could indicate that Nb8 does not interfere with the IGF-1-stimulated 
translocation of GLUT4-vesicles to the PM. This could be important for the 
development of small-molecule inhibitors based on this Nb’s epitope as 
hyperglycemia, an adverse effect that is ascribed to the inhibition of AKT2, is 
frequently observed when using pan-AKT inhibitors in clinical trials[6,253,256,483,484]. 
However, there could also be AS160-independent mechanisms and the expression 
of GLUT1, the main glucose transporter in most mammalian tissues, including 
MDA-MB-231 cells, is also regulated by AKT. Therefore, investigating the effects 
of Nb8 on glucose uptake should still be a priority if one were to consider using 
Nb8’s epitope as a therapeutic target[507]. 
Protein phosphorylation is a dynamic process, and the members of a pathway 
are not instantly phosphorylated in response to GF stimulation[508–510]. In a way, it 
could be compared to a ripple spreading across the surface of a pond after a stone 
was thrown into it. Certain clusters or nodes within a pathway are slower to respond 
to stimulation, owing to their hierarchy in the pathway, subcellular localization or 
the kinetic parameters of the phosphorylating enzyme. For example, in adipocytes 
AKT phosphorylation reaches a plateau after only one minute of stimulation with 
insulin, while mTORC1 and some of its substrates only do so after five to twenty 
minutes[508]. This means that the choice to analyse the phosphoproteome after five 
minutes IGF-1 stimulation will have determined the obtained results. It is highly 
likely that we have failed to detect events that occur earlier or later in the pathway 
as the phosphorylation of some proteins was already being downregulated or had 
yet to occur in the EGFP Nb-expressing cell line. This could be addressed by 
investigating the differences in the phoshpoproteome between Nb8 and the EGFP 
Nb at other time points (both shorter and longer) which would give us a time-course 




It was interesting to note that the pan-AKT inhibitor, MK-2206, did not always 
have the same effects as Nb8, even though it also down-regulates phosphorylation 
of the AKT2 HM. This inhibitor did not affect Cyclin D1 expression levels and, in 
line with this, it does not appear to affect cell cycle progression in MDA-MB-231 
cells either[437]. Cell proliferation is regulated by AKT1, AKT2 and possibly also 
AKT3, and both AKT1 and AKT2 promote Cyclin D1 expression (1.5.2). So, if 
anything, one expects that an inhibitor which blocks both isoforms would have a 
larger effect than a Nb that targets only AKT2. 
Our investigation of focal adhesions and stress fibers in Nb8-expressing cells 
also showed a remarkable difference with MK-2206-treated cells. This pan-AKT 
inhibitor had no effect on these cytoskeletal structures, which could be due to the 
opposed functions of AKT1 and AKT2 in regulating cell migration[244]. 
But the opposing effects of the AKT isoforms do not explain why MK-2206 has 
no effect on cell proliferation, and therefore cannot be the whole picture. Feedback 
mechanisms that ensure the shutdown of the pathway can become unhinged by 
the prolonged lack of AKT activity, leading to the activation of other signalling 
pathways such as the MAPK/ ERK and MET/STAT3 pathways [183,511–513]. This can 
oppose the effects of AKT inhibition and lead to acquired drug resistance. That Nb8 
only reduces phosphorylation of the HM indicates that a Nb8:AKT2 complex still 
retains some residual catalytic activity, which could suffice to activate certain 
feedback mechanisms. 
The upregulation of RTKs (EGFR, HER3, IGF-1R and INSR) or adaptor proteins 
and activation the MAPK/ERK pathway has been shown to occur when AKT 
signalling is suppressed by allosteric inhibition[183,512,514]. While only the EGFR was 
quantified in the SG proteomics screen, its expression was not affected by Nb8 and 
the same is true for the phosphorylation of ERK1 Thr202 and Tyr204, two sites 
associated with activation of this kinase. This indicates that this particular feedback 
loop is not affected by Nb8. 
mTORC1 is also part of a feedback loop, and there are several signs that Nb8 
reduces mTORC1 activity (induction of autophagy, reduced RPS6KA1; TFEB and 
EEF2K phosphorylation). This feedback loop involves phosphorylation and 
degradation of IRS-1/2, and Nb8 did reduce the phosphorylation of several IRS-1/2 
sites, including IRS-1 Ser270. Therefore, it should be investigated if Nb8 affects 
this feedback loop and if, by inhibiting IRS-1/2 degradation, this Nb prolongs IGF-1 
and Insulin signalling[183,515]. 
Combination therapy is the main approach employed to combat this type of 
acquired resistance, but the feedback loops that regulate the PI3K/AKT pathway 
are complex and poorly understood, particularly where AKT isoform-specific 
mechanisms are concerned, and have to be studied in much more detail to 
determine the optimal approach for preventing acquired therapy resistance[183]. 
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Although Nb9 also had a cytotoxic/cytostatic effect, we were unable to pin down 
exactly what cellular process was affected by this Nb. Contrary to Nb8, we have a 
better idea on the MOA of this Nb as it blocks the interaction of the AKT2 PH domain 
with PIP3 (Figure 22). However, despite the much higher affinity of Nb9 for the 
AKT2 PH domain, it had no effect on the phosphorylation of the AKT2 HM in IGF-
1-stimulated cells. It is possible that Nb9’s expression levels were not high enough 
to overcome the sudden, local spike in PIP3 concentration[29,67]. This Nb could 
possibly affect the re-association of AKT2 to PIP3 or PI(3,4)P2 while activated AKT2 
migrates though the cytoplasm, and reduce the duration of AKT2 activity[73]. 
Conclusion (almost there…) 
This work introduces new tools, these being Nbs, which allow the specific targeting 
of AKT1 and AKT2. AKT is not a novel target for cancer therapy and there already 
exist tools for targeting AKT (pan-AKT inhibitors and gene knockdown), but we 
believe there is still much room for improvement and used an original approach to 
tackle the problem of isoform-specific AKT inhibition. Our results emphasize the 
importance of using different, complementary techniques to study protein function, 
as each technique has its own advantages and disadvantages. 
An in-depth characterization showed that at least two Nbs have an intrinsic effect 
on AKT2, another AKT2 Nb could be used as an inert tracer, and a single AKT1 Nb 
shows promise for opposing the activation of this isoform, but requires further 
evaluation. We demonstrate that Nb8 can be used to modulate AKT2 in living cells 
and offer new insights into the function of this isoform. Furthermore, we establish 
the importance of the regulatory domain and hydrophobic motif in AKT2 signalling, 
a potential new allosteric regulation site that has not yet been considered as a 
therapeutic target. We believe that Nb8 shows great promise for deciphering the 
isoform-specific and context-dependent functions of AKT2, and hope that our novel 
approach inspires further investigation into a new type of allosteric, isoform-specific 
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